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Abstract 
Peptidomimetic compounds have been shown to exhibit both anti-HIV and anti-malarial 
activity. A multicomponent reaction was used to create a library of peptidomimetic compounds 
with an α-hydroxy-β-amino acid unit. The Passerini reaction between an aldehyde, carboxylic 
acid and isocyanide was used to prepare compounds containing both ester and amide 
functionalities. These compounds were then subjected to a deprotection-acyl migration 
strategy giving rise to the target compounds. This approach, known as the Passerini Amine 
Deprotection Acyl Migration (PADAM) sequence was successfully used to create a library of 
novel peptidomimetic compounds. From this library, 22 compounds were tested for activity 
against HIV and malaria.  
The Passerini reaction gives rise to a product containing a new stereogenic centre, and as the 
starting aldehyde used (N-Boc-phenylalaninal) has a stereogenic centre, the products were 
isolated as a mixture of diastereomers. Our research was also focused on finding ways of 
influencing the stereoselectivity of the reaction and the separation of the resulting 
diastereomers. The diastereomeric ratio of the Passerini products was found to be 
approximately 2:1 for all the reactions performed. This ratio could be modified slightly when 
using certain carboxylic acids and isocyanides that were either very bulky or had a stereogenic 
centre.  
Attempts to enzymatically resolve the diastereomeric products were not successful after trials 
using a library of 25 lipase enzymes. However, use of preparative HPLC enabled the successful 
separation of most of the diastereomeric mixtures, affording compounds with high purity. X-ray 
crystallography enabled us to identify the major diastereomers as having the R,S configuration, 
whilst the minor diastereomers had the S,S configuration at the two stereogenic centres. 
A possible explanation for the observed stereoselectivity is based on the Felkin-Anh chelation 
control model. It suggests that mono-protected amino aldehydes follow a chelation controlled 
mechanism in nucleophilic addition reactions. Chelation occurs, albeit in the form of hydrogen 
bonding, between the NH and carbonyl oxygen. 
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The library of compounds was tested for activity against both HIV-1 and malaria. Only three 
compounds showed moderate activity against the malaria parasite, inhibiting parasitic growth 
by 37-42% at 5 µM respectively. Significantly, all of the active compounds contained an 
adamantyl moiety. Unfortunately no anti-HIV activity was seen for any of the compounds 
tested in the HIV-assay. 
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CHAPTER 1: INTRODUCTION 
1.1 HIV and AIDS 
Acquired Immunodeficiency Syndrome (AIDS) is a condition attributed to the Human Immuno-
deficiency Virus (HIV). The virus results in the infected person being susceptible to opportunistic 
infections and if untreated leads to the total collapse of the immune system and death. 
1.1.1 Prevalence 
The origin of HIV is still subject to much debate and controversy across the scientific 
community. The virus is believed to have originated in central Africa during the 1930s, with the 
first symptomatic outbreak occurring in Kinshasa (Democratic Republic of Congo) during the 
1970s before reaching epidemic proportions throughout sub-Saharan Africa during the 1980s.1 
Despite the origin controversy, its devastating effects and fatalities across the world cannot be 
denied. HIV is transmitted via the exchange of a variety of body fluids from infected individuals, 
such as blood, breast milk, semen and vaginal secretions.
 
Figure 1: HIV map.2 
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From the onset of the scourge, an estimated 75 million people have been infected with the 
virus and 39 million of them have died, according to a 2013 WHO report, making it one of the 
top killer viral infections in recent history.2 Globally, about 35.3 million people were living with 
the virus by the end of 2012. Estimates state that about 0.8% of adults of the world population 
aged between 15 – 49 years are currently infected with the virus. Although the burden of the 
epidemic continues to vary considerably between countries and regions, sub-Saharan Africa 
continues to be the most severely affected region, with nearly 1 in every 20 adults living with 
HIV and accounting for 71% of the people living with HIV worldwide. Furthermore, 70% of the 
global total cases of new HIV infections emanate from this region.3 The map depicted (Figure 1) 
shows the spread of HIV infections across the globe, indicating the magnitude to which 
continents and various regions are affected. Africa is clearly the hardest hit with most of the 
infected people being the poor, unlikely to be able to afford treatment. 
All across the world, women and children continue to be the worst affected and vulnerable 
groups, owing to the socio –economic, cultural and economic factors of the society that we live 
in. Stigmatisation of infected people also prevents such people from seeking treatment at an 
early stage, which increases their risk of contracting opportunistic infections and death. Current 
mitigation efforts are targeted at these marginalized groups in order to improve their risk 
profile. Awareness campaigns are also ongoing to ensure that people are conscious of, and 
knowledgeable about, the disease and the measures which can be taken to control and 
minimise the effects of HIV. Governments continue to spend millions of dollars towards these 
efforts; money which could under different circumstances be channelled towards other 
developmental goals.  
1.1.2 HIV Life Cycle 
HIV is a lentivirus, which belongs to the genus of retroviruses. The two main viral strains are 
HIV-1 and HIV-2, with HIV-1 being the most prevalent and fatal viral strain. The name 'lentivirus' 
literally means 'slow virus' because they take such a long time to produce any adverse effects in 
the body. The viruses also persist lifelong in the host’s body and establish chronic infections 
marked by continual viral replication. These characteristics emanate from the ability of the 
viruses to integrate into the host chromosome, whilst evading the host’s immunity.  
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Figure 2: HIV life cycle (http://aidsinfo.nih.gov/images/factsheet/hiv-lifecycle-05.jpg) 
Chapter 1: Introduction 
 
4 
 
As a result of the characteristics of the HI virus, it has a very long incubation period; to the 
extent that those who are infected by the virus may not be aware that they are HIV-positive 
until they are clinically tested.3, 4 This makes the infected person likely to infect other people 
unknowingly, until the onset of opportunistic diseases triggers testing. 
Upon entering the host’s body, the HIV attaches itself to the CD4+T lymphocyte receptors and 
exploits a vast network of human proteins in order to replicate inside human cells.4 Three 
constitutive enzymes, namely, reverse transcriptase, integrase and protease, play a pivotal role 
in this process. The viral replication process goes through several stages as the virus matures 
and infects new cells, whilst destroying the white blood cells which fight against bacteria and 
other infections.5 This causes the infected person to be susceptible to opportunistic infections 
which leads to death. All the stages of the virus lifecycle are explained and described in Figure 
2, which also indicates the validated targets for drug intervention at each stage to try and 
reduce the rate of replication of the virus in the body. 
1.1.3 Treatment methods 
Since the first confirmed case of HIV was reported in 1981, no cure has been discovered yet and 
the race is still on for that elusive treatment which will give hope to humankind again.4 Despite 
the lack of success in finding a cure, scientists have been persistent in the search for novel 
drugs to control and minimize the effects of the disease.  Research is currently focused on the 
synthesis of drugs that attack the virus at different stages of its lifecycle, so as to control or 
eliminate the detrimental effects the virus has on human health, as indicated in Figure 2.  
During the mid-nineties, scientists discovered antiretroviral drugs (ARVs) that reduced the rate 
of viral replication in the human body, which in turn reduced the overall rate of collapse of the 
immune system.6 To date, 31 ARVs have been approved by the Food and Drug Adminstration 
(FDA) to treat HIV infection. These treatments do not cure the disease, but rather the drugs 
reduce the amount of virus in the body after infection or after the onset of AIDS.7 Initially, AIDS 
sufferers were not likely to live longer than a few years but now they can live longer than 20 
years after being infected. Since 1996, the annual number of AIDS related deaths has steadily 
declined due to the significant increase in the number of people receiving antiretroviral 
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therapy. The disease has stopped being the death sentence it previously was. AIDS patients 
must, however, continue to take the ARVs lifelong in order to maintain their quality of health. 
The first regimens of highly active antiretroviral therapy (HAART) were approved in early 1996 
by the FDA.6 Different ARVs are classified according to their target and these classes are: 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase 
Inhibitors (NNRTIs), Protease Inhibitors (PIs), Fusion Inhibitors (FIs), Entry Inhibitors (EIs) and 
Integrase Inhibitors (also EIs). These drugs are used in combination from two or more drug 
classes. Because of the positive outcome of the antiretroviral drugs in managing the epidemic, 
there is now a drive to get as many infected people on the treatment programme as possible.  
According to the WHO website, there is still a wide deficit between those requiring and those 
receiving treatment, with only 35% of people eligible for antiretroviral therapy in low and 
middle income countries receiving treatment.2 Drug cost and availability are the greatest 
impeding factors preventing people from receiving these lifesaving medications, especially for 
impoverished countries where infected people rely on donor and government issued drugs. 
Awareness campaigns have also had a positive impact on reducing the number of new 
infections. People are now taking preventative measures to protect themselves against being 
infected or infecting other people. Studies have also shown that risky behaviour of unprotected 
sex with multiple sexual partners is on the decline, signalling that all efforts targeted at control 
of the disease are clearly having a positive effect.  
There is also a new challenge, which is the development of drug resistance. This mostly occurs 
when patients fail to take medicines as prescribed, creating an opportunity for HIV to mutate to 
strains that are resistant to antiretroviral drugs. The mutated virus will then continue to 
replicate without suppression by the current drugs. It is estimated that 10-25% of newly 
infected persons harbour at least 1 resistant viral strain.8 All these challenges provide the need 
for continual development of drugs to reduce cost, increase availability and combat the drug 
resistant strains. Although the rate of new drug approval is slow, significant progress is being 
made. At least several antiretroviral drugs, (darunavir9, dolutegravir10, raltegravir11 and 
elvitagravir12) have been approved in the past 10 years. Raltegravir was the first integrase 
inhibitor to be FDA approved. Investigation into compounds that act against targets such as 
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protein cofactors is also underway. This continual search for new methods of treating HIV 
infections minimises fears of a new scourge emerging, as a result of an increase in drug 
resistant strains compounded by lack of potent drugs.  
1.1.4 Protease inhibitors (PIs) 
For this project our interest is the design and synthesis of compounds as possible PIs, thus we 
will discuss this class in more detail.  
The proteins required by HIV for replication are prepared as a polyprotein, with several proteins 
strung together. In order for the virus to be infectious, this polyprotein must be timeously 
cleaved to give functional proteins and mature viruses capable of infecting new healthy 
cells.13, 14 The protease enzyme plays this vital role of proteolytic processing of the viral 
polypeptide chain. This action is indispensible and facilitates the replication of the virus in the 
body. Due to the critical function that protease plays in the viral lifecycle, it was identified as 
one of the crucial targets for viral control.15 Inhibition of protease is very important as it 
disrupts viral replication, producing non-infectious viral particles. The consequence of this is 
reduction of the viral load in the human host.  
1.1.4.1 Structure of Protease enzyme 
                                     
Figure 3: HIV protease enzyme complexed with amprenavir.5 
HIV-1 protease (PR) is a small enzyme composed of two identical protein chains, each only 99 
amino acids long. It functions as a homodimer with only one active site which is C2-symmetric 
in the free form.16 More than 140 structures of the HIV-1 PR, its mutants and enzymes 
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complexed with various inhibitors have been reported so far. Figure 3 shows one of the 
reported structures of the enzyme complexed with amprenavir, a protease inhibitor. 
The enzyme protein chains assemble to form a long tunnel, covered by two flexible protein 
"flaps" with a water molecule trapped inside. The flaps open up to allow entry of the viral 
polypeptide chain. The enzyme then wraps around a viral polypeptide chain, closing and 
holding it tightly until peptide hydrolysis occurs.17 There are hydrophobic pockets around the 
active site where the hydrophobic amino acid side-chains are accommodated, ensuring that the 
viral protein is perfectly held in the active site. The active site is at the centre of the tunnel, 
where the water molecule acts as a nucleophile, attacking the carbonyl carbon in the hydrolysis 
of the proteins. Figure 4 is a schematic representation of how a peptide is held in the tunnel of 
the protease enzyme where S1, S1’, S2, S2’ etc., indicate hydrophobic pockets filled by amino acid 
side chains indicated by R1, R1’, R2, R2’ etc. Studies have shown that the protease chain is 
stretched straight through the active site and two aspartic acid residues facilitate cleavage of 
the peptide bond. 
 
Figure 4: Cleavage site of the viral polyprotein. 
Designing of inhibitors to act against HIV protease is now an achievable task because the 
structure of the protease enzyme has been elucidated and the mechanism of how the viral 
protein chain binds has been established.18 From the mechanism (Figure 5), the important 
functionalities were established and compounds mimicking the transition state of peptide 
cleavage have been synthesised to effectively compete with the natural substrate for this active 
site. These compounds fit into the active site but will not be hydrolysed because they have a 
non-scissile bond instead of the amidic group of the natural substrate. 
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Figure 5: Protease enzyme mechanism. 
1.1.4.2 Protease Inhibitor drugs 
Due to the vital role of HIV protease, many protease inhibitors have been synthesized to fight 
HIV as they help to prolong the life of those infected with the virus. To date 10 PIs have been 
approved by the FDA and these have been shown to reduce the viral load in infected patients.2 
Some of the PI drugs in current use are shown in Figure 6. 
 
Figure 6: FDA approved PIs. 
The inhibitors have at least four hydrophobic groups capable of filling the enzyme’s 
hydrophobic pockets and also have a 1,2-secondary alcohol amino functionality that acts as a 
transition-state mimic (circled in Figure 6). Research has shown that synthesized compounds 
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with fewer groups show little or no activity against protease because of lack of binding in the 
active site. The PIs also have two oxygen atoms on either side of the non-scissile bond which 
interacts with a special water molecule that is trapped under the flaps of the HIV protease. The 
drugs possess groups capable of participating in hydrogen bonding interactions as well, so as to 
improve their binding affinity. 
PI design is also influenced by the fact that an inhibitor that binds in the enzyme active site via 
multiple interactions, especially hydrogen bonding with the HIV protease backbone atoms, 
generally retains these affinities with mutant strains. Ghosh et al. showed that minimal 
conformational changes occur to the backbone structure of mutant enzymes, and hence it can 
be concluded that similar inhibitor-enzyme interactions should remain, maintaining the 
inhibitor affinity and potency.8 Inhibitor-bound HIV protease structures have revealed tight 
hydrogen bonding between the inhibitor and the protease backbone, hence any new potential 
inhibitors designed should contain groups capable of forming hydrogen bonds with the enzyme 
backbone.  
Although numerous studies have led to the discovery and development of a number of HIV-1 
protease inhibitors, a “perfect” protease drug seems elusive, because therapeutic benefit is 
short-lived and treatment success is usually limited due to the evolution of drug-resistant 
variants.19 Resistance to protease inhibitors is the consequence of amino acid substitutions that 
emerge either inside the substrate-binding pocket or at distant sites.20 This search for new PIs 
provided the basis for this work: synthesis of peptidomimetic compounds as potential HIV 
protease drugs. 
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1.2 Malaria 
 
Figure 7: Trends in malaria infections (Source: WHO world malaria report 2013). 
Malaria is the most deadly tropical parasitic disease, endemic to about 104 countries, most of 
which are located within the tropics (Figure 7). In 2012 alone, malaria accounted for about 627 
000 deaths with 207 million reported cases. Africa accounted for 80% of reported cases and 
90% of deaths, the majority (77%) of whom were children below the age of 5.21  
This tropical disease is caused by five parasitic species that belong to the genus Plasmodium, 
namely P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. Of these, P. falciparum 
causes the most deadly form of malaria and it is common in Africa. P. vivax is the second most 
widespread malaria-causing parasite and it is prevalent in countries outside Africa, but the 
malaria it causes is less severe. This disease is transferred from one person to another by the 
female Anopheles mosquito. This provides a complex life cycle for the disease as it has two 
hosts, but it also provides a wide scope for drug targets and control.   
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1.2.1 Current treatment and control methods 
Malaria is a preventable and treatable disease provided medication is taken timeously and 
mosquito breeding grounds are destroyed. Quinine (Figure 8) was the first antimalarial drug to 
be used, but it was largely replaced by its derivative chloroquine due to side effects. Despite 
this, quinine is still in use in some countries today.21 Over the years, drug resistance prompted 
more research into antimalarial drug discovery as more and more people were dying from the 
disease. As a preventative measure against the disease, anti-malarial drugs such as sulfadoxine-
pyrimethamine and amodiaquine were and are offered to the highest risk groups, namely 
children and pregnant women. Resistance of Plasmodium falciparum, the most lethal form of 
malaria, to these first line drugs, was the biggest culprit in the increasing mortality rate. To 
combat this problem, artemisinin based therapies used in combination with other drugs, known 
as artemisinin-based combination therapy (ACT), were introduced to treat severe cases of 
malaria.21 Use of bed nets and other social aspects have also been, and are continuously being, 
promoted. 
                     
Figure 8: Examples of antimalarial drugs. 
The mode of action of quinine, chloroquine and other derivatives is not clearly understood due 
to the complexity of the process. However, these drugs are believed to act primarily by binding 
to haem released following the digestion of haemoglobin in the host red blood cells by the 
parasite.22 This process prevents detoxification of haem which is normally detoxified by 
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conversion into insoluble haemozoin (malaria pigment). The binding of the drugs prevents 
formation of haemozoin and the free drug-haem complex is believed to exert a toxic effect on 
the parasite. The quinine based drugs are weak bases and also exert their anti-malarial effect by 
accumulating within the acidic digestive vacuole of the parasite.23 Consequently the parasite 
either starves, builds up toxic levels of partially degraded haemoglobin, or both, resulting in 
parasitic death. 
Artemisinin has a totally different mechanism of action from the quinine-based drugs and has 
therefore been effective against chloroquine-resistant strains of malaria. Its mode of action lies 
in the endoperoxide group acting as a molecular trigger for the disruption of redox homeostasis 
within the parasitic cell, eventually resulting in death of the parasite.24 The difference in the 
mode of action means that artemisinin has had success in treating chloroquine and quinine 
resistant malaria. Despite these successes, drug resistance also emerged with artemisinin and 
continues to be a major problem, which requires continual action through novel drug 
development.21 There is a need for the development of new drugs with novel targets so as to 
circumvent problems associated with drug resistance.  
1.2.2 Plasmodium falciparum proteases as drug targets 
Plasmodium falciparum, the major causative agent of malaria, is found in Africa and encodes 
over 10 aspartic proteases responsible for the life cycle of the parasite in the human body.23 
These enzymes are known as plasmepsins and appear to be involved in the initial steps of the 
degradation of haemoglobin. This is one of the critical stages of the life cycle of the parasite 
during human infection which provides nutrients for parasitic growth and maturation.25 
Because of the importance of the degradation of haemoglobin stage in the parasitic life cycle, 
plasmepsins make for an attractive antimalarial drug target.26 Research has identified 
Plasmepsin I, II, III and IV as attractive drug targets for the treatment of malaria. 
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Figure 9: Potential Plasmepsin inhibitors. 
Plasmepsin II and IV are two of the better targets as they are responsible for clipping long 
protein chains to release active protein in the red blood cells, much like HIV protease does. 
Research has shown that peptidomimetic compounds can be used as inhibitors against 
Plasmepsin II and IV, which also blocks the degradation of haemoglobin in cell-culture, which 
kills the parasite by starvation.27 Figure 9 shows peptidomimetic compounds which have shown 
good activity against these enzymes whilst exhibiting low toxicity.28, 29 These results support 
plasmepsins as a new promising target for the synthesis of potential new antimalarial drugs.  
1.3 Peptidomimetic compounds 
Over the last three decades scientists discovered biologically active peptides and characterized 
them as hormones, vasoactive peptides, enzymes and neuropeptides etc. Their interaction with 
membrane-bound receptors, influence on cell-cell communication and control of a series of 
vital functions became of great interest in the biomedical field. This interest prompted 
investigations into synthesis of peptide mimics which are now known as peptidomimetic 
compounds. These compounds are described as compounds whose essential elements 
(pharmacophore) mimic a natural peptide or protein in 3D space and which retain the ability to 
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interact with the biological target and produce the same biological effect.30 Their molecular 
structures are adjusted to enhance stability, biological activity and pharmacokinetic properties.  
Historically, peptides did not have much success as drugs because of their unfavourable 
delivery methods and short plasma half-life. However development of peptidomimetics has 
provided drugs which are orally available and have a longer half-life which increases efficacy. 
Much success of oral availability has been seen with HIV antiretroviral drugs. New delivery 
technologies, such as the use of nano particles, have also stimulated research into finding new 
peptidomimetics as potential drugs.30  
 
Figure 10: Structures of captopril and enalapril. 
These compounds are providing a powerful tool for the development of inhibitors created to 
mimic the endogenous peptide, which helps in treating various physiological disorders.31 
Current areas of application include endocrinology, urology, obstetrics, oncology and as 
functional excipients. Captopril and enalapril (Figure 10) are examples of peptidomimetic 
compounds which have been successfully synthesised and are being used for treatment of high 
blood pressure as angiotensin-converting enzyme (ACE) inhibitors. ACE is a naturally occurring 
metalloprotease which is responsible for cleaving decapeptide angiotensin to octapeptide 
angiotensin II by utilising a Zn2+ ion trapped in the enzyme.32 The cleaved angiotensin II has 
strong hypertensive properties inducing vasoconstriction and augmenting the levels of 
aldosterone, which in turn promotes the retention of water and sodium ion, consequently 
increasing blood pressure. Inhibition of this enzyme is paramount in people suffering with high 
blood pressure, hence the development of captopril and enalapril. Success of these drugs lies in 
their higher affinity for the enzyme and increased coordination to the Zn2+, which in turn 
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suppresses the function of ACE. Another advantage of these drugs is that, they are orally 
bioavailable, have a longer half-life and produce prolonged effects.  
Since our interest lies in the inhibition of protease enzymes, we focused our attention on 
creating a library of peptidomimetic compounds as potential antimalarial and anti HIV drugs. 
Previous work in our laboratory has shown that such compounds have potential activity against 
protease enzymes found in both the HIV and malaria parasite. Structural similarities are also 
present in both FDA approved PI drugs and potential antimalarial agents, as they possess a 1,2-
secondary alcohol amino moiety circled in the structures shown in Figure 6 and Figure 9. 
The design and development of peptidomimetics initially involves a structure-activity 
relationship investigation of the natural peptide in order to ascertain and identify major 
pharmacophore elements that are responsible for the biological effect. In this way, the natural 
peptide complexity is reduced, making it possible for the active pharmacophore to be 
synthesised and optimised.31 In order to find a hit compound, libraries of analogues are then 
synthesised and screened against the target enzymes. In this process, peptide bonds are 
replaced with “look alikes” called isosteres which are less likely to be hydrolysed. Rigidification 
via cyclisation is also utilised to minimise conformational flexibility as this is an important factor 
to maximise drug-receptor interactions. For our research, the target pharmacophore has 
already been optimised and what is required is to synthesise a library of analogues in search of 
hit compounds.33 
The preparation of peptidomimetics has generally been approached by employing both 
naturally occurring amino acids and synthetic amino acids (that possess several features which 
are not present in the naturally occurring amino acids) and combining them in a linear synthesis 
to produce the desired product. Modification of commercially available enantiopure reagents, 
such as sugar derivatives, can also be used to make other necessary starting materials for the 
preparation of the desired isosteres. Synthetic routes used are normally lengthy and complex, 
and hence there is a need for the development of shorter synthetic routes. 
A convenient approach to the synthesis of peptidomimetics is through the use of multi-
component coupling reactions (MCRs) in combination with linear synthesis. While each method 
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has its own set of advantages, MCRs are advantageous in that complex structures are prepared 
in a single highly atom efficient step.34 In the majority of commercially available drugs and some 
of the inhibitors that are currently being tested clinically against HIV protease, a 
nonhydrolysable hydroxyethylene or hydroxyethylamine moiety is used as the basic core for 
the development of these inhibitors, a core which is readily achievable by employing the MCR 
approach. 
1.3.1 Multi-component Coupling Reactions (MCRs) 
MCRs are reactions where three or more starting materials react with each other in one-pot to 
produce products such that the majority of the atoms of the reactants are found in the 
product.35 They are a versatile means of obtaining complex molecules in one step and have 
been employed in various applications including the synthesis of polymers and dendrimers.36, 37 
These reactions are often high yielding, simple procedures, which exhibit superior atom 
economy and are time-saving.38 A number of such reactions have been developed over the past 
century and modifications of some of the classical ones have also occurred. The most widely 
used reactions include, but are not limited to, Passerini 3-component reaction (3CR), Ugi 4-
component reaction and Biginelli 3-component reaction.  
1.3.1.1 Passerini reaction   
 
Scheme 1: Passerini reaction. 
The Passerini reaction was discovered in 1923 by Passerini who was a Professor of chemistry in 
Italy.38 The Passerini reaction couples an isocyanide, carboxylic acid and aldehyde in a single 
step in a one pot reaction (Scheme 1).39, 40 This reaction produces a product with one amide 
and one ester functionality, making it less useful for the synthesis of peptidomimetic 
compounds. Since not much product diversity was offered by this reaction, it was not popular 
until recently when researchers started employing amide containing starting materials in the 
Passerini reaction which offered the diversity they were looking for.  
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As a result of this advancement, the Passerini reaction continues to be used in organic 
synthesis. Of significant benefit in employing the Passerini reaction is the high atom economy 
and the fact that the reaction gives very few or no side products. The reaction is also generally 
high yielding; with yields ranging between 70% and 100% in most cases.41, 42 All these 
advantages make it an attractive tool in drug synthesis. The major drawback of the Passerini 
reaction is the lack of stereocontrol over the formation of the new stereogenic centre. When 
achiral starting materials are used, a racemic mixture of products is produced and in general 
enantiomers are very difficult to separate. This is not ideal, especially when target compounds 
are potential enzyme inhibitors or drug candidates. Enantiomers have been shown to have 
different biological effects on different biological targets, hence the need to produce 
enantiomerically pure compounds. 
 
Scheme 2: Reagents and conditions: i) MeCN, r.t., 16 h, air ii) NaOH, dioxane, r.t., 1 h. 
Since the Passerini reaction had already been established as a useful reaction in synthesising 
complex molecules, researchers embarked on finding ways of making the reaction either 
enantioselective or diastereoselective. Frey et al. developed an asymmetric synthetic route for 
the synthesis of mandelamides, compounds which have applications in medicine and 
agriculture.43 The researchers used 1,2,3,4-tetra-O-acetyl-α-D-galacturonic acid as an 
asymmetric inducing agent to control the stereochemical outcome of the new stereogenic 
centre (Scheme 2) in the Passerini reaction. The acid component was then removed by 
saponification of the ester bond formed to yield the desired mandelamide with an e.r. of 93:7. 
The resulting e.r. showed that the Passerini reaction exhibited a high diastereoselectivity, which 
was the result the research team was after. Configuration assignment of the enantiomers was 
done by comparison with commercially available D-(-) and L-(+) mandelic acids after 
mandelamide hydrolysis. However, separation of the enantiomers was not achieved in this 
study. 
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Due to the potential of the Passerini reaction to produce potentially biologically active 
compounds with ease, a few other researchers have also investigated ways of making the 
reaction stereoselective.44, 45 
 
 
Scheme 3: Reagents and conditions CH2Cl2, r.t., 24-48 h. 
Krishna et al. were one of a few groups of researchers to investigate the selectivity of the 
Passerini MCR.45 They employed p-toluenesulfonylmethyl isocyanide (TosMIC) in the reaction 
with a variety of chiral aldehydes derived from sugar molecules (Scheme 3). A few of the 
examples of the products and their d.e. are shown in Scheme 3. Since the aldehyde already had 
a fixed stereogenic centre, the reaction would be diastereoselective instead of being 
enantioselective. For all the combinations tested the de of products ranged from 28% - 90% 
showing that moderate selectivities could be achieved by varying the reactants. However, it is 
important to note that the diastereomers produced using this approach were not separable by 
normal chromatography. They assigned the configurations of the diastereomers based on 
coupling constants of diastereomeric signals in the 1H NMR spectra.  
The success of using TosMIC and chiral aldehydes led the same group of researchers to 
investigate the selectivity of the Passerini reaction using more sterically hindered aldehydes.46 
They employed chiral epoxy aldehydes to create a library of compounds, with the best results 
shown in Scheme 4. 
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Scheme 4: Reagents and conditions: i) CH2Cl2, r.t., 48 h. 
From their results, they concluded that steric hindrance of the aldehyde in the Passerini 
reaction could be used for asymmetric induction as it had, on average, considerably increased 
the d.r. of the products. Determination of d.r. was made using the 1H NMR spectra by 
measuring coupling constants of protons adjacent to the epoxide ring, hence the proton at the 
newly formed stereogenic centre was either syn or anti to the epoxide ring. The stereochemical 
result was explained by using the transition state model shown in Scheme 5. They proposed 
that the isocyanide reacts with a loosely bound adduct formed between the carboxylic acid and 
the aldehyde. The adduct formed results from the protonation of the carbonyl oxygen of the 
epoxy aldehyde by the carboxylic acid. This provides a stereofacial preference with the 
isocyanide attacking the carbonyl carbon from the less hindered side, i.e., from the Re face to 
afford a syn major product for the trans-epoxy aldehyde, and from the Si face to afford a major 
anti-product for the cis-epoxy aldehyde. The separation of the diastereomers formed was not 
achieved by column chromatography. 
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Scheme 5: R1- alkyl substituent, R2- Ph. 
As the research into improving the selectivity of the MCR continues, there is growing interest in 
the use of α-amino acid derived aldehydes, carboxylic acids and/or isocyanides in the Passerini 
reaction.47 This is done to both investigate selectivity due to the presence of a resolved 
stereogenic centre and to introduce diversity in the backbone structure of the products.  
 
Scheme 6: Reagents and conditions: i) CH2Cl2 ii) TFA iii) Et3N.. 
Banfi et al. investigated the diastereoselectivity of the Passerini reaction by using a variety of 
amino acids in the preparation of aldehydes which were then employed in the reaction.41 After 
the Passerini reaction, the amino group was deprotected and the acyl group migrated to the 
nitrogen in a reaction sequence known as the “Passerini amine deprotection acyl migration” 
(PADAM) approach, and it was used to synthesise oligopeptides which were of interest as 
enzyme inhibitors. Irrespective of the aldehyde used, the d.r. observed was approximately 2:1 
for all combinations tested, as shown in Scheme 6. However, the identity of the major and 
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minor diastereomer was not established in this study. When enantiomerically pure carboxylic 
acids were employed, only two diastereomers were detected by NMR spectroscopy indicating 
that the starting α-amino acids did not undergo significant racemisation under the reaction 
conditions. The products of the Passerini reaction can undergo further modification allowing for 
additional variation of the structure to achieve targeted compounds. It is noteworthy that in all 
these investigations no one was able to isolate and confirm the absolute configuration of major 
and minor diastereomers. 
1.4 Enzymatic kinetic resolution (Bio-catalysis) 
The Passerini reaction using a chiral aldehyde produces diastereomers and therefore it is 
important to be able to separate the two chiral compounds, as they can have different or 
opposite biological activities. Separation of the diastereomers by normal column 
chromatography has not proved to be possible hence other ways of achieving this have to be 
sought.41, 42 Biocatalysis is a potential route for the separation of diastereomers.  Many 
different types of enzymes have been used to kinetically resolve potentially bioactive 
compounds.48, 49 Among the biocatalysts in organic synthesis, lipases are the most frequently 
used because this class of enzyme is able to perform both enantioselective hydrolytic reactions 
as well as the formation of a wide range of ester and amide bonds.50, 51 Lipase enzymes can be 
used for both transformations depending on the reaction medium and the presence of an 
acetate donor. They are most frequently employed in the enantioselective hydrolytic 
reactions,52 however esterification is also a selective method which can be used successfully.53 
Lipases are uniquely characterized by their ability to catalyse the hydrolysis of ester bonds at 
the interface between an organic phase containing the substrate and an aqueous phase in 
which the enzyme is dissolved. The other advantage of using lipases for the hydrolysis or 
esterification reaction is that they are very selective and specific with respect to structure and 
stereochemistry of the substrate and product.  
 
In our research, we anticipated that we could either test the use of lipase enzymes in the 
selective hydrolysis of the ester functional group in one of the Passerini products, or 
alternatively, test the selective esterification of the free hydroxyl group of one of the 
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deprotected and rearranged products (Scheme 7). The products formed would be significantly 
different chemically and separation by either column chromatography or crystallization would 
thus be possible.   
 
Scheme 7: Reagents and conditions: i) Lipase enzyme, buffer, solvent ii) Lipase enzyme, vinyl acetate, 
solvent. 
A wide variety of organic molecules have been biosynthesized due to the catalytic activities of 
enzymes. Kamal et al. also successfully used lipase enzymes for a critical step in the synthesis of 
both enantiomers of fluoxetine, the world leading anti-depressant drug (Scheme 8).48 The drug 
had previously been offered as a racemate, but research had shown that the R-enantiomer was 
more potent, hence the desire to produce enantiomerically pure product. 
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Scheme 8: Reagents and conditions: i) Vinyl acetate, Pseudomonas cepacia lipase, Et2O, 40°C. 
MCRs have also already been combined efficiently with biocatalytic methods in, for example, 
the synthesis of enantiopure precursors or for the enantioselective enzymatic hydrolysis of the 
products (Passerini reactions).54 Szymanski et al. successfully utilised lipase enzymes to resolve 
a racemic mixture of Passerini products (Scheme 9).55 This provided enantiopure building blocks 
for further reactions. 
 
Scheme 9: Reagents and conditions: i) CH2Cl2, 20°C, 48 h ii) Lipase from Wheat Germ, phosphate buffer 
7.0/Et2O (8:2), 20°C, 48 h. 
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Although the enantiomeric excess was not as high as expected, the approach offered a new and 
alternative way to synthesise peptidomimetic compounds which was short, and utilised 
reagents which were non-toxic, cheap and recyclable, all of which are desirable properties in 
synthesis. This approach to synthesis was also successfully employed in similar reactions by 
Kourist et al. (Scheme 10) with different substrates.51  
 
Scheme 10: Reagents and Conditions: i) CH2Cl2 ii) Esterase 56, buffer. 
The success of combining MCRs with biocatalysis has been reported by other researchers as 
well, although progress in this field is relatively slow.56, 57, 58 
1.5 Planned synthetic approach  
Previous work done by Gravestock and co-workers involved the use of the PADAM approach for 
the synthesis of peptidomimetic compounds with the potential to act against HIV-1 protease 
(Scheme 11).42 In this approach, the Passerini product rearranges via O,N-migration after N-
deprotection, to give an N-acyl compound with a free hydroxyl group.42, 47 The free hydroxyl 
group is a common feature in all FDA-approved HIV protease inhibitors (shown in Figure 6). The 
hydroxyl group is of great importance because PIs have been designed as transition state 
mimics, where the inhibitors show structural similarity to the tetrahedral intermediate formed 
during peptide hydrolysis.59 
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Scheme 11: Reagents and conditions: i) CH2Cl2, r.t, ii) TFA 10 equiv iii) Et3N 10 equiv. 
N-Boc protected phenylalanine was used as the aldehyde component of the Passerini reaction 
because this affords a product bearing a substituent which closely resembles the cleavage site 
of the natural substrate.15 A phenylalanine residue of the viral protein has been shown to bind 
in the hydrophobic pocket of the HIV protease at most of the cleavage sites. In this project we 
will extend this previous work, using the PADAM approach to prepare a library of compounds 
for testing against HIV-1 and malaria. Because the aldehyde already has a defined stereogenic 
center, the product of the Passerini reaction will be a mixture of diastereomers, provided that 
the stereochemical integrity of the aldehyde is maintained. Fortunately, previous work 
conducted on the synthesis of the aldehyde has shown that it does not racemise and the 
integrity of the stereogenic centre is maintained during the PADAM sequence.42, 47  
N-Boc phenylalaninal can easily be prepared via the Weinreb amide (without racemisation) 
from the commercially available N-Boc-L-phenylalanine as reported by Fehrentz et al.60 Use of a 
chiral aldehyde component will also enable an investigation of the diastereoselectivity of the 
Passerini reaction. Chiral carboxylic acids and isocyanides will also be introduced to further 
ascertain the extent to which these components influence the selectivity of the reaction.  
Readily available isocyanides will be used initially and then chiral isocyanides (synthesised from 
amino acids and glucose) will be employed to increase the functionality of the target 
compounds and add an additional chiral component to the Passerini reaction. Amino acids can 
be converted into isocyanides (Scheme 12) by conversion of the amino group into a formamide, 
followed by dehydration to the isocyanide. Our plan is to convert the carboxylic acid portion of 
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the amino acids into the Weinreb amide, which would allow further modification after the 
PADAM sequence to yield highly functionalised peptidomimetic compounds. 
 
Scheme 12: Reagents and conditions: i) CDI, N,O dimethylhyroxylamine.hydrochloride, CH2Cl2 ii) 
HCOOH, Ac2O, TFA iii) POCl3, Et3N, CH2Cl2. 
 
1.6 Aims of the project  
Since peptidomimetic compounds have been shown to be of medicinal importance as potential 
drug candidates against HIV-protease and the malaria parasite, this project aims at synthesising 
a library of such compounds using the PADAM approach. Because the Passerini reaction results 
in the formation of a new stereogenic centre, it is also of interest to establish whether the 
diastereoselectivity of the reaction can be controlled by the reagents utilised and if so, to what 
extent. Once the compounds have been synthesised, we will assess the feasibility of employing 
biocatalysis to resolve the resulting diastereomers before the compounds are tested for 
biological activity. 
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CHAPTER 2: RESULTS AND DISCUSSION 
The overall aim of the project was to synthesise a library of peptidomimetic compounds as 
potential enzyme inhibitors. Thus it was important to include different functionalities that 
would probe the different possible ligand-enzyme interactions. Different groups may be 
instrumental in increasing binding interactions between enzyme and substrate via hydrogen 
bonding, dipole-dipole interactions, ionic interactions and through hydrophobic interactions. 
Protease inhibitors have been shown to require both hydrophobic groups which fit into various 
enzyme pockets around the active site and also polar groups which are capable of hydrogen 
bonding.18 It is also important to vary the sizes of these groups so as to find the best fit. 
With these factors in mind, a total of 7 commercially available carboxylic acids (1-7, Figure 11 
and 6 isocyanides (8-13, Figure 12) were used in different combinations with (R)- or (S)-N-Boc-
phenylalaninal to create a compound library using the Passerini reaction. The 
diastereoselectivity of the Passerini reaction was also investigated. N-Boc-phenylalaninal was 
always used as the aldehyde component because the HIV protease cleavage site is adjacent to 
hydrophobic amino acid residues such as phenylalanine in the viral protein. 
 
Figure 11: Commercially available carboxylic acids used in Passerini reactions. 
Three of the isocyanides (11-13, Figure 12) were synthesised because they were either too 
expensive to buy or they were not commercially available. 
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Figure 12: Isocyanides. 
2.1 Synthesis of N-Boc-L-phenylalaninal 
We first prepared the aldehyde component of our Passerini reaction with much success using 
the method which was developed in 1982 by Fehrentz et al.60 
 
Scheme 13: Reagents and Conditions: (i) 1.2 eq CDI, CH2Cl2, rt (ii) 1.2 eq N,O 
dimethylhydroxylamine.HCl, CH2Cl2, 82%. 
Synthesis began by converting commercially available N-Boc-L-phenylalanine 7 into Weinreb 
amide 14 (Scheme 13). Boc protection of the nitrogen was preferred because this protecting 
group is easy to remove and would allow for the acyl migration to occur in the PADAM 
sequence. Compound 7 was dissolved in CH2Cl2 and reacted with carbonyldiimidazole (CDI), 
which was added in small portions and effervescence was observed. Gas evolution is a clear 
indication that the carboxylic acid has been activated for nucleophilic substitution, and this 
activation step is vital in the synthesis of the Weinreb amide, since addition of the imidazole 
activates the carbonyl group for nucleophilic substitution.61 After stirring at room temperature 
for 1 hour, the reaction mixture was treated with N,O-dimethylhydroxylamine hydrochloride 
and the reaction was left to stir overnight. After this time, thin layer chromatography (TLC) 
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showed the presence of a new product and no starting material. The desired product was 
isolated and purified by silica gel column chromatography as a clear viscous oil in a yield of 82%.  
The formation of 14 was confirmed by 1H NMR spectroscopy by the presence of two singlets: 
one at δ 3.16 for the N-CH3 protons and one at δ 3.65 for the O-CH3 protons, with each signal 
integrating for three protons. This was a clear indication that the Weinreb amide had been 
formed. The characteristic Boc group protons were observed at δ 1.39 as a singlet integrating 
for 9 protons. The proton at the stereogenic centre (H-2) appeared at δ 5.04 – 4.86 as a 
multiplet, whilst the NH was visible at δ 5.27 – 5.09 as a multiplet integrating for one proton. 
The benzylic protons (H-3) gave rise to 2 signals in the 1H NMR spectrum since they are 
diastereotopic. One appeared as a doublet of doublets and the other as a multiplet. The 
multiplet appeared at δ 2.95 – 2.80 integrating for one proton and the doublet of doublets was 
visible at δ 3.05 with J = 13.5 and 6.1Hz. The phenyl protons appeared as a multiplet at δ 7.37 – 
7.12 and integrated for 5 protons. The 13C NMR spectrum further confirmed the formation of 
this compound by the presence of signals in the carbonyl region at δ 172.32 for C-1 and at δ 
155.16 for the Boc C=O. The two methyl carbon atoms of the Weinreb amide functional group 
appeared at δ 61.50 for C-9 and at δ 32.03 for C-8. The quaternary carbon atom of the Boc 
group gave rise to a signal at δ 79.54, while the Boc methyl groups appeared at δ 28.31 in the 
13C NMR spectrum. The IR spectrum showed a strong signal at 1666 cm-1 which is characteristic 
for the carbonyl bond of an amide functional group. The absence of an OH stretch peak was 
further evidence that the Weinreb amide had been formed.                         
 
Scheme 14: Reagents and Conditions: 1.5 eq LiAlH4, dry THF, 0°C, 2 h, 88%. 
Having successfully prepared the Weinreb amide 14, we then reduced it to the desired 
aldehyde by treatment with LiAlH4 in THF. The desired product 15 was achieved in a yield of 
88% (Scheme 14). The product was not purified by silica gel column chromatography in order to 
minimise the chance of racemisation. No primary alcohol, which would have indicated over-
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reduction, was observed. This confirms the findings of Fehrentz et al. who synthesized a 
number of aldehydes from naturally occurring amino acids.60 It is believed that the Weinreb 
conversion proceeds through a very stable metal chelation intermediate between the carbonyl 
oxygen and Weinreb nitrogen which collapses during the acid work up. The formation of the 
product was confirmed by 1H NMR spectroscopy by the disappearance of the two methyl 
singlet peaks at δ 3.65 and δ 3.16 and the appearance of a new characteristic aldehyde singlet 
at δ 9.63. 13C NMR spectroscopy also indicated the absence of signals at δ 61.50 and δ 32.03 
owing to the methyl groups of the Weinreb amide, and the presence of a new characteristic 
carbonyl carbon peak at δ 199.44. The IR spectrum showed a strong sharp signal at 3365 cm-1 
due to the N-H stretch. The melting point obtained (83-84 °C) was comparable with the 
reported literature value of 86 °C.60 To ensure that the stereochemical integrity had been 
retained, optical rotation was performed and the results obtained (*αD]
20
589 +44.0 (c 2.0, 
CH2Cl2), -44.5 (c 2.0, MeOH)) were comparable to those of previously reported findings 
(*αD]
20
589 +40.4 (c 2.0, CH2Cl2), -44.4 (c 2.0, MeOH)).
60  
 
The aldehyde derived from the unnatural amino acid, compound 16 (N-Boc-D-phenylalaninal), 
was synthesised using the same method as described for the synthesis of compound 15. 
Product formation was confirmed by 1H NMR spectroscopy by the presence of the aldehyde 
singlet (H-1) at δ 9.61 and the characteristic carbonyl signal in the 13C NMR spectrum at δ 
199.44. All the other signals were as expected for the desired product. The melting point 
obtained was the same as for compound 15 at 83-84 °C whilst the specific optical rotation was 
(*αD]
20
589 -36.2 (c 2.0, CH2Cl2)) which is comparable to literature values.
62 The optical rotation is 
roughly equal in magnitude but opposite in sign, which is what is expected for enantiomers. 
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2.2 Passerini reaction to prepare (3S)-3-((tert-butoxycarbonyl)amino)-1-
(cyclohexylamino)-1-oxo-4-phenylbutan-2-yl acetate 17 and subsequent 
deprotection-acyl migration 
After the successful synthesis of N-Boc-L-phenylalaninal, the synthesis of a library of 
peptidomimetic compounds using the Passerini reaction commenced.  
             
Scheme 15: Reagents and conditions: CH2Cl2, r.t., 3 d, 93%. 
The first compound synthesised in this series was obtained by reacting N-Boc-L-phenylalaninal 
15, commercially available cyclohexyl isocyanide 8 and acetic acid 1 in a one pot reaction for 3 
days (Scheme 15). Equimolar quantities were used for each reactant and the reaction was 
carried out at room temperature in air. Care was taken with handling the isocyanide as it has a 
strong pungent smell. After 3 days the product was purified using silica gel column 
chromatography, with a mixture of both diastereomers collected. Partial diastereomeric 
separation of the product did not occur using this method. The product was recovered in a 
good yield of 93%. 
The 1H NMR spectrum confirmed the presence of the desired product. A multiplet was 
observed at δ 7.31 – 7.14 integrating for 5 protons resulting from the aromatic protons. One of 
the signals from a proton attached to N was split into two: one at δ 6.01 - 5.90 and the other at 
δ 5.83 - 5.75 with both signals being multiplets and integrating collectively for 1H. This might be 
due to either the presence of rotamers caused by restricted rotation around the amide or 
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carbamate C-N bonds, or simply due to the presence of the diastereomers. Variable 
temperature 1H NMR spectroscopy could have been performed to establish which factor was 
predominant, but further analysis will be done as future work. However, the ratio of these 
signals of 2:1 suggests that the observation is due to the diastereomers, as it corresponds to the 
ratio calculated by HPLC analysis (2.14:1.00 Figure 13). The proton at H-2, the newly formed 
unresolved stereogenic centre, appeared as an overlapping multiplet signal with one of the N-H 
protons at δ 5.28 – 4.90 (2H). The proton at H-3 also appeared as a multiplet at δ 4.35 – 4.22 
integrating for 1 proton. This complex splitting pattern observed is due to coupling with the 
neighbouring stereogenic centre proton, benzylic protons and the NH combined with the 
presence of diastereomers. For each of the two diastereomers, the benzylic protons (H-4) 
appear as a doublet, indicating that no geminal coupling is occurring. The first signal was 
observed at δ 2.94 with J = 7.5 Hz while the second signal was found at δ 2.83 with J = 7.2 Hz. 
The methyl protons of the ester group H-10 appear as two singlet signals, one at δ 2.13 whilst 
the other signal was at δ 2.09 in a ratio of 2:1. 
The remaining signal from the Boc methyl protons appeared at δ 1.43 – 1.29 as a multiplet 
integrating for nine protons. Signals from the protons of the cyclohexyl ring were not clearly 
resolved but they integrated for 10 protons as expected. 
The 13C NMR spectrum further confirmed the presence of diastereomers as doubling of some 
peaks was observed. Four carbonyl ester signals were observed at δ 169.80, δ 169.09, δ 166.86 
and δ 166.59 instead of only 2 signals. The carbonyl carbon characteristic of the Boc group also 
gave rise to two signals at δ 155.50 and δ 154.94. The newly formed stereogenic centre C-2 
appeared as 2 peaks, one at δ 74.32 and the second one at δ 73.73. Doubling of C-3 was also 
observed with signals appearing at δ 53.27 and δ 52.79. The cyclohexyl C-H, (C-11) appeared at 
δ 48.29 and δ 48.18 for the two diastereomers and the benzylic carbon C-4 at δ 38.05 and δ 
37.27.  
In order to determine the diastereomeric ratio of the compound accurately, High Performance 
Liquid Chromatography was performed. Since this was a new compound, there was no 
published method in literature for the separation of these compounds and various solvent 
systems and flow rates were tested to find one which gave maximum baseline peak separation 
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with an elution time of less than 20 minutes. For the separation of organic molecules, a C-18 
column is normally used and it was the starting point for our experimental work. Product (1 mg) 
was dissolved in 1 ml of solvent and 25 µl of the solution was injected onto the column for 
separation.  
The first mobile phase to be tested was a mixture of iso-propanol/hexane using isocratic elution 
at different ratios, starting with a ratio of 1:9. No separation was observed. HPLC was then 
performed using gradient elution but still no separation was observed. The mobile phase was 
then changed to acetonitrile/water (MeCN/H2O) starting with a 1:1 mixture. Partial separation 
was observed, but the elution time was too long at 30 minutes. The solvent ratio was then 
changed to 3:2 and baseline separation was observed, although the elution time was still at 25 
minutes. To reduce the elution time whilst maintaining baseline separation of the separated 
diastereomeric peaks, gradient elution was then used. This was done by gradually increasing 
the ratio of MeCN/H2O from 1:1 to 4:1. This method afforded the best chromatogram which 
had a reduced elution time and baseline separation of the diastereomers (Figure 13). The d.r. 
was then calculated by comparing the area underneath the two product peaks 1 and 2 giving a 
ratio of 2.14:1.  
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Figure 13: HPLC chromatogram of compound 17. 
It was clearly evident that formation of one diastereomer was favoured over the other. Any 
fears of racemisation of the resolved stereogenic centre were allayed by analysing the 
compound using a Phenomenex 5µ Lux cellulose chiral column. The same method used for 
separation of the diastereomers on the reverse phase C-18 column was used with the chiral 
column. Fortunately, the method was transferable, although baseline peak separation was not 
achieved. Variation of solvent ratios did not provide complete baseline separation, but 
fortunately only 2 peaks corresponding to the expected diastereomers were observed. 
Product peak 1 
Product peak 2 
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The diastereomeric mixture was then subjected to Boc deprotection, followed by acyl migration 
for the completion of the PADAM sequence (Scheme 16). An excess of trifluoro-acetic acid was 
added to a solution of compound 17 dissolved in CH2Cl2 and the reaction mixture was left 
stirring for 2 hours. Excess solvent and TFA were removed in vacuo and the product was 
redissolved in CH2Cl2 followed by the addition of triethylamine. The PADAM product 18 was 
then isolated and purified by silica gel column chromatography and HPLC analysis gave a d.r. of 
2.08:1. The d.r. shows that the stereogenic centre at C-3 did not racemise during the 
deprotection and acyl migration steps.  
 
Scheme 16: Reagents and Conditions: (i) 10 eq TFA, CH2Cl2; (ii) 10 eq Et3N, CH2Cl2, 94%. 
Synthesis of compound 18 was confirmed by the disappearance of the characteristic Boc signals 
at δ 1.43 – 1.29 in the 1H NMR spectrum and δ 155.50 and δ 154.94 in the 13C NMR spectrum. 
Further discussion of the spectra will be done at a later stage due to complexity of the spectra 
of unseparated diastereomers. The diastereomers were ultimately successfully separated using 
preparative HPLC. Once the PADAM sequence had been shown to afford the desired product, 
the diastereomeric mixtures of both the Passerini product 17 and PADAM product 18 were 
individually subjected to enzymatic kinetic resolution. 
2.3 Attempted enzymatic kinetic resolution  
Lipase enzymes have been established to be the most versatile and flexible biocatalysts for 
organic synthesis and, despite their specific nature, they have been found to be quite 
compatible with a wide variety of synthetic organic molecules.51 This provided a basis for our 
investigation into enzymatic kinetic resolution of diastereomers produced in the Passerini 
reaction. 
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All the enzymes used in these experiments were first tested for activity by testing the hydrolysis 
of benzyl acetate and the acetylation of benzyl alcohol. The test reactions were done using a 
phosphate buffer (pH 7), and either toluene, EtOAc or MeCN as solvent, in parallel with a 
control reaction to ensure that hydrolysis did not occur in the absence of the enzyme. The test 
reactions worked for all the solvents used affording an average yield of benzyl alcohol of 42% in 
4 hours.  After this a series of reactions were then set up to establish whether any of the 25 
selected enzymes would be able to selectively hydrolyse the ester group at the newly formed 
stereogenic centre of our Passerini product 17, considering the success achieved by other 
researchers using this approach.56 To the best of our knowledge, this is the first time an 
attempt has been made to enzymatically resolve diastereomeric products of the Passerini 
reaction. All of the successful enzymatic resolutions reported so far were to resolve 
enantiomeric products of the Passerini reaction. 
 
Scheme 17: Reagents and Conditions: Lipase enzyme, phosphate buffer pH 7.0, MeCN, 35 °C. 
After establishing the activity of the enzymes we had chosen, compound 17 was then subjected 
to enzymatic kinetic resolution (Scheme 17). MeCN was used as the solvent of choice as it is 
miscible with the buffer and would ensure that both the enzyme and the substrate are in the 
same phase, which should increase the rate of reaction. This provided the first challenge as the 
substrate would not dissolve when water miscible solvents were used. Toluene was then used 
as the solvent for the reaction as it is immiscible with water and dissolved the substrate. To 
assist in the interphase interactions, a surfactant (Tween, a polyoxyethylene-sorbitan esterified 
with a long-chain fatty acid) was used. Novozyme 525 was the first enzyme to be tested on our 
substrate, as it is known to be versatile.  
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Figure 14: HPLC chromatogram of attempted enzymatic hydrolysis of 17. 
The reaction was monitored by HPLC where the disappearance of one diastereomeric peak and 
appearance of another new peak would indicate successful hydrolysis of one diastereomer. 
There appeared to be formation of a new product by HPLC after 10 days (Figure 14) and the 
reaction was stopped and the products separated by column chromatography. Upon inspection 
of the 1H NMR spectrum, however, it was evident that the desired product had not formed and 
instead a reaction between the enzyme and surfactant had occurred, as some signals from 
Tween were present in the spectrum. Furthermore the d.r. of the diastereomers had not 
changed, indicating that the desired diastereoselective hydrolysis was not occurring. Enzymes 
Starting material (17) New peak 
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are usually employed for the selective separation of enantiomers but in this experiment we 
were trying to separate diastereomers. This might have affected the reactivity and selectivity of 
the enzymes.  
The experiment was then carried out in the absence of Tween, but there was no observable 
reaction after 14 days, and as a consequence the reaction was abandoned. The procedure was 
then carried out in different solvents, including EtOAc, Et2O and DMF with Triton-60 as the 
surfactant, but still no reaction was observed. A total of 25 lipase enzymes were tested on this 
substrate but yielded no positive results.  
 
Scheme 18: Reagents and Conditions: Lipase enzyme, vinyl acetate, solvent, 35 °C. 
After unsuccessful trials of the hydrolysis reaction, the esterification reaction was tested on 
compound 18 (Scheme 18). Mozhaev et al. reported success with the enzymatic acylation of 
bergenin, a compound with 5 hydroxyl groups.50 They achieved high selectivity where only one 
hydroxyl group was acylated, possibly due to steric constraints (Figure 15). Based on their 
findings, we decided to test the acylation reaction on our substrate 18. 
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Figure 15: Mono acylation of bergenin. 
Once again the reaction was monitored using HPLC but unfortunately no new product 
formation was observed using either MeCN, EtOAc, toluene or Et2O as solvent, despite varying 
the temperature. 
In an attempt to probe the reaction and optimise reaction conditions, substrate 17 was 
modified to form the secondary alcohol 19 (Scheme 19). This was achieved by treating 17 with 
potassium hydroxide in methanol overnight. The procedure yielded the expected product, 
signified by the loss of the methyl peak in the 1H NMR spectrum at δ 2.13 and δ 2.09 and the 
appearance of a broad singlet at δ 5.53 for the OH. There was also loss of two C-10 signals in 
the 13C NMR spectrum at δ 20.85 and δ 20.65. IR also showed a peak for the OH stretch at 3300 
cm-1. 
 
Scheme 19: Reagents and Conditions: 9 e.q. KOH, methanol, overnight, 99%. 
Compound 19 was then used in the enzymatic acylation reaction (same reaction conditions as 
in Scheme 18), but unfortunately despite this change, there was no observable reaction with 
any of the library of enzymes tested. Changing solvents did not appear to have any effect on 
facilitating the reaction. We suspected that the Boc protecting group, which is a bulky group, 
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might have provided steric hindrance precluding entry to the enzyme active site since it is very 
close to the target site. 
These results were disappointing indeed as not a single enzyme of the 25 selected showed any 
activity with the three substrates that had been tested. This led to the conclusion that no 
substrate binding was occurring at the active site of the enzymes, the substrate was not 
entering the active site at all or the acetate was not a sufficiently good leaving group in the 
hydrolysis reaction. We probed further the possibility that the acetate was not a good leaving 
group. In order to make the acetate a better leaving group, compound 20 was prepared by the 
Passerini reaction using chloro-acetic acid 6 as the acid component (Scheme 15), in a yield of 
85% and a d.r. of 1.94:1.00. The NMR spectra of the compound confirmed the formation of the 
desired product and will be discussed in detail as separated diastereomers at a later stage. 
This substrate was then used in the enzymatic hydrolysis reaction (Scheme 17) with the hope 
that the heteroatom would increase the chances of the substrate being hydrolysed. 
Unfortunately no positive result emanated from this attempt. Upon revisiting work of 
previously successful applications of the enzymatic kinetic resolution on Passerini products, it 
was observed that none had attempted to resolve substrates as structurally large as the ones 
being employed in this work.63 The second possibility, that the substrate was too large to enter 
the active site, was thus then explored.    
 
To investigate whether there was a problem with steric hindrance due to the bulky cyclohexyl 
and phenyl groups inhibiting entry of the substrate into the active site, compound 21 was 
synthesized where the cyclohexyl isocyanide was replaced with n-butyl isocyanide 9 in Scheme 
15. The compound was recovered in an excellent yield of 96% and a d.r. of 1.72:1.00 which was 
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slightly lower than that observed for compounds 17 and 20. The altering of the d.r. was 
probably as a result of using a smaller, straight chain isocyanide in the Passerini reaction.  
Successful preparation of compound 21 was confirmed by the presence of a quartet at δ 0.91 
with a coupling constant of 7.2 Hz representing 3 protons in the 1H NMR spectrum for H-14. 
This is expected from the terminal carbon of the n-butyl chain. The methyl group of the ester H-
10 was also clearly visible as a multiplet at δ 2.23 – 2.04 integrating for 3 protons. The 13C NMR 
spectrum also showed the expected two signals for the diastereomeric C-2 signals at δ 74.63 
and δ 73.99 and the C-14 signal at δ 13.70. The melting point of the compound was found to be 
125-126 °C. 
After confirmation of the structure, compound 21 was then used as the substrate in an 
enzymatic hydrolysis using previously described conditions (Scheme 17). The solubility of this 
substrate was slightly better when water miscible solvents were used. Acetonitrile was then 
used as solvent of choice for the reactions as literature reports indicate that high yields and 
selectivity were obtained when this solvent was used. At first, 10 enzymes were tested, 
Novozyme 525, Lipase Rhizopus oryzae, Wheat germ lipase, Lipase Pseudomonas fluorescens, 
Lipase Candida rugosa, Porcine pancrease lipase, Candida antartica lipase, Lipase Rhizopus 
arrhizus, Lipase Aspergillus sp. and Lipase Pseudomonas cepacia.  
From this set, only Candida antartica lipase and Lipase Aspergillus were found to produce new 
HPLC peaks after 14 days. The two enzymes were then used again in optimized reactions where 
the quantity of enzyme used was increased and the temperature varied. Tracking the reaction 
by HPLC indicated a lack of selectivity as both diastereomers were being hydrolysed, although 
at different rates (Figure 16). This was another setback which required new solutions, as 
changing the conditions did not provide any remedy to the problem. The reaction was 
abandoned pending availability of a new library of enzymes.  
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Figure 16: HPLC chromatogram for enzymatic resolution of compound 21. 
The bio-catalysis route was put on hold pending further investigation into what could be done 
to optimize the reaction or even to enhance selectivity. It was evident from the use of 
compound 21 that steric hindrance might be playing a role in the lack of activity, whilst the lack 
of selectivity may be due to the enzyme not recognizing the two diastereomers as chemically 
different. However, these findings shed light on what could be done to improve the reactivity 
and selectivity. Hydrolysable groups could be introduced to the substrate further away from the 
unresolved centre than the current group with the hope that enzyme hydrolysis might still be 
stereoselective.64  
Having failed to resolve the compounds using more environmentally benign catalytic methods, 
an HPLC preparative system was then employed to separate the Passerini products in small 
New product peaks 
Starting material 
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quantities. This was done in order to facilitate biological testing of the library of compounds 
that were to be synthesised in their stereochemically pure form, as individual diastereomers 
could exert different effects in a biological system. The preparative HPLC allows for isolation of 
the individual diastereomers in quantities that are adequate for further analysis. The 
instrument utilises a separation column that is 10 times bigger than the analytical column, and 
allows for larger quantities of sample to be analysed. Fortunately, the analytical method we had 
developed was transferable to the preparative system, with only a minor adjustment of flow 
rate which had to be increased to 20 ml/min. 
The major problem associated with this method was that several HPLC runs had to be 
performed in order to collect a reasonable quantity of each product. This meant that large 
volumes of HPLC-grade solvent were used as at least 10 runs had to be performed for each 
compound. In addition, this method was found to be successful only with compounds that 
showed good baseline separation on the C-18 reverse phase analytical column. As a result, not 
all Passerini products prepared were separated into the individual diastereomers using the 
preparative HPLC system. 
2.4 HPLC separation of 17  
Compound 17 was the first to be separated by the preparative HPLC affording 17A (major 
diastereomer) and 17B (minor diastereomer). 
 
At this stage, we did not know which diastereomer was the major product. However, crystal 
structures of 2 other separated compounds at a later stage enabled the assignment of the 
configurations. It was also interesting to note that the minor diastereomer was less soluble 
than the major diastereomer in most solvents. The identity of 17A and 17B was confirmed by 
Chapter 2: Results and Discussion 
 
44 
 
1H NMR and 13C NMR spectroscopy. The H-3 proton appeared as a multiplet at δ 4.38 -4.23 and 
δ 4.37 – 4.19 for the two different diastereomers 17A and 17B respectively. The H-4 protons 
are also characteristic and they appeared as a doublet at δ 2.83 (J = 7.2 Hz) integrating for 2 
protons for 17A and at δ 2.94 (J = 7.6) integrating for 2 protons for 17B. C-2 was also seen as a 
unique signal in the 13C NMR spectrum with significantly different shifts for the two 
diastereomers: δ 73.86 for 17A and δ 74.42 for 17B. These differences clearly show that there is 
a difference in the conformational arrangement of these two molecules.   
2.5 Synthesis of the cyclohexyl isocyanide series 
After the successful separation of the diastereomeric mixture 17, a range of analogues 
employing cyclohexyl isocyanide 8 and different carboxylic acids (2, 4, 5, 6 and 7) were 
synthesised (Figure 17). The yields for these compounds (22 – 26, Figure 17) were good, 
ranging between 85% and 99%. The reactions proceeded as expected with the exception of 
compound 26, which precipitated out of solution as it was being formed. This resulted in 
further purification of the compound being very difficult as it would only dissolve in heated 
DMSO. It was then partially purified by repeatedly washing with CH2Cl2 in an attempt to remove 
unreacted starting material.  
The formation of one diastereomer is favoured and results in an approximately 2:1 ratio of 
products. Bulky acids did not improve the ratio, while the use of propionic acid 2 slightly 
decreased the d.r. to 1.87:1.00. 
Table 1: d.r. for compounds in the cyclohexyl series. 
Compound 17 20 22 23 24 25 26 
d.r. 2.14:1.00 1.94:1.00 1.87:1.00 2.01:1.00 2.08:1.00 1.93:1.00 - 
 
The d.r. for compounds 17, 20 and 22 - 26 are shown in Table 1, with the ratio for most 
compounds being 2:1 except for 17 and 22. Complete baseline resolution was not achieved 
during the analysis of compound 23, and therefore the reported ratio of peaks is an 
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approximation of the area under the peaks. Due to the insolubility of 26, HPLC analysis could 
not be performed to establish the d.r. Furthermore, determination of the d.r. using 1H NMR 
spectroscopy for this compound was not accurate because of overlapping of signals.  However 
from the d.r. results we could obtain, a general trend is apparent and it can therefore be 
concluded that use of the chiral N-Boc-phenylalaninal has an effect on diastereoselectivity in 
the Passerini reaction.  
 
Figure 17: Passerini products from derived from cyclohexyl isocyanide. 
After the successful synthesis of the Passerini products utilizing cyclohexyl isocyanide, they 
were then subjected to preparative HPLC in order to isolate individual diastereomers. Only 
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compounds 23 and 26 were not separated due to the lack of baseline resolution for 23 and 
solubility problems for 26. It was observed that for all the separated analogues, the minor 
diastereomer B was less soluble in all solvents tested than the major diastereomer A. It was 
beginning to appear as a trend and was not unexpected, as diastereomers have been shown to 
have different chemical and physical properties. In the characterisation of the separated 
diastereomers, the signals in the NMR spectra for both protons and carbons at positions 2, 3 
and 4 for all the compounds were the most significant and will be discussed in more detail. 
For both diastereomers (A and B) for all the compounds (20 – 26), the protons at H-3 appeared 
as a multiplet integrating for one proton. An interesting observation for compound 20 was the 
signals for the protons at H-10. They appeared as a singlet for 20A at δ 4.03 integrating for 2 
protons and as two doublets at δ 4.18 (J = 14.7 Hz) and at δ 4.12 (J = 14.7 Hz) for 20B 
integrating for two protons. Thus it appears that geminal coupling between H-10 protons 
occurs in one diastereomer but not the other. 
The protons at H-2 appeared as a multiplet at δ 5.30 – 5.10 for 20A, δ 5.26 – 5.07 for 22A, δ 
5.25 – 5.07 for 24A and δ 5.22 – 5.00 for 25AB, in each case integrating for 2 protons due to 
overlapping with a signal from another proton.  The proton-carbon correlation NMR spectra 
(HSQC) for these compounds showed that the second signal is due to an NH proton as there 
was no correlation to a second 13C signal. For the minor diastereomers, the H-2 protons did not 
overlap with the NH signal except in the case of 25B. This is clear evidence of the 
conformational differences between the two diastereomers, and strongly supports the 
assumption that the same diastereomer is formed as a major product in every case. For 20B the 
H-2 proton integrates for 1H and appears as a doublet at δ 5.17 (J = 3.5 Hz), while for 22B, 24B 
and 25B it appears as a multiplet at δ 5.23 – 4.98, δ 5.27 – 5.01 and δ 5.26 – 5.01 respectively.  
In the 13C NMR spectra of the Passerini products, the C-3 signals for the major diastereomer 
appear slightly more upfield than the minor diastereomer. This trend is consistent for all the 
separated diastereomers, while two signals are present in the 13C NMR spectra of unseparated 
compound 23. The same trend is also observed for C-2 in the 13C NMR spectra of these 
compounds (Table 2). 
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Table 2: Chemical shifts for C-2 and C-3 signals. 
Compound 20A 20B 22A 22B 23 24A 24B 25A 25B 
C-3 δ 52.71 53.09 52.31 52.85 53.36, 
52.90 
53.08 53.16 52.96 53.37 
C-2 δ 75.12 75.96 73.19 73.63 74.05, 
73.48 
73.28 73.94 73.43 73.85 
From these results it can be concluded therefore that the signals at δ 52.90 and δ 73.48 for 23 
are due to the major diastereomer whilst the signals at δ 53.36 and δ 74.05 are due to the 
minor diastereomer. High Resolution Mass Spectrometry (HRMS) results for the compounds 
were as expected, and the masses for the separated diastereomers were the same. The 
compounds were also found to have high melting points of between 157 °C – 193 °C. 
The Passerini products (both separated and diastereomeric mixtures) were then subjected to 
the deprotection-acyl migration sequence (Scheme 16) in order to achieve the 1,2-amino-
hydroxyl functionality of the target compounds (Figure 18). In each case the desired product 
was obtained, and whilst the reaction proceeded smoothly, the resolved diastereomers 
required more reaction time to go to completion than the diastereomeric mixture had in 
previous experiments. The reaction was high yielding with overall yields of the reaction ranging 
between 84% and 96%, with the exception of 27A and 27B with yields of 42% and 56% 
respectively. This low yield can be attributed to the fact that the reaction did not go to 
completion as starting material was recovered (≈ 35%). The PADAM products were overall less 
soluble than the Passerini products, possibly owing to the fact that the deprotected product is 
more likely to have an orderly arrangement in the solid state because of the reduced bulky 
groups and a more linear structure. 
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Figure 18: PADAM products for the cyclohexyl series. 
The success of the reaction was confirmed by the appearance of a new O-H signal in the IR 
spectra of the products as shown in Table 3. The signal was not as broad as expected in some 
instances, probably due to the lack of hydrogen bonding due to the possible conformational 
arrangement of the molecule. 
Table 3: Wave number of OH signal in IR spectra of PADAM products of cyclohexyl series. 
Compound 18A 18B 26A 26B 27 28A 28B 29A 29B 30A 30B 31 
cm-1 3350 3386 3347 3390 3278 3341 3303 3274 3279 3404 3399 3269 
It is interesting to note that the O-H signals in the IR spectra for the separated diastereomers do 
not follow a particular sequence, as was observed with H-2 and C-2 signals in the 1H NMR and 
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13C NMR spectra. Once again, the HRMS results for all compounds were as expected. In order to 
ascertain whether racemisation was occurring during the deprotection and acyl migration 
steps, d.r. analysis was performed for diastereomeric mixtures. The ratio of diastereomers did 
not change, and hence we can assume that racemisation did not occur during the two reaction 
steps. The d.r. of compound 17 was 2.14:1.00 and after the deprotection acyl migration 
sequence to afford 18, the d.r. was 2.08:1.00. Similarly, the d.r. of compound 23 was 2.01:1.00 
and after the PADAM sequence to afford 28, the product was found to have a d.r. of 2.00:1.00. 
The previously observed solubility trend of the diastereomers continued with the PADAM 
products. The minor product was less soluble in most solvents, although to a greater extent 
than before. This resulted in the use of different deuturated solvents for NMR spectroscopy, 
making comparison of the chemical shifts for the separated diastereomers difficult. However 
the migration of the acyl functionality was proved by the upfield shift of the signal for the H-2 
protons in the 1H NMR spectrum of each product. In the case of Passerini products, the H-2 
protons appeared in the range of δ 5.00 – 5.30 in the 1H NMR spectra, however in the 
rearranged products, the H-2 proton appears upfield at δ 4.31 – 3.83 for all the analogues.  
For compound 18A, the H-2 signal appears as a multiplet at δ 4.21 – 3.98 integrating for 2 
protons, where the signal overlaps with the H-3 signal. For compound 18B, the H-2 signal 
appears as a doublet at δ 4.17 (J = 3.5 Hz). For compound 27A, the H-2 and H-3 signals are 
overlapping and appear as a multiplet integrating for 2 protons at δ 4.18 – 4.04 whilst for 
compound 27B the H-2 signal is separate appearing at δ 3.90 – 3.83 as a multiplet integrating 
for 1 proton. H-2 and H-3 signals are at δ 4.30 - 4.04 (2H) for the unresolved compound 28. For 
compound 29A the H-2 proton signal does not overlap with other signals and appears as a 
singlet at δ 4.09, whilst for compound 29B the H-2 and H-3 signals are overlapping at δ 4.26 - 
4.18. For compounds 30A and 30B the H-2 protons appear as multiplets at δ 4.09 – 4.02 and δ 
3.98 – 3.91 respectively. The signal due to the H-2 signal for compound 31A and 31B also 
appear as multiplets at δ 4.16 – 4.07 and δ 4.25 – 4.18 respectively, whilst for compound 32 the 
signal also appears as a multiplet at δ 3.98 – 3.90. 
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There is no significant change in the chemical shift of the signal due to H-3 in the 1H NMR 
spectrum after rearrangement, as the structural change occurs three bonds away. In instances 
where the same solvent was used for performing NMR spectroscopic experiments, the C-2 in 
the 13C NMR spectrum for the minor product appears more downfield than the major 
diastereomer, the same trend as was observed for the Passerini products. This was observed 
for compound 29A where the C-2 signal appeared at δ 73.62 and the C-3 signal appeared at δ 
55.49, while for 29B, the C-2 signal appeared at δ 75.20 and the C-3 signal appeared at δ 57.58.      
13C NMR spectra for compounds 31A and 31B were also performed in the same solvent system, 
and the C-2 signals were observed at δ 72.21 and δ 73.23 respectively and the C-3 signals were 
observed at δ 55.38 and δ 56.72. Interestingly the signal due to H-10 in the 1H NMR spectrum 
still appears as a singlet at δ 3.83 for 31A and two doublets at δ 3.96 and δ 3.90, both with a 
coupling constant of 15.0 Hz, for 31B. This shows that despite the acyl migration occurring, the 
protons are still in the same chemical environment for 31A but in different environments for 
31B, which shows geminal coupling. 
Compound 18B was successfully crystallised and an X-ray crystal structure was obtained 
(Appendix 1). From the crystal structure we were able to confirm that this minor diastereomer 
has an S,S configuration. Analysis of the 1H and 13C NMR spectra for the separated 
diastereomers showed that all the major diastereomers display similar chemical shifts and 
splitting patterns, and similarly the minor diastereomers display similar chemical shifts and 
splitting patterns. From this observation it can be concluded that the diastereomeric selectivity 
is conserved throughout the cyclohexyl series. It can therefore be deduced that all minor 
diastereomers have an S,S configuration, whilst the major diastereomer in each case has an S,R 
configuration. The stereochemical integrity at C-3 is maintained throughout the PADAM 
sequence, as previously shown in similar studies.65 
2.6 Synthesis of the xylyl series. 
After the successful synthesis of the cyclohexyl series of analogues, the same approach was 
used for the synthesis of the second series of analogues, by substituting cyclohexyl isocyanide 
(8) with xylyl isocyanide (10) in the Passerini reaction (Scheme 15, page 31). This was done to 
introduce diversity and structural variation in the target library of compounds and to determine 
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whether branched isocyanides had an effect on diastereoselectivity in the Passerini reaction. A 
total of 7 analogues were synthesised (compounds 33 – 39, Figure 19). The reactions were still 
high yielding, with yields ranging between 82% and 99%, except for compound 39 which was 
isolated in a yield of 49%. This low yield was a result of product losses during purification of the 
compound.  
 
Figure 19: Passerini products derived from xylyl isocyanide. 
The solubility of compounds in this series was significantly poorer than that of the previous 
series. Lack of solubility has been identified as one of the major problems of peptidomimetic 
analogues, as such a problem is likely to affect the pharmacokinetics of the compounds.31 
Compound 39 precipitated out of solution as it was being synthesised and all attempts to purify 
the compound by column chromatography or recrystallization were unsuccessful. 
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Table 4: d.r. for compounds 33 -39. 
Compound 33 34 35 36 37 38 39 
D.R 1.88:1.00 1.83:1.00 2.06:1.00 1.88:1.00 2.21:1.00 1.72:1.00 1.75:1.00 
HPLC analysis was performed on all the compounds shown in Figure 19, in order to determine 
the diastereomeric ratio of the products. Due to the insolubility of the compounds a larger 
volume of solvent was used and samples were heated in an attempt to ensure complete 
dissolution prior to performing HPLC analysis. The results of the analysis are shown in Table 4 
and once again indicate a ratio of approximately 2:1 for all products. However, selectivity is 
shown to differ slightly as the carboxylic acids employed in the reaction change. There is a slight 
decrease in selectivity when chloro-acetic acid and N-Boc-phenylalanine are used (compounds 
38 and 39). The d.r. decreases to 1.72:1.00 and 1.75:1.00 as compared to a selectivity of greater 
than 1.80:1.00 observed for the other analogues in this series. Despite this slight change in 
selectivity, it is evident that N-Boc-phenylalaninal still has a greater influence over the 
diastereoselectivity of the Passerini reaction than the carboxylic acid and isocyanide fragments. 
Using a branched isocyanide did not appear to have any influence whatsoever on the 
diastereoselectivity of the Passerini reaction in this series. 
For all the compounds analysed by HPLC, only compound 33 showed baseline separation in the 
chromatogram. It was thus the only compound which could be separated on preparative HPLC 
for collection of the individual diastereomers. Although the solvent system was varied widely, 
no combination tested was able to give adequate separation of compounds 34 – 39 on the 
analytical system. The formation of the products was confirmed by NMR and IR spectroscopy 
and HRMS. IR spectroscopy showed the presence of a strong carbonyl signal from the ester 
functionality of the compounds, as shown in Table 5.   
Table 5: IR spectroscopic C=O stretch signal for xylyl Passerini products. 
Compound 33A 33B 34 35 36 37 38 39 
cm-1 1738 1744 1736 1712 1734 1737 1759 1748 
The HRMS results were also as expected, further confirming that the desired products were 
formed. All expected peaks in the 1H and 13C NMR spectra were observed with the 
characteristic C-2, C-3 and C-4 signals identified (Table 6). The proton spectra showed the 
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presence of both rotamers and diastereomers. The integration ratio of various signals in the 1H 
NMR spectra was not the same as the d.r. obtained using HPLC, as evidenced by compounds 34 
and 35. This apparent anomaly points to rotamer effects, a common observation in 
peptidomimetic compounds.  
Table 6: 1H and 13C NMR Chemical shifts for xylyl products. 
 H-4 H-3/C-3 H-2/C-2 
 1H NMR 1H NMR 13C NMR 1H NMR 13C NMR 
33A δ 2.99 – 2.80 (2H, m) δ 4.54 – 4.38 (1H, m) δ 53.19 δ  5.40 – 5.18 (1H, m) δ 74.14 
 
33B δ 3.13 (1H, dd, J = 
14.1, 6.0 Hz), 3.06 – 
2.88 (1H, m) 
 
δ 4.43 – 4.34 (1H, m) δ 53.44 δ 5.36 (1H, d, J = 3.9 
Hz) 
δ 74.93 
34 δ 3.18 – 3.09 (0.54H, 
m, H-4a), 3.05 – 2.80 
(1.5H, m, H-4a and H-
4b) 
 
δ 4.52 – 4.35 (1H, m) δ 53.44, δ 
53.29 
 
δ 5.43 – 5.28 (0.55H, 
m, H-2), 5.32 (0.56H, s, 
H-2) 
δ 74.77, 
δ 73.91 
35 δ 3.09 (0.31H, dd, J = 
14.0, 5.4 Hz, H-4a), 
2.99 – 2.52 (1.72H, m, 
H-4a & 4b) 
 
δ 4.54 – 4.29 (1H, m) δ 53.29 δ 5.53 – 5.23 (1H, m) δ 74.77, 
δ 73.92 
36 δ 3.22 – 2.64 (2H, m, 
H-4) 
δ 4.53 – 4.32 (1H, m) δ 53.55, δ 
53.42 
δ 5.59 – 5.26 (1H, m) δ 74.57, 
δ 73.64 
 
37 δ 3.20 – 2.68 (2H, m) δ 4.50 – 4.32 (1H, m) δ 53.57, δ 
53.42 
δ 5.45 – 5.27 (1H, m) δ 74.53, 
δ 73.57 
 
38 δ 3.23 – 2.62 (2H, m) δ 4.60 – 4.35 (1H, m) δ 55.84, δ 
53.09 
δ 5.46 – 5.22 (1H, m) δ 76.46, 
δ 75.51 
 
39 δ 3.07 – 2.79 (2H, m) δ 4.43 – 4.23 (1H, m) Not 
confirmed 
by HSQC 
δ 5.22 – 5.12 and 5.06 
– 4.94 each 1H 
δ 76.19, 
δ 74.98 
 
 
It was noteworthy that the 13C NMR spectroscopic signals for C-2 and C-3 for 33B appeared 
slightly downfield compared to those of the major product 33A. This suggests that the same 
conformational diastereomer is formed as the major product in the xylyl series as was observed 
for the cyclohexyl isocyanide series. The 1H NMR spectroscopic signals for H-4 in each case are 
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not as clearly separated as would be expected for diastereomeric protons. The presence of the 
diastereomers in the unseparated compounds is clearly evident because there are two signals 
for C-2 in the 13C NMR spectrum for each of the unseparated compounds. For compound 34, 
the H-2 signal in the 1H NMR at δ 3.18 – 3.09 correlates to the C-2 signal at δ 73.91 in the HSQC 
spectrum. This suggests that these signals are for the minor diastereomer. Splitting patterns are 
distorted because of the likely presence of rotamers and the mixture of diastereomers. 
 
Figure 20: PADAM products for xylyl series. 
After the successful synthesis of the Passerini products in this series, we were in a position to 
subject them to the deprotection acyl-migration sequence. The products of the sequence are 
shown in Figure 20. The reactions proceeded as expected with yields ranging from 70% to 96% 
and the HRMS results were as expected. Solubility of the compounds remained a problem, with 
compounds either dissolving only in acidic solution or heated DMSO. However, despite this 
challenge, NMR spectroscopy was performed for all the compounds.  
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For compound 40A IR spectroscopy showed the disappearance of the carbonyl signal at 
1738 cm-1 for the ester functionality and appearance of an additional amide carbonyl signal. 
The 2 carbonyl signals were visible at 1658 cm-1 and 1617 cm-1.  In the 1H NMR spectrum the 
aromatic protons for the mono substituted phenyl ring appeared as two multiplets at δ 7.25 – 
7.17 (4H) and δ 7.13 – 7.08 (1H). This splitting pattern is different to what was observed for the 
other products in this series where all the aromatic protons appeared together as one 
multiplet. The aromatic protons of the xylyl ring appeared as a multiplet at δ 7.00 – 6.93. The 
overlapping of the H-3 proton signal and NH was still observed with compound 40A, where the 
signal appears at δ 4.52 – 4.46 as a multiplet integrating for 2 protons. The H-2 proton signal 
shifts upfield as expected and appears as a doublet at δ 4.06 (J = 2.2 Hz). The multiplicity of the 
signal indicates that it has the proton at H-3 as its neighbour and there is no coupling to OH. 
The two H-4 protons are clearly in two different environments due to the two observed signals, 
one at δ 2.89 (dd, J = 13.4, 8.1 Hz) and the other at δ 2.82 (dd, J = 13.3, 7.4 Hz) each integrating 
for 1 proton. The Boc signal at δ 1.43 – 1.10 disappeared, showing that N-deprotection had 
occurred. The aromatic methyl protons appeared as a singlet at δ 2.06 integrating for 6 protons 
whilst the H-10 signal appeared as a singlet at δ 1.80 integrating for 3 protons. 
In the 13C NMR spectrum, the two expected carbonyl signals appeared at δ 172.74 and δ 171.44 
and all the expected aromatic carbons were accounted for. Of significance was the 
disappearance of the Boc carbonyl signal at δ 154.94 and the appearance of the secondary 
alcohol carbon (C-2) at δ 71.31. The C-3 signal appeared at δ 53.74. The aromatic methyl carbon 
atoms (C-13 and C-13’) appeared as one signal at δ 17.09 and correlate with the proton signal 
at δ 2.06 in the HSQC spectrum. 
Fortunately, NMR spectroscopic analysis for 40B could be performed in the same solvent as 
40A, and hence the chemical shifts are directly comparable. A difference was observed with the 
phenyl protons which appeared as a multiplet at δ 7.13 – 7.03 integrating for 5 protons as 
compared to the separated signals (4H and 1H) observed for 40A. The H-4 protons appeared as 
a multiplet at δ 3.02 – 2.88 and the remainder of the signals were the same as for 40A. In the 
13C NMR spectrum, the difference in chemical shifts was evident with the C-3 signal observed at 
δ 54.11 and δ 53.75 and the C-2 signal at δ 73.58. These observed chemical shifts are consistent 
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with the observed trend for the Passerini diastereomers. However, there were two signals 
for C-3 (as above) and C-13 (δ 17.29 and δ 17.09) for compound 40B, and this was attributed to 
rotamers. It is noteworthy that the rotamers were only present in the minor diastereomer. 
The spectra obtained for compound 41 derived from propionic acid 2 were comparable to 
those of compound 40, with the only difference in the 1H NMR spectrum being the extra CH2 
signal which appeared as an overlapping signal with the H-14 signal at δ 2.12 – 1.99 integrating 
for 8 protons. The rest of the signals for compound 41 were as expected, with the presence of 
the diastereomers being confirmed by of two H-2 proton signals in the 1H NMR spectrum. These 
signals appeared as multiplets at δ 4.07 – 3.97 for the major diastereomer and δ 4.23 – 4.17 for 
the minor diastereomer, in a ratio of approximately 2.7:1.0. The diastereomeric ratio calculated 
using 1H NMR spectroscopy (2.7:1.0) is much higher than that calculated using HPLC (2:1). HPLC 
is usually a more accurate method for determining d.r., however in this case complete baseline 
separation was not achievable and hence the ratios are only an approximate value. The 
complication presented by the presence of rotamer made using the NMR method for 
calculating d.r. ill-advised. In the 13C NMR spectrum, C-2 gave rise to two signals for the two 
diastereomers at δ 74.30 and δ 71.94 whilst C-3 appeared at δ 53.70. 
Similarly for compound 42, C-2 appeared as two signals at δ 74.46 and δ 71.96 whilst C-3 
appeared at δ 53.72 and δ 53.67. The H-2 proton gave rise to two doublets in the 1H NMR 
spectrum for the two diastereomers; one at δ 4.20 (J = 3.3 Hz) for the major diastereomer and 
the other at δ 4.03 (J = 2.5 Hz) for the minor diastereomer. The ratio of the two signals was 
approximately 2.7:1.0 which was comparable to the ratio of signals seen for compound 41. 
For compound 43 derived from pivalic acid 4, the H-2 and H-3 signals overlapped in the 1H NMR 
spectrum giving rise to a multiplet at δ 4.56 – 4.22, whilst the H-4 signals appeared separate as 
two multiplets at δ 3.38 – 3.13 and δ 3.12 – 2.81. In the 13C NMR spectrum, the expected C-2 
signals appeared at δ 75.54 and δ 73.84, whilst the C-3 signals appeared at δ 57.58 and δ 55.57 
for the two diastereomers. 
Significant doubling of most signals in the 1H NMR spectrum was observed for compound 44 
derived from t-butyl acetic acid 5, because the tert-butyl group causes conformational 
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differences due to its steric bulk. One of the NH signals appeared as two singlets at δ 8.45 for 
the major diastereomer, and δ 8.25 for the minor diastereomer. Aromatic methyl protons 
appeared as a multiplet at δ 2.29 – 2.08 integrating for 6 protons. The tert-butyl protons 
appeared as two singlets at δ 1.10 and δ 0.85, with the ratio of protons of approximately 1:2. In 
the 13C NMR spectrum, the C-3 signals appeared as expected at δ 56.59 and δ 53.86 and the C-2 
signals at δ 75.87 and δ 73.67 for the two diastereomers.  
Compounds 45 and 46 gave rise to NMR spectra with similar patterns to those observed for 
compounds 41 – 44. The N-Boc deprotection occurred at both NH’s for compound 46, and this 
was confirmed by the disappearance of all Boc signals in the 1H NMR spectrum and the 
appearance of a broad NH2 signal at δ 1.63 integrating for 2 protons. The migration of the 
phenylalanine component shows that this approach is versatile and can be used with a wide 
range of carboxylic acids, including amino acids.  
2.7 Synthesis of the adamantyl series 
In order to introduce further structural diversity in our library of compounds, we utilised 
adamantyl isocyanide 11 as one of the components in the Passerini reaction. 
 
Scheme 20: Reagents and conditions: (i) excess HCOOH, excess Ac2O (ii) excess POCl3 and Et3N, dry 
CH2Cl2, 0 °C, 75%. 
This approach began with the synthesis of adamantyl isocyanide (11) which is readily prepared 
from adamantylamine as shown in Scheme 20. Although adamantyl isocyanide is commercially 
available, it is very expensive and we chose to prepare it ourselves.42 The formylation step 
proceeded smoothly and the identity of the product was confirmed by 1H NMR spectroscopy by 
the presence of the formyl proton signal at δ 8.38. The formylated adamantyl product was used 
in its crude form in the subsequent dehydration step without further purification. The work up 
of the dehydration step must be performed with care to avoid product losses. 
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Interestingly, signals for both the isocyanide carbon C-1 and C-2 appear as triplets in the 13C 
NMR spectrum. Crews et al. report the same observation and explained this phenomenon as a 
result of coupling between 13C and 14N as the latter is also an NMR-active nucleus, but it has I = 
1 (not I = 1/2, like proton).
66 This means there are three possible energy levels when under the 
influence of a magnetic field. The electronic symmetry about the isocyanide 14N nucleus results 
in a slow quadrupolar relaxation and thus a triplet is observed with coupling constants of 
approximately 5 Hz. Both the C-1 and C-2 carbons experience this effect giving rise to triplet 
signals centred at δ 151.59 (J = 5.2 Hz) and δ 54.22 (J = 11.3 Hz) respectively in the 13C NMR 
spectrum. The yield was reasonable at 75% and the product had the characteristic pungent 
isocyanide smell. 
With the adamantyl isocyanide in hand we were now in a position to prepare an adamantyl 
series of Passerini products using N-Boc-L-phenylalaninal and the range of carboxylic acids 
shown in Figure 11 (page 21).   
Synthesis of the compounds in this series (Figure 21) was successful and the reactions 
proceeded relatively faster than the cyclohexyl isocyanide and xylyl isocyanide series. Product 
yields were all above 80% and all the compounds were readily soluble in CH2Cl2 and CHCl3. The 
High Resolution Mass Spectrometry results were as expected for both the diastereomeric 
mixtures and the separated diastereomers. The melting points of these compounds were 
generally high, with values above 150°C. The IR spectra were similar to those seen for the 
previously prepared analogues, with the strong ester carbonyl signal between 1718 cm-1 and 
1777 cm-1 being indicative of the presence of the desired ester functionality. 
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Figure 21: Passerini products derived from adamantyl isocyanide. 
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Table 7: d.r. for compounds 47 – 53. 
Compound 47 48 49 50 51 52 53 
D.R 1.96:1.00 1.75:1.00 1.95:1.00 2.12:1.00 2.01:1.00 1.97:1.00 2.49:1.00 
The d.r. for the compounds was once again approximately 2:1 with the exception of 
compounds 48 and 53 (Table 7). As was observed for the cyclohexyl and xylyl series prepared 
previously, the analogues synthesised with propionic acid (2) has the lowest d.r. ratio in the 
series (compound 48). Use of N-Boc-L-phenylalanine (7) as the carboxylic acid in the reaction 
enhanced the formation of the major diastereomer increasing the d.r. to approximately 2.5:1 
(compound 53). Although the change is small, this result sheds some light on how to influence 
the diastereoselectivity of the Passerini reaction. Baseline separation of diastereomers by HPLC 
was achieved for all the compounds on the analytical system. This resulted in all of the 
compounds being separated and collected as single diastereomers with purity of > 99% using 
preparative HPLC. All the comparable and distinct signals in the 1H NMR and 13C NMR spectra 
are shown in Table 8. 
Table 8: Chemical shifts for the Passerini products of the adamantyl series. 
 H-4 H-3/C-3 H-2/C-2 
 1H NMR 1H NMR  13C 
NMR 
1NMR 13NMR 
47A δ 2.82 (2H, d, J = 7.3 Hz) 
 
δ 4.34 – 4.23 (1H, m) δ 52.19 δ 5.08 – 4.97 (1H, m) δ 73.77 
47B δ 2.93 (2H, d, J = 7.8 Hz) 
 
δ 4.33 – 4.18 (1H, m) δ 53.36 δ 5.22 – 5.04 (1H, m) δ 74.48 
48A δ 2.82 (2H, d, J = 7.3 Hz) δ 4.35 – 4.23 (1H, m) δ 52.96 
 
δ 5.11 – 5.00 (1H, m) δ 73.54 
48B δ 2.94 (2H, d, J = 7.6 Hz) δ 4.30 – 4.19 (1H, m) δ 53.38 δ 5.00 – 4.92(1H, m) δ 74.27 
 
49A δ 2.82 (2H, d, J = 7.4 Hz) δ 4.33 – 4.22 (1H, m) δ 52.98 δ 5.11 – 5.02 (1H, m) δ 73.48 
 
49B δ 2.93 (2H, d, J = 7.5 Hz) δ 4.31 – 4.19 (1H, m) δ 53.36 δ 5.00 – 4.93 (1H, m) δ 74.14 
 
50A δ 2.89 – 2.73 (2H, m) δ 4.37 – 4.18 (1H, m) δ 53.18 δ 5.18 – 5.03 (1H, m) δ 73.29 
 
50B δ 3.02 – 2.87 (2H, m) δ 4.32 – 4.18 (1H, m) δ 53.27 δ 4.97 – 4.90 (1H, m) δ 74.07 
 
51A δ 2.90 – 2.74 (2H, m) δ 4.34 – 4.18 (1H, m) δ 53.04 δ  5.14 – 5.03 (1H, m) δ 73.50 
 
51B δ 2.93 (2H, d, J = 7.6 Hz) δ 4.29 – 4.17 (1H, m) δ 53.42 δ 4.99 – 4.88 (1H, m) δ 73.92 
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52A δ 2.85 (2H, d, J = 7.3 Hz) δ 4.39 – 4.30 (1H, m) δ 52.77 δ 5.16 – 5.06 (1H, m) δ 75.01 
 
52B δ 3.05 – 2.89 (2H, m) δ 4.35 – 4.25 (1H, m) δ 53.20 δ 5.14 – 5.01 (1H, m) δ 75.94 
 
53A δ 3.13 – 2.95 (2H, m) δ 4.25 – 4.12 (2H, m) 
overlapped with H-6 
 
* δ 5.14 – 5.02 (1H, m) δ 74.27 
53B δ 3.27 – 3.16 (1H, m) 
and 3.16 – 2.99 (1H, m) 
could not be 
confirmed by HSQC 
 
* δ 5.20 – 5.07 (1H, m) δ 75.74 
*Could not be confirmed by HSQC. 
The most fascinating trend in these results is the consistency in chemical shifts and multiplicity 
of signals. This observation also confirmed that the stereochemical identity of the products of 
the Passerini reaction were the same for the major and minor diastereomer in this series of 
analogues. The H-2 proton signal in the 1H NMR spectra appeared as multiplets for all 
compounds in this series. Restricted rotation about the amide bonds is the likely contributing 
factor for this observation. The coupling constant for the signal due to H-4 was always smaller 
for the major diastereomers (J = 7.3 - 7.4) than the minor diastereomers (J = 7.5 - 7.8). This also 
strongly suggests that therefore similar conformational arrangements at position C-2 and C-3 
for the major diastereomers.  
The now established trend in the 13C NMR spectra where the C-2 and C-3 signals for the major 
diastereomer are found slightly upfield when compared to the minor diastereomer, is true for 
all the analogues in this series. By analogy with the previous series, the major diastereomer has 
the S,R configuration and the minor diastereomer has the S,S configuration. The characteristic 
H-10 1H NMR spectroscopic signal for 52A was evident at δ 4.00 as a singlet integrating for 2 
protons and for 52B the signal appeared as two doublets integrating for 2 protons at δ 4.15 and 
δ 4.09 with J = 14.8 Hz, which is the same trend as was observed for the similar analogues 20A 
and 20B. Other chemical shifts in the 1H and 13C NMR spectra for the analogues in this series 
were as expected. 
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Figure 22: PADAM products for adamantyl series. 
The deprotection and acyl migration step was complete in a much shorter time than was 
observed for the other series of analogues. The products were isolated in high yields of 
between 70 - 100% (Figure 22). Confirmation of formation of the desired alcohol in each case 
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was confirmed by the appearance of a broad OH signal in the IR spectrum as denoted in 
Table 9.  
Table 9: IR OH signals for Adamantyl PADAM products. 
 54A 54B 55A 55B 56A 56B 57A 57B 58A 58B 59A 59B 60A 60B 
cm
-1 
3345 3357 3342 3362 3374 3360 3301 3318 3346 3301 3320 3313 3311 3313 
               
The confirmation of the formation of the desired products was further obtained from the 1H 
and 13C NMR spectra, with the characteristic signals observed as with the previous series. The 
NMR spectroscopic data is shown in Table 10. 
Table 10: Chemical shifts for adamantyl PADAM products 
 H-4 H-3/C-3 H-2/C-2 
 1H NMR 1H NMR  13C NMR 1NMR 13NMR 
54A δ 3.10 (1H, dd, J = 
13.7, 6.2 Hz) and 2.92 
(1H, dd, J = 13.7, 9.2 
Hz) 
 
δ 4.14 – 4.01 (1H, m) δ 55.91 δ 3.97 (1H, dd, J = 6.8, 
3.4 Hz) 
δ 73.22 
54B δ 3.10 – 2.99 (1H, m) 
and 2.99 – 2.88 (1H, 
m) 
δ 4.26 – 4.13 (1H, m) δ 57.39, 
δ 57.29, 
δ 57.24 
 
δ 4.13 – 4.06 (1H, m) δ 74.78, 
δ 74.68 
55A δ 3.08 (1H, dd, J = 
13.8, 6.2 Hz) and 2.97 
(1H, dd, J = 13.8, 9.3 
Hz) 
 
δ 4.19 – 4.09 (1H, m)  δ 55.74 
 
δ 4.01 – 3.92 (1H, m) δ 73.52 
55B δ 3.11 (1H, dd, J = 
14.1, 10.0 Hz,) and 
2.99 (1H, dd, J = 14.1, 
5.6 Hz) 
 
δ 4.21 – 4.14 (1H, m) δ 57.91 δ 4.14 – 4.09 (1H, m) δ 75.13 
56A δ 3.11 (1H, dd, J = 
13.8, 6.2 Hz) and 2.99 
– 2.90 (1H, m) 
 
δ 4.20 – 4.09 (1H, m) δ 55.73 δ 4.01 – 3.93 (1H, m) δ 73.49 
56B δ 3.13 (1H, dd, J = 
13.8, 6.2 Hz) and 2.98 
– 1.97 (1H ,m) 
 
δ 4.26 – 4.15 (1H, m) δ 56.48 δ 3.99 (1H, d, J = 6.5 
Hz) 
δ 74.24 
57A δ 3.12 – 2.96 (2H, m) 
 
δ 4.27 – 4.16 (1H, m) δ 55.46 δ  4.02 – 3.95 (1H, m) δ 73.85 
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57B δ 3.18 (1H, dd, J = 
14.2, 10.5 Hz) and 3.05 
(1H, dd, J = 14.1, 5.4 
Hz) 
δ 4.24 – 4.15 (1H, m) δ 57.59 δ 4.14 – 4.09 (1H, m) δ 75.28 
58A δ 3.16 (1H, dd, J = 
13.8, 6.4 Hz) and 2.92 
(1H, dd, J = 13.8, 9.3 
Hz) 
 
δ 4.24 – 4.15 (1H, m) δ 55.59 δ  4.00 – 3.92 (1H, m) δ 73.43 
58B δ 3.14 (1H, dd, J = 
14.3, 10.3 Hz) and 3.04 
(1H, dd, J = 14.2, 5.3 
Hz) 
 
δ 4.27 – 4.15 (1H, m) δ 57.77 δ 4.15 – 4.08 (1H, m) δ 75.36 
59A δ 3.08 (1H, dd, J = 
13.7, 6.1 Hz) and 2.87 
(1H, dd, J = 13.5, 8.9 
Hz) 
 
δ 4.36 – 4.24 (1H, m) δ 55.35 δ 4.01 (1H, s, H-2) δ 72.26 
59B δ 3.09 – 2.95 (2H, m) 
 
δ 4.34 – 4.24 (1H, m) δ 57.41 δ 4.21 – 4.14 (1H, m) δ 73.97 
60A 3.24 – 3.04 (2H, m, 
overlapping with H-
7a), 3.04 – 2.91 (1H, 
m, H-4b) 
 
δ  4.34 – 4.23 (1H, m) * δ 4.05 – 3.99 and 3.94 
– 3.90 (1H, 2xm) 
δ 73.38 
60B 3.14 – 3.05 (2H, m, 
overlapping with H-
7a), 2.97 (1H, dd, J = 
14.0, 5.1 Hz, H-4b) 
 
δ 4.24 – 4.13 (2H, m) 
overlapping with H-2  
δ 57.51 δ 4.24 – 4.13 (2H, m) 
overlapping with H-3 
δ 74.93 
*Could not be confirmed by HSQC. 
The trends observed in the 1H and 13C NMR spectra for the PADAM products of the cyclohexyl 
and xylyl series of analogues continued in this series without any exceptions. The chemical 
shifts of the 1H and 13C signals for the major products were slightly more upfield than those of 
the minor products. In the 1H NMR spectra, the chemical shift for the proton at H-2 shifts 
upfield when compared to the chemical shift for H-2 of the Passerini products. This is because 
H-2 is more deshielded by the ester functional group in the Passerini product, when compared 
to the secondary alcohol of the PADAM product. The H-3 signal remained virtually unchanged, 
although the splitting pattern was not as expected. This might be due to rotamers resulting 
from restricted rotation about the amide bonds. This phenomenon was more pronounced for 
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54B which showed three signals for C-2 and two signals for C-3 in the 13C NMR spectrum. Just as 
was observed in the cyclohexyl series, the rotamer effect is mainly observed in the NMR spectra 
for minor diastereomers. Compound 60A also had two H-2 signals with a ratio of 7:1 which 
appeared as multiplets at δ 4.05 – 3.99 and δ 3.94 – 3.90 in the 1H NMR spectrum. Both these 
signals correlated to the signal at δ 73.38 in the 13C NMR spectrum, proving that the signals 
result from the same proton. The splitting pattern observed for the H-4 protons in the 1H NMR 
spectrum clearly illustrated the diastereotopic nature of these protons because they couple to 
one another. 
It was very difficult to assign the configuration based on the splitting patterns of the proton at 
the newly formed stereogenic centre, since the splitting pattern was uneven and inconsistent in 
the spectra. Only the crystal structure would be able to unequivocally prove the configuration 
of the diastereomers. We were therefore delighted by the successful crystallization of 55A as it 
meant that we were able to obtain a crystal structure from two different series of analogues. 
This time we were able to crystallise the major diastereomer, and the configuration was 
confirmed to be the R,S configuration (Figure 23). From this structure it can therefore be seen 
that the integrity of the stereogenic centre in the starting aldehyde is maintained throughout 
the reaction sequence. 
 
Figure 23: X-ray crystal structure for 55A (data in appendix I). 
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2.8 Synthesis of phenylalanine isocyanide series. 
 
Scheme 21: Reagents and Conditions:(i) excess HCOOH + Ac2O (ii) excess POCl3 + Et3N, dry CH2Cl2, 0 °C, 
78%. 
To test the effect of chiral isocyanides on the stereochemical outcome of the Passerini reaction, 
chiral isocyanides were synthesised. We chose to use N-Boc-L-phenylalanine derived from the 
naturally occurring amino acid, in our first synthesis of a chiral isocyanide as it was readily 
available (Scheme 21). To this end, Boc-phenylalanine was converted to the Weinreb amide 14, 
as we planned to use the Weinreb amide functionality in a post PADAM modification using 
Grignard reagents. Subsequent N-deprotection and formylation was completed in one step, 
yielding the desired compound 14a which was used crude in the dehydration step to afford the 
isocyanide 12 as an oil in a yield of 81%. This isocyanide was less pungent in odour than the 
simpler isocyanides used before.  
Formation of the desired product was confirmed by IR spectroscopy due to the presence of a 
strong sharp signal at 2143 cm-1 characteristic of the isocyanide triple bond. In the 1H NMR 
spectrum, the loss of the formyl and NH signals was also observed. The characteristic C signal 
for the isocyanide carbon was also clearly visible at δ 159.28 in the 13C NMR spectrum. The 
triplet signal that we had observed for the isocyanide carbon in the 13C NMR spectrum for 
adamantyl isocyanide was not observed for L-phenylalanine isocyanide. 
L-phenylalanine isocyanide 12 was then used as a starting material in the synthesis of a new 
series of analogues using the Passerini reaction (Scheme 15). All the compounds prepared using 
12 are shown in Figure 25 (compounds 61 – 63). The numbering of atoms was kept constant at 
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the core (C-1 to C-4) but was changed for the other atoms for the purpose of discussion. 
 
Figure 24: Passerini products for phenylalanine isocyanide series. 
The first notable property about this series of compounds was the high solubility of all the 
compounds when compared to the previously synthesised cyclohexyl, xylyl and adamantyl 
series. The melting points were also lower when compared to the other analogues, with values 
of less than 160 °C while HRMS results were as expected (Table 11). 
Table 11: Melting points, d.r. and HRMS results for compounds in the phenylalanine series. 
Compound 61 62 63 
 
D.R 1.52:1.00 1.34:1.00  
 
m.p./°C  124 - 125 159 - 160 106 – 107 
 
Calculated HRMS 528.2710 542.2866 584.3336 
 
Found HRMS 528.2710 542.2868 584.3338 
 
The d.r. of the compounds was also lower on average, with the largest ratio of approximately 
1.5:1.0 observed for compound 61. Once again the analogue synthesised using propionic acid, 
compound 62, had a lower d.r. of 1.34:1.00 as compared to 1.52:1.00 for compound 61. 
Although the d.r. values were lower than previously obtained we now had evidence that 
introduction of a chiral isocyanide could change the d.r. of the products formed. Ideally we 
would choose to optimise the d.r. in favour of one diastereomer by using an isocyanide derived 
from unnatural phenylalanine and this will be subject to future work. In this way we would 
hope to investigate the use of matched aldehyde and isocyanide rather than the mismatch 
observed in these examples. 
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Formation of compound 61 was confirmed by 1H and 13C NMR spectroscopy. The phenyl 
protons were observed as a multiplet at δ 7.40 – 6.99 integrating for 10 protons while the 
signals for the H-3 and H-8 protons overlapped and appeared as a multiplet at δ 4.46 – 4.15. 
The methoxy protons H-11 appeared as a multiplet as well at δ 3.83 – 3.58. The multiplet signal 
observed is due to the diastereomeric signals being closely related and not being resolved into 
two distinct singlets. The presence of diastereomers is also evident in the 13C NMR spectrum, 
where there are 8 signals for the four carbonyl carbon atoms present in the compound at δ 
171.23, δ 170.88, δ 169.35, δ 168.92, δ 167.55, δ 166.77, δ 155.40 and δ 154.84, with the last 
two signals belonging to the Boc C=O of each diastereomer. The C-2 signals are also present at 
δ 74.35 and δ 73.68. The signals for compound 62 were as expected with the characteristic C-2 
signals being observed at δ 74.19 and δ 73.51 in the 13C NMR spectrum. 
 
Figure 25: HPLC chromatogram for compound 63. 
Surprisingly, synthesis of compound 63 appeared to be selective as only one peak was visible in 
the HPLC chromatogram as shown in Figure 25. 
Product peak 
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The presence of one diastereomer was also confirmed by the 13C NMR spectrum in which only 
one C-2 signal was visible at δ 73.21. The doubling up of the 13C NMR spectroscopic signals 
observed previously with the other analogues was not evident in the 13C NMR spectrum of 
compound 63. What could not be established was whether this observation was due to 
selectivity in the reaction or whether it was due to the unanticipated ability to separate the 
compounds during column chromatography. Unfortunately the determination of D.R was only 
performed after purification by column chromatography and not to track the progress of the 
reaction. This meant that formation of the other diastereomer could not be confirmed. The low 
yield obtained suggests that separation of diastereomers occurred during purification. This may 
be the case, as we would expect a higher yield of the single product if the reaction had been 
selective. Due to time constraints, the reaction was not repeated in order to confirm this 
hypothesis, but this will be considered for future work.  
During the research we came across another method for the Passerini reaction which suggested 
that, the reaction’s selectivity was influenced by thermodynamic factors. Baretto et al.  
reported loss of selectivity of the Passerini reaction when equimolar amounts of starting 
material were allowed to react under microwave conditions.67  
 
We decided to synthesise compound 64 to verify this suggestion. The expected product was 
recovered in a good yield of 83%, with a d.r. of 1.00:0.93 (Figure 26). Unfortunately because of 
the unavailability of the starting material, the reaction could not be repeated using 
conventional method. However, to test the results of the microwave reaction compound 17 
was synthesised again under microwave conditions. The resulting d.r. was 1:1 as compared to 
the 2:1 previously obtained when conventional heating was used. 
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Figure 26: HPLC chromatogram for compound 64. 
These results show that the probable pathways for the formation of the two diastereomers 
become equally possible when sufficient energy is provided to the reaction, indicating that the 
diastereoselectivity observed is due to an energy difference between the two pathways. One of 
the pathways is more favourable because it requires less activation energy. Although only two 
compounds were synthesised in our laboratories using microwave irradiation, we obtained 
similar results to those reported before by others though they prepared different compounds.67 
Compounds 61, 62 and 64 were then subjected to the full PADAM sequence affording products 
65 - 67 (Figure 27), pending further investigation into the results obtained for compound 63.  
Product peaks 
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Figure 27: PADAM products of the phenylalanine series. 
The NMR spectroscopic data for both compounds 65 and 66 indicated the presence of only one 
diastereomer although the starting material was a mixture of diastereomers. For compound 65 
there was a remarkable difference in the chemical shifts of the signals for the H-3 proton and 
the H-8 proton in the 1H NMR spectrum. The H-3 proton signal appeared as a multiplet at δ 4.23 
– 4.09, whilst the H-8 proton signal appeared as a singlet at δ 5.14. The H-9 protons gave rise to 
two signals, with one signal overlapping with the H-4 and H-10 signal at δ 3.23 – 2.98 which 
appeared as a multiplet and the other signal appearing as a doublet of doublets at δ 2.91 with 
coupling constants of 13.7 Hz and 7.7 Hz and integrating for one proton. There was only one 
signal in the 13C NMR spectrum for C-2 which appeared at δ 73.40 and similarly one signal for C-
3 visible at δ 55.95. There were also only three carbonyl signals, as expected in the spectrum of 
a single diastereomer. The deprotection-acyl migration step has been shown to be high yielding 
for the previous series of analogues, but in this instance, the yield was only 53%, which suggests 
that we had only isolated the major diastereomer from the reaction.  
The same signal pattern observed for compound 65 was also observed for compound 66. In the 
1H NMR spectrum, the H-3 signal appeared as a multiplet at δ 4.25 – 4.13 and the H-9 signals 
also appeared as a multiplet as δ 5.24 – 5.10. The H-4, H-10 and H-11 signals overlapped and 
appeared as a multiplet at δ 3.21 – 2.85 integrating for 7 protons. HSQC correlation confirmed 
the multiplet to be due to the H-4, H-10 and H-11 protons. In the 13C NMR spectrum, there 
were single signals for C-3 at δ 55.56 and for C-2 at δ 73.35. The yield for the deprotection-acyl 
migration step was also low at 54% and this strongly suggests the isolation of only one 
diastereomer. The chemical shift of the C-2 and C-3 signals in the 13C NMR spectrum, when 
compared with the separated diastereomers of previously prepared series, suggests that the 
diastereomer recovered has the S,R configuration.  
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By comparison compound 67 did not show the exclusive presence of one diastereomer as there 
were signals for both diastereomers in the NMR spectra particularly in the 13C NMR spectrum. 
There were two signals for C-2, one at δ 74.65 (minor diastereomer) and the other at δ 73.14 
(major diastereomer). The yield for the product was 62%, which is slightly higher than the yield 
obtained observed for the other two compounds in this series. 
These findings suggest that separation of the diastereomers occurred during column 
chromatography, rather than during the reaction. However, the presence of the two 
diastereomers was not clearly visible on TLC for compounds 65, 66 or 67. To verify these 
findings the reactions will have to be repeated, but due to time constraints this was not done, 
and will be considered for future work 
2.9 Synthesis of the glucose isocyanide series. 
The use of a chiral isocyanide derived from phenylalanine in the Passerini reaction showed a 
slight effect on the diastereoselectivity of the reaction, and this finding had to be probed 
further. To verify whether the selectivity of the reactions could further be influenced by the use 
of chiral isocyanides, glucose isocyanide (13) which contains multiple stereogenic centres and is 
sterically hindered, was synthesised (Scheme 22).68 
 
Scheme 22: Reagents and Conditions:(i) 1 eq Na metal, 4 equiv methyl formate, MeOH, reflux 
overnight (ii) Ac2O, pyridine (iii) Excess POCl3, Et3N, dry CH2Cl2, 0 °C, under N2, 59%. 
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IR spectroscopy confirmed the formation of the isocyanide by the presence of a characteristic 
isocyanide triple bond signal at 2153 cm-1. Typically, the synthesis of glucose isocyanide 13 is 
complicated by the formation of anomers, which are usually separated before the final 
dehydration step. However, in our synthesis, the separation was unsuccessful and a mixture of 
anomers was recovered. This was evident in the 13C NMR spectrum where two signals for the 
anomeric carbon (C-1) were observed, one at δ 91.23 and the other at δ 88.37. In the 1H NMR 
spectrum there was also evidence of the two anomers with the presence of two anomeric 
proton signals. Both of the signals appeared as doublets, one at δ 6.41 with J = 3.6 Hz for the 
major anomer and the other at δ 5.81 with J = 8.5 Hz for the minor anomer. The major isomer 
was determined to be for the equatorial product (β), because the coupling constant of 3.6 Hz 
corresponds to that expected for an equatorial proton. The ratio of the anomers was calculated 
to be 3:1. Despite the isocyanide being isolated as an anomeric mixture, it was used as such in 
the Passerini reaction with the hope that the products arising from the different anomers 
would be separable either by column chromatography or cystallisation. 
A total of 5 compounds (68 – 69) were synthesised using this isocyanide, as shown in Figure 28.   
 
 
Figure 28: Passerini products for glucose isocyanide series. 
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The unoptimised yields for the reaction were varied, ranging from 28% to 99%. The product 
identity in each case was confirmed by 1H and 13C NMR spectroscopy. There was significant 
doubling up of peaks in the 13C NMR spectra of the products, and the characteristic C-2 and C-3 
signals could not be easily distinguished. It was interesting to note that compound 69 
synthesised using propionic acid (2), had a less complicated spectrum than other analogues in 
this series. However, the High Resolution Mass Spectrometry results were as expected and the 
melting points were also higher for this series than those of previously discussed series of 
analogues (Table 12). 
Table 12: Melting points and HRMS results for glucose series. 
Compound 68A 68B 69  70 71 
m.p./°C  202-204 209-210 181-182 186-187 202-203 
 
Calculated HRMS 667.2714 667.2714 681.2871 723.3340 872.3817 
 
Found HRMS 667.2714 667.2714 681.2874 723.3340 872.3842 
 
 
 Compound 68 was synthesised twice, using both the aldehyde derived from natural and 
unnatural phenylalanine to establish whether this would have any effect on the 
diastereoselectivity of the Passerini reaction. Our proposed theory was that the aldehyde was 
controlling the selectivity via the resolved stereogenic centre, and hence introducing an 
isocyanide with a resolved stereogenic centre would either increase or decrease the selectivity 
observed. By using the Boc-phenylalaninal 16, we hoped to see a significant increase in the 
formation of one diastereomer, since we assumed that there would be one pathway which 
would be significantly more favourable. Unfortunately, comparison of the HPLC chromatograms 
of compounds 68A and 68B did not show any of the anticipated results (Figure 29 and Figure 
30). 
The presence of 3 peaks in the chromatograms of 68A and 68B instead of the expected 2 peaks, 
prevented us from drawing any conclusions about the effect of changing the aldehyde. We had 
no way of knowing which of the peaks was due to the anticipated diastereomers and which one 
was due to the presence of anomers. The three product peaks were also observed in the 
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chromatogram, for compound 71 (Figure 31). The only notable difference was the difference in 
the ratio of the 3 peaks observed in the different chromatograms.  
 
 
Figure 29: HPLC chromatogram for compound 68A. 
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Figure 30: HPLC chromatogram for compound 68B. 
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Figure 31: HPLC chromatogram for compound 71. 
Because of the presence of too many variables in the Passerini reaction employing glucose 
isocyanide, the investigation of its effect on diastereoselectivity was suspended pending 
synthesis of enantiomerically pure isocyanide. The only conclusion that could be drawn from 
this series of analogues was that glucose isocyanide could be successfully employed in the 
Passerini reaction. 
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2.10 Proposed mechanism for the Passerini reaction 
From the observed results it is clear that the diastereoselectivity of the reaction remained quite 
consistent throughout the different series, with only minor differences being observed when 
the Passerini reaction was performed at room temperature in CH2Cl2. In each series of 
compounds prepared, the constant factor was the aldehyde derived from phenylalanine. We 
therefore suggest that the chiral aldehyde had a more significant influence on the observed 
diastereoselectivity.  
 
Scheme 23: Mechanism for Passerini reaction. 
The mechanism for the Passerini reaction is well documented (Scheme 23) and is said to be 
concerted, in the sense that intermediates cannot be isolated to clearly deduce a mechanistic 
pathway. However, it is likely that the carboxylic acid protonates the carbonyl oxygen of the 
aldehyde if aprotic solvents are used, making it susceptible to nucleophilic attack by the 
isocyanide. In our reactions, because the aldehyde bears a stereogenic centre, it can be 
attacked on one of two diastereotopic faces, the Re face or Si face, which are distinguished by 
steric hindrance due to the presence of the NHBoc group. Since the mechanism involves 
nucleophilic attack on the aldehyde, we initially proposed that a Felkin-Ahn model could explain 
the selectivity observed (Scheme 24). In this case attack at the Re face is favoured because this 
path offers the least steric hindrance due to the placement of the hydrogen and benzyl groups 
resulting in the S,S configuration for the major product. The minor product would be formed by 
the less favoured approach of the Nu on the Si face resulting in an S,R configuration.  
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Scheme 24: Felkin Ahn model for the Passerini reaction mechanism. 
However, to our surprise, the experimental results we obtained were contrary to that predicted 
by the Felkin-Ahn model. The experimental results showed that the major diastereomer had an 
S,R configuration, whilst the minor diastereomer had an S,S configuration. These results were 
baffling indeed and implied that another factor was at play in the diastereoselectivity of the 
Passerini reaction.  
Further analysis revealed that the selectivity that was observed suited a chelation controlled 
model, although no chelating agent was added to the reaction. Hili disclosed in his PhD thesis 
that mono-protected amino aldehydes follow a chelation controlled mechanism in nucleophilic 
addition reactions, which explains the anti Felkin-Anh mechanism observed in our Passerini 
reaction.69 From Scheme 25 it can be observed that chelation control occurs, albeit in the form 
of hydrogen bonding between the NH and carbonyl oxygen. This changes the bulky group 
present in the perpendicular position, in turn altering the most favourable pathway. In this 
model the benzyl group now lies perpendicular to the carbonyl group, hence the isocyanide is 
more likely to attack via the Si face resulting in a product with an S,R configuration. This 
explains the selectivity observed in our Passerini reactions. 
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Scheme 25: Anti Felkin Anh mechanism. 
This proposed mechanism explains our observed results, and confirms that the intramolecular 
hydrogen bonding between the hydrogen attached to the nitrogen and the carbonyl oxygen of 
the aldehyde which occurs, prearranges the aldehyde which in turn significantly affects the 
selectivity of the Passerini reaction at room temperature. The average D.R obtained for all the 
analogues we synthesised is comparable to those obtained by Banfi et al., when they 
synthesised a library of compounds derived from amino acids.47 However, they did not 
determine which was the major and minor diastereomers and they synthesised different types 
of analogues from the ones that we synthesised.  
2.11 Biological testing results of synthesised compounds. 
A library of compounds, comprising a few separated diastereomers from the cyclohexyl, xylyl 
and adamantyl series of peptide mimics were sent for biological testing against HIV (NICD) and 
malaria (Prof Van Zyl, University of the Witwatersrand, Department of Pharmacy and 
Pharmacology). Whole cell anti-HIV infectivity assays were performed, but unfortunately none 
of the compounds showed inhibition (Table 13). Lopinavir was used as control and none of the 
compounds were comparable to the control value as indicated by the IC50 values. The lack of 
activity seems to indicate that the compounds were not entering the cell at all as a 
diastereomeric mixture of compound 57 had shown activity with an IC50 value of 25.0 µM in an 
enzymatic assay.42 To further verify this finding, enzyme assays will have to be performed once 
larger quantities of each product have been made. To establish the toxicity of the compounds, 
the CC50 and CC20 tests were performed. The CC50 is defined as the concentration of the drug 
that results in toxicity to 50% of the cells compared with untreated cells and the high values 
obtained indicate that the tested compounds are quite toxic. 
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Table 13: Biological results for whole cell HIV assay. 
Compound Toxicity (CC50)µM Toxicity (CC20)µM Activity (IC50)µM 
 1 2 Average S.D 1 2 Average S.D   
18A 100.0 100.0 100.0 0.0 75.7 79.0 77.3 2.4 >77.3 not active 
18B 100.0 100.0 100.0 0.0 52.6 80.4 66.5 19.6 >66.5 not active 
26A 100.0 100.0 100.0 0.0 59.6 74.0 66.8 10.2 >66.8 not active 
26B 96.0 100.0 98.0 2.8 48.1 49.1 48.6 0.7 >48.6 not active 
28A 91.2 100.0 95.6 6.2 43.6 34.5 39.0 6.4 >39.0 not active 
28B 100.0 100.0 100.0 0.0 81.9 76.5 79.2 3.8 >79.2 not active 
29A 100.0 100.0 100.0 0.0 52.3 42.1 47.2 7.2 >47.1 not active 
29B 95.8 92.3 94.1 2.5 51.8 34.7 43.3 12.1 >43.2 not active 
40A 100.0 100.0 100.0 0.0 51.3 54.3 52.8 2.1 >52.7 not active 
40B 89.4 97.3 93.3 5.6 49.8 49.1 49.4 0.5 >49.4 not active 
53A 90.7 95.7 93.2 3.5 41.7 38.0 39.8 2.6 >39.8 not active 
53B 77.9 76.8 77.3 0.8 29.7 24.3 27.0 3.8 >27.0 not active 
54A 78.3 81.2 79.8 2.1 28.2 28.3 28.3 0.1 >28.2 not active 
54B 100.0 100.0 100.0 0.0 69.4 77.5 73.4 5.8 >73.4 not active 
55A 32.4 37.4 34.9 3.5 12.8 16.4 14.6 2.5 >14.6 not active 
55B 21.7 22.0 21.8 0.2 6.0 8.0 7.0 1.4 >6.9 not active 
56A 28.5 27.7 28.1 0.6 10.8 12.9 11.8 1.5 >11.8 not active 
56B 90.5 74.6 82.5 11.2 20.1 10.6 15.4 6.7 >15.3 not active 
57A 65.7 63.6 64.7 1.5 45.2 40.7 43.0 3.2 >42.9 not active 
57B 40.2 51.5 45.9 8.0 18.2 21.9 20.0 2.6 >20.0 not active 
Lopinavir         0.0010  
 
Three compounds 50A, 60A and 60B showed inhibition of parasitic growth in the antimalarial 
assay (Table 14). It is interesting to note that compound 50A is a Passerini product which has 
not gone through the amine deprotection and acyl migration sequence. Another noteworthy 
point is the fact that only products from the adamantyl series showed activity. However, the 
inhibition values were too high for IC50 of the compounds to be performed. 
Table 14: Antimalarial assay against FCR-3chloroquine-resistant strain – sybr green I assay; n=3. 
Compounds tested at 5µM 
 % parasite growth at 
5µM 
  
Compound Average SD 
18A 81.74 11.63 
18B 84.94 13.65 
27A 85.34 7.74 
27B 84.01 10.44 
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28A 86.78 9.92 
40A 82.97 12.74 
40B 110.82 13.10 
54A 84.53 16.19 
54B 87.45 6.70 
55A 87.20 10.01 
55B 80.90 12.08 
56A 86.87 14.16 
58A 80.65 8.91 
58B 82.57 8.49 
50A 63.46 7.75 
50B 94.46 7.79 
60A 59.68 8.33 
60B 58.74 7.56 
Dihydroartemisinin 
(200nM) 
50.03 11.55 
Dihydroartemisinin (IC50: 
nM) 
0.00269075 0.0003464 
 
The lack of significant biological activity of our compounds implies that we should revisit the 
design of the compounds, or synthesise a new set of analogues before biologically testing them 
again.  
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CHAPTER 3: CONCLUSION 
In this research we aimed to synthesise a library of peptidomimetic compounds for biological 
testing against HIV-1 and malaria. These compounds were synthesised using the Passerini 
reaction, a multicomponent reaction that couples an aldehyde, isocyanide and carboxylic acid. 
N-Boc-phenylalaninal was used as the aldehyde component for all the analogues synthesised 
because hydrophobic residues like phenylalanine are present in the currently used HIV-1 
protease inhibitors. The Passerini reaction yielded a diastereomeric mixture of products, which 
were in most cases not separable by purification using silica gel column chromatography. The 
Passerini product was then subjected to N-deprotection which resulted in acyl migration to give 
the desired compound, using an approach named Passerini Amine Deprotection Acyl Migration 
sequence (PADAM). The sequence yielded our desired target compounds which had an α-
hydroxy-β-amino acid functionality. 
Synthesis began with the successful preparation of the aldehyde which was then employed in 
the preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-oxo-4-
phenylbutan-2-yl acetate, being the Passerini product of N-Boc-phenylalaninal, acetic acid and 
cyclohexyl isocyanide. Deprotection of this diastereomeric mixture resulted in the formation of 
the PADAM product (3S)-3-acetamido-N-cyclohexyl-2-hydroxy-4-phenylbutanamide. 
Both the Passerini and PADAM products were then subjected to kinetic enzymatic resolution in 
an attempt to resolve the diastereomers. A range of lipase enzymes were employed for both 
the hydrolysis and acetylation reactions, but success was not achieved. Although other 
researchers have reported success with the enzymatic resolution of Passerini products, close 
inspection of the literature showed that enantiomeric mixtures of smaller substrates were 
successfully resolved, while nothing has been reported for substrates of the size used in this 
research. The catalytic activity of an enzyme is solely dependent on the substrate entering the 
active site and the larger the substrate, the less chance it has of fitting in the active site in order 
to be hydrolysed or acetylated. This reasoning was strongly supported when a smaller substrate 
(3S)-3-((tert-butoxycarbonyl)amino)-1-(butylamino)-1-oxo-4-phenylbutan-2-yl acetate was 
synthesised by replacing cyclohexyl isocyanide with n-butyl isocyanide. After subjecting the 
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compound to enzymatic hydrolysis, there was an observable reaction, although it lacked 
selectivity. Several other analogues were synthesised in the hope that variation of the structure 
would increase the chances of enzymatic resolution, but once again this was not successful. In 
our research the widely purported versatility of lipase enzymes did not work in our favour. 
Further investigations regarding enzymatic resolution will have to be performed.  
Preparative HPLC was then engaged successfully as an alternative to resolving the 
diastereomers of the Passerini reaction. Success depended on the ability to attain baseline 
separation of the diastereomeric peaks when developing the method. Resolution of compound 
(3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-oxo-4-phenylbutan-2-yl acetate 
gave pure separated diastereomers, (2R,3S)-3-((tert-butoxycarbonyl)amino)-1-
(cyclohexylamino)-1-oxo-4-phenylbutan-2-yl acetate and (2S,3S)-3-((tert-butoxycarbonyl) 
amino)-1-(cyclohexylamino)-1-oxo-4-phenylbutan-2-yl acetate. The PADAM sequence was then 
successfully completed on the separated diastereomers resulting in compounds (2R,3S)-3-
acetamido-N-cyclohexyl-2-hydroxy-4-phenylbutanamide and (2S,3S)-3-acetamido-N-cyclohexyl-
2-hydroxy-4-phenylbutanamide. 
After confirmation of the PADAM sequence and the successful resolution of the diastereomeric 
products of the Passerini reaction, the first series of analogues was prepared using cyclohexyl 
isocyanide with propionic acid, butyric acid, pivalic acid, tert-butyl acetic acid, chloroacetic acid 
and N-Boc-L-phenylalanine. Determination of the d.r. was performed using HPLC analysis of the 
Passerini products. The d.r. for analogues in this series ranged from 1.87:1.00 to 2.14:1.00. The 
13C NMR spectra for the separated diastereomers exhibited similar patterns of peaks which led 
us to conclude that the configuration of the major and minor diastereomers was the same in 
each case. Successful crystallisation of the minor diastereomer (2S,3S)-3-acetamido-N-
cyclohexyl-2-hydroxy-4-phenylbutanamide, showed an S configuration at the new stereogenic 
centre. This led us to assign an S,S configuration to the minor diastereomers and an S,R 
configuration to the major diastereomers. 
The second series of analogues was then synthesised by replacing cyclohexyl isocyanide with 
xylyl isocyanide. The d.r. of the products ranged from 1.72:1.00 to 2.21:1.00. The selectivity 
observed for this series was not significantly different from that observed for the cyclohexyl 
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series. Only one compound was separable by preparative HPLC in this series. This was a result 
of observed co-elution of diastereomers of the other analogues. However, the same pattern in 
the 13C NMR spectra observed in the cyclohexyl series was also observed in the xylyl series of 
analogues. This suggested that the configuration of the major diastereomers and minor 
diastereomers was the same as that obtained for the cyclohexyl series. 
Synthesis of the third series of analogues employed adamantyl isocyanide. The d.r. of the 
analogues ranged from 1.75:1.00 to 2.49:1.00. The lowest d.r. was for the analogue synthesised 
with propionic acid and the highest d.r. was for the analogue synthesised with phenylalanine. 
The highest d.r. was likely due to the steric hindrance offered by a bulkier phenylalanine and 
the presence of an additional stereogenic centre. All of the analogues in this series were 
separable by preparative HPLC yielding pure diastereomers. The observed patterns in the 1H 
and 13C NMR spectra for the major diastereomers and minor diastereomers were as expected 
from previous series. By analogy with the cyclohexyl series, the configuration for the major 
diastereomers was assigned R,S  and that of minor diastereomers was assigned S,S. Successful 
crystallisation of the major diastereomer (2R,3S)-N-adamantan-1-yl-2-hydroxy-4-phenyl-3-
propionamidobutanamide confirmed the configuration of major diastereomers to be R,S. 
In an attempt to significantly affect the selectivity of the Passerini reaction, we incorporated 
chiral isocyanides into the Passerini reaction. We first synthesised phenylalanine isocyanide 
from the naturally occurring amino acid. Only three analogues were synthesised in this series 
because of limited starting materials. The d.r. for the products was 1.52:1.00 for the acetic acid 
derived analogue and 1.34:1.00 for the propionic acid derived analogue. Once again the 
propionic acid containing analogue had the lowest d.r. The analogue synthesised using tert-
butyl acetic acid was recovered as one diastereomer, possibly as a result of separation during 
purification by silica gel column chromatography. Analogues synthesised from glucose 
isocyanide will have to be revisited, as the glucose isocyanide was found to be present in both 
epimeric forms. 
In general the d.r. was found to be approximately 2:1 for analogues prepared using carboxylic 
acids and isocyanides not containing a stereogenic centre, showing the significant role played 
by the aldehyde in diastereoselectivity. Interestingly, analogues containing propionic acid 
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always had a lower d.r. for all the series prepared. Only one carboxylic acid with a stereogenic 
centre was used in the Passerini reaction and the highest diastereoselectivity was observed for 
this carboxylic acid in the adamantyl series, where a d.r. of 2.49:1.00 was obtained. When an 
isocyanide with a stereogenic centre was used in the reaction the d.r. was lowered to 
approximately 1.5:1.00. This led us to suggest that the isocyanide had a mismatch effect when 
combined with the effect of the aldehyde. However, because of time constraints further 
investigations into this observation could not be performed. Despite this, the results obtained 
thus far strongly suggest that the Passerini reaction can be influenced by steric bulk and existing 
stereogenic centres offered by starting materials. 
The Felkin-Ahn chelation model best explains our observed results with respect to the major 
and minor diastereomers obtained. It suggests that mono-protected amino aldehydes follow a 
chelation controlled mechanism in nucleophilic addition reactions. This chelation control occurs 
in the form of hydrogen bonding between the NH and carbonyl oxygen.  
X-ray crystallography of compounds (2R,3S)-3-acetamido-N-cyclohexyl-2-hydroxy-4-phenyl 
butanamide and (2R,3S)-N-adamantan-1-yl-2-hydroxy-4-phenyl-3-propionamidobutanamide, 
enabled the assignment of the absolute configurations of the diastereomers and assignment of 
configurations for the other diastereomers was done by analogy. The major diastereomer was 
identified as that with the R,S configuration while the minor diastereomer had the S,S 
configuration.  
Having successfully synthesised our target compounds, 20 stereochemically pure diastereomers 
were sent for biological testing against both HIV-1 and malaria. In the antimalarial assay three 
compounds showed inhibition of parasitic growth by 37 – 42% at 5 µM concentration. This is a 
good starting point for the development of peptidomimetic antimalarials. What is interesting is 
that all the compounds that showed activity are part of the adamantyl series of analogues. 
Adamantyl-based compounds are showing increasing utility in the treatment of many different 
conditions, including viral infections. These promising results provide a basis for further 
investigations into the synthesis of additional such analogues. HIV-1 biological assays did not 
yield any promising results. 
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Future work 
Since the PADAM approach has been shown to be effective and versatile in synthesising 
peptidomimetic compounds, there is a need to find enzymes which can effectively resolve the 
diastereomers that are formed. The phenylalanine isocyanide series will have to be revisited to 
conclusively establish the reason for the isolation of individual diastereomers after purification. 
The synthesised glucose isocyanide was shown to have epimerized, affecting the results 
observed after the Passerini reaction. There is need to synthesise a single epimer of the glucose 
isocyanide before using it as a starting material in order to clearly establish its effect on 
diastereoselectivity. Since the biological testing results were negative for the anti HIV-1 assay, 
there is a need to establish whether it was because the compounds were not active against the 
enzyme or whether the compound was not entering the cell. Only one Passerini product was 
tested for activity against the malaria parasite and showed moderate parasitic inhibition. It will 
therefore be worthwhile to resynthesize the Passerini compounds and assess their antimalarial 
activity since focus was only given to the PADAM products. 
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CHAPTER 4: EXPERIMENTAL PROCEDURES 
4.1 General Experimental Procedures 
4.1.1 Purification of Solvents and Reagents 
All solvents used for reactions and column chromatography were purified by distillation and 
when required solvents were stored over activated molecular sieves (4Å) under a nitrogen 
atmosphere. THF and toluene were dried over sodium wire and distilled, with benzophenone as 
indicator. CH2Cl2 and MeCN were distilled from calcium hydride. All other reagents and solvents 
for HPLC were obtained from commercial sources and used without further purification.  
4.1.2 Chromatography 
Thin layer chromatography was carried out using aluminium-backed Machery-Nagel 
ALUGRAMSil G/UV254 plates pre-coated with 0.25 mm silica gel 60. Column chromatography 
was performed on Merck silica gel of particle size 0.035 – 0.070 mm employing different types 
of solvents. An Agilent 3000 instrument was used for all preparative HPLC on an Agilent prep 
C18 reverse phase column (21.2x20 mm)  with a binary solvent system using gradient elution of 
MeCN/H2O and a flow rate of 20 ml/min. For all analytical HPLC a Dionex Ultimate 3000 
instrument was used, employing a Luna C18 reverse phase column gradient elution, at a flow 
rate of 1ml/min with detection at 217 nm. 
4.1.3 Spectroscopic and physical data 
All melting points were obtained using a Stuart SMP10 melting point apparatus and are 
uncorrected.  
Infrared spectra were obtained using a Bruker Vector 22 spectrometer where measurements 
were made by directly loading the sample onto the diamond cell. All signals are reported on the 
wavenumber scale (ν/cm-1). 
1H NMR and 13C NMR spectroscopy were performed using a Bruker Avance-300 or a Bruker 
Avance-500 spectrometer at 75 MHz and 125 MHz respectively. Chemical shifts are reported in 
parts per million and referenced against the internal standard, tetramethyl silane (TMS), which 
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occurs at zero parts per million downfield and coupling constants are given in Hertz. 13C NMR 
chemical shifts are reported to 2 decimal places, as this allows for assignment of C signals of 
diastereomeric products. The difference in diastereomeric signals is only evident at the second 
decimal place. 
High resolution mass spectra (HRMS) were recorded on a Waters Synapt G2. All data was 
quoted in relative abundance (m/z). 
4.2 Preparation of (S)-tert-butyl (1-(methoxy(methyl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamate 14 
Commercially available N-Boc-L-phenylalanine (4.00 g, 0.0151 mol) was dissolved in CH2Cl2 
(40 ml) and CDI (1.2 eq., 2.93 g, 0.0181 mol) was then added in portions, allowing effervescence 
to cease before each subsequent addition. The reaction was left stirring for 30 min in air before 
adding N,O-dimethylhydroxylamine hydrochloride (1.2 eq., 1.76 g, 0.0181 mol). The mixture 
was allowed to stir overnight at room temperature in air. The reaction mixture was then diluted 
with CH2Cl2 (90 ml) followed by addition of H2O (90 ml). The organic layer was separated and 
further washed with 2M NaOH (90 ml) followed by 1M HCl (90 ml) and then dried over MgSO4. 
Solvent was removed in vacuo and the product was purified using column chromatography (3:7 
EtOAc/hex) yielding 14 as clear viscous oil (3.82 g, 82%). 
 
Rf: 0.37 (3:7 EtOAc/hex); IR: νmax(cm
-1): 3326 (NH), 2960 (CH), 1716 
(C=O), 1666 (C=O), 1390 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.37 – 7.12 
(5H, m, Ar-H), 5.27 – 5.09 (1H, m, NH), 5.04 – 4.86 (1H, m, H-2), 3.65 
(3H, s, H-9), 3.16 (3H, s, H-8), 3.05 (1H, dd, J = 13.5, 6.1 Hz, H-3a), 2.95 
– 2.80 (1H, m, H-3b), 1.39 (9H, s, (CH3)3C); 
13C NMR (75 MHz, CDCl3) δ 
172.32 (C-1), 155.16 (Boc C=O), 136.62 (C-4), 129.45 (C-6 and C-6’), 128.33 (C-5 and C-5’), 
126.73 (C-7), 79.54 ((CH3)3C), 61.50 (C-9), 51.56 (C-2), 38.90 (C-3), 32.03 (C-8), 28.31 ((CH3)3C).  
4.3 Preparation of (S)-tert-butyl (1-oxo-3-phenylpropan-2-yl)carbamate 15 
Dry THF was placed in a flame heated 250 ml two neck round-bottomed flask under N2 followed 
by addition of N-Boc-L-phenylalanine Weinreb amide 14 (3.00 g, 9.73 mmol). The stirring 
Chapter 4: Experimental Procedures 
 
90 
 
solution was then cooled to 0°C and LiAlH4 (1.3 eq., 0.46 g, 12.16 mmol) was added in one 
portion. The reaction was allowed to proceed under N2 for 2 h after which 1M KHSO4 (15 ml) 
was added slowly whilst stirring vigorously for 20 min. The mixture was then transferred to a 
separating funnel and washed with EtOAc (90 ml) followed by 1M HCl (90 ml). The organic layer 
was separated and washed with a saturated solution of NaHCO3  (90 ml) followed by brine (90 
ml). The organic layer was then dried over MgSO4 and solvent removed in vacuo yielding 
compound 15 as a white solid (2.15 g, 88%). 
 
 Rf = 0.42 (3:7 EtOAc/Hex); [αD]
20
589 +44.0 (c 2, CH2Cl2), -44.5 (c 2, MeOH); 
m.p.: 83 – 84 °C (lit m.p. 86 °C)60; IR: νmax(cm
-1):  3365 (N-H), 3060 (C=CH), 
2848 (C-H), 1728 (C=O), 1687 (C=O), 1250 (C-C); 1H NMR (300 MHz, CDCl3) δ 
9.63 (1H, s, H-1), 7.38 – 7.13 (5H, m, Ar-H), 5.14 – 5.00 (1H, m, NH), 4.52 – 4.35 (1H, m, H-2), 
3.11 (2H, d, J = 7.2 Hz, H-3), 1.43 (9H, s, (CH3)3C); 
13C NMR (75 MHz, CDCl3) δ 199.44 (C-1), 
155.40 (Boc C=O), 135.95 (C-4), 129.32 (C-6 and C-6’), 128.71 (C-5 and C-5’), 127.01 (C-7), 80.11 
[(CH3)3C], 60.80 (C-2), 35.38 (C-3), 28.26 [(CH3)3C]. 
4.4 Preparation of (R)-tert-butyl (1-oxo-3-phenylpropan-2-yl)carbamate 16 
Compound 16 was successfully synthesised from N-Boc-D-phenylalanine using the same 
method as described for compound 15 (1.48 g, 87%). 
 
 Rf = 0.42 (3:7 EtOAc/Hex); [αD]
20
589 -36.2 (c 2, CH2Cl2); m.p.: 83 – 84 °C; IR: 
νmax(cm
-1) 3365 (N-H), 3060 (C=CH), 2848 (C-H), 1728 (C=O), 1687 (C=O), 
1250 (C-C); 1H NMR (300 MHz, CDCl3) δ 9.61 (1H, s, H-1), 7.37 – 7.12 (5H, m, 
Ar-H), 5.28 – 4.83 (1H, m, NH), 4.47 – 4.34 (1H, m, H-2), 3.19 – 2.98 (2H, m, H-3), 1.43 (9H, s, 
(CH3)3); 
13C NMR (75 MHz, CDCl3) δ 199.44 (C-1), 155.38 (Boc C=O), 135.86 (C-4), 129.32 (C-6 
and C-6’), 128.73 (C-5 and C-5’), 127.04 (C-7), 80.15 [(CH3)3C], 60.78 (C-2), 35.41 (C-3), 28.26 
[(CH3)3C]. 
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4.5 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-
1-oxo-4-phenylbutan-2-yl acetate 17 
N-Boc-L-phenylalaninal 15 (1.00 g, 4.01 mmol) was dissolved in CH2Cl2 (9 ml) followed by drop 
wise addition of cyclohexyl isocyanide 8 (492 µl, 4.01 mmol) and acetic acid 1 (271 µl, 4.01 
mmol). The reaction mixture was allowed to stir at room temperature in air for 3 d. Excess 
solvent was then removed in vacuo and the product was purified by normal phase silica gel 
column chromatography (elution CHCl3/MeOH 1:0 to 49:1). This afforded compound 17 (1.56 g, 
93%) as a white solid, as a mixture of diastereomers. This product was then analysed by HPLC to 
establish the d.r. Compound 17 (1 mg) was dissolved in 1 ml of MeCN after which 25 µl of the 
solution was manually injected onto the column. An example of the program that was used to 
separate the diastereomers in order to obtain maximum baseline separation is given below.  
Pressure. Lower Limit = 0 mbars       
Pressure. Upper Limit = 350 mbars       
Maximum Flow Ramp Down = 6.000   
Rise_Time = 2.00        
UV_VIS_1.Wavelength = 217            
Flowrate  = 1.000 ml/min       
% acetonitrile = 50.0        
% water = 50.0       
@ 2.00 min Flow = 1.000 ml/min       
@2.00 min % acetonitrile Gradient Start = 50.0, End = 60.0, Duration = 2.00   
@2.00 min % water Gradient Start = 50.0, End = 40.0, Duration = 2.00    
@4.00 min Flow = 1.000 ml/min        
@4.00 min % acetonitrile Gradient Start = 60.0, End = 70.0, Duration = 4.00    
@4.00 min % water Gradient Start = 40.0, End = 30.0, Duration = 4.00    
@8.00 min Flow = 1.000 ml/min        
@8.00 min % acetonitrile Gradient Start = 70.0, End = 80.0, Duration = 4.00   
@8.00 min % water Gradient Start = 30.0, End = 20.0, Duration = 4.00     
@12.00 min Flow = 1.000 ml/min        
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@12.00 min % acetonitrile = 80.0        
@12.00 min % water = 20.0     
@20.00 min stop batch 
All the other methods used for separating diastereomers were based on the slight modification 
of the above method. 
 
Rf = 0.50 (49:1 CHCl3/MeOH); D.R = 2.14:1.00; IR (solid) vmax   
(cm-1): 3352 (NH), 2932 (C-H), 2854 (C-H), 1745 (C=O), 1686 
(C=O), 1649 (C=O), 1523 (C=C), 1226 (C-O); 1H NMR (500 MHz, 
CDCl3) δ 7.31 – 7.14 (5H, m, Ar-H), 6.01 – 5.90 (0.33H, m, NH), 
5.83 – 5.75 (0.60H, m, NH), 5.28 – 4.90 (2H, m, NH and H-2), 4.35 – 4.22 (1H, m, H-3), 3.85 – 
3.71 (1H, m, H-11), 2.94 (1H, d, J = 7.5 Hz, H-4a), 2.83 (1H, d, J = 7.2 Hz, H-4b), 2.13 (1H, s, H-10), 
2.09 (2H, s, H-10), 1.96 – 1.84 (2H, m) and 1.76 – 1.57 (4H, m, cyclohexyl-CH2), 1.43 – 1.29 (9H, 
m, (CH3)3C), 1.23 – 1.07 (4H, m, cyclohexyl-CH2);
 13C NMR (126 MHz, CDCl3) δ 169.80, 169.09, 
166.86 and 166.59 (C=O), 155.50 and 154.94 (Boc C=O), 137.35 and 137.27 (C-5), 129.21 (Ar-C), 
129.13 (Ar-C), 128.46 (Ar-C), 126.57 (Ar-C), 126.55 (Ar-C), 79.48 [(CH3)3C], 74.32 and 73.73 (C-2), 
53.27 and 52.79 (C-3), 48.29 and, 48.18 (C-11), 38.05 and, 37.27 (C-4), 32.88, 32.85 and 32.73 
(C-12 and 12’), 28.23 *(CH3)3C], 25.40 and 24.71 (C-13, 13’ and C-14), 20.85 and 20.65 (C-10). 
Synthesis of compound 18 is explained in section 4.11 as separated diastereomers. 
4.6 Enzymatic kinetic resolution 
4.6.1 Enzyme test reactions (hydrolysis reaction) 
Benzyl acetate (50 mg, 0.33 mmol) was dissolved in toluene (2 ml) and 0.01M sodium 
phosphate buffer pH 7.5 (5 ml) and allowed to stir at a controlled temperature of 35°C. Lipase 
enzyme (50 mg or 10 µl) was then added and reaction was allowed to proceed for 3 h after 
which TLC was performed to determine whether or not the active enzyme had successfully 
hydrolysed the substrate. A control experiment was set up without the enzyme, to ascertain 
and confirm that hydrolysis was not occurring in the absence of the enzyme. 
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4.6.2 Enzyme test reactions (acylation reaction) 
Benzyl alcohol (50 µl, 0.44 mmol) was dissolved in MeCN (5 ml) to which vinyl acetate (1.5 eq., 
135 µl, 0.66 mmol) was added. The temperature of the stirring solution was adjusted and 
controlled at 35 °C, after which lipase enzyme (50 mg or 10 µl) was added. The reaction was 
allowed to proceed for 3 h after which TLC was performed to determine whether or not the 
enzyme had successfully catalysed the acetylation reaction. A control experiment was set 
without the enzyme to ensure that no reaction occurred in the absence of the enzyme. A total 
of 30 enzymes were tested and 25 were found to be active against the test substrate. 
List of active enzymes 
1. Novozyme 525    14. Alcalase 24 
2. Porcine pancreas lipase   15. Novozym 425 
3. Lipozyme TL IM (Novozyme)   16. Lipolase 100T 
4. Lipase AYS Amano (LAYW045145)  17. SP398 LAN00052 
5. Lipase Penicillium roqueforti   18. Lipase AK C7 solution No 54-001 
6. Lipase AK-D Amanas    19. Esterase Rhizopus 
7. Lipase AH-D Amano    20. Candida Antarctica lipase 
8. Lipase CR Analytical    21. Lipase Rhizopus arrhizus 
9. Lipozyme RM Lux 0111(25)   22. Lipase Aspergillus s.p 
10. Wheat germ lipase    23. Lipase Pseudomonas cepacia 
11. Lipase Candida rugosa   24. Lipase Pseudomonas fluorescens 
12. Lipase Rhizopus oryzae   25. Novozym 388 
13. Grist brocades  
 
4.6.3 Attempted enzymatic kinetic resolution of compound 17 
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Compound 17 (50 mg, 0.12 mmol) was dissolved in toluene (5 ml) followed by the addition of 
phosphate buffer pH 7.5 (20 ml). The reaction temperature of the reaction mixture was 
adjusted and controlled at 35 °C. A few drops of Tween, a surfactant, were added followed by 
the enzyme substrate. The reaction was allowed to proceed in air for 28 d whilst tracking for 
hydrolysis of the substrate using HPLC analysis. There was no observable reaction for all active 
enzymes and the experiment was abandoned. The same procedure was applied for compounds 
20 and 21, but evidence of enzymatic hydrolysis was only evident with compound 21. 
4.7 Preparation of tert-butyl ((2S)-4-(cyclohexylamino)-3-hydroxy-4-oxo-1-
phenylbutan-2-yl)carbamate 19 
Compound 17 (400 mg, 0.96 mmol) was dissolved in MeOH (4 ml) followed by addition of KOH 
(9 eq., 482 mg, 8.60 mmol). The reaction mixture was left stirring in air at room temperature 
overnight. After completion of the reaction, H2O (10 ml) was added, followed by 6N HCl (5 ml). 
The product was then extracted using EtOAc (2x10 ml) and dried over MgSO4. Excess solvent 
was removed in vacuo. Purification of the product by column chromatography (49:1 
CHCl3/MeOH) afforded compound 19 (355 mg, 99%) as a white flaky solid. 
 
Rf = 0.47  (49:1 CHCl3:MeOH); d.r. = 2.10:1.00; 
1H NMR (300 
MHz, CDCl3) δ 7.40 – 7.14 (5H, m, Ar-H), 6.85 (0.35H, d, J = 8.4 
Hz, NH), 6.69 (0.71H, d, J = 8.4 Hz, NH), 5.53 (1H, br-s, OH), 5.16 
(0.70H, d, J = 8.4 Hz, NH), 4.98 (0.36H, d, J = 7.2 Hz, NH), 4.12 – 3.91 (2H, m, H-2 and H-3), 3.86 – 
3.68 (1H, m, H-9), 3.16 – 2.79 (2H, m, H-4), 1.97 – 1.78 (2H, m) and 1.78 – 1.53 (3H, m, 
cyclohexyl-CH2), 1.48 – 1.31 (14H, m, (CH3)3C and cyclohexyl-CH2); 
13C NMR (75 MHz, CDCl3) δ 
171.52 and 170.68 (C-1), 157.38 (Boc C=O), 138.06 and 138.17 (C-5), 129.34 (C-7 and C-7’), 
128.51 (C-6 and C-6’), 126.55 (C-8), 80.58 and  80.23 [(CH3)3C], 75.05 and 73.59 (C-2), 55.60 (C-
3), 48.08 and 47.90 (C-9), 35.56 (C-4), 33.56, 33.23, 33.12 and 32.82 (cyclohexyl-CH2), 28.23 
[(CH3)3C], 25.50, 24.80 and 24.76 (cyclohexyl-CH2). 
4.8 Attempted enzymatic esterification of 19 
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Compound 19 (50 mg, 0.13 mmol) was dissolved in MeCN (5 ml) followed by the addition of 
vinyl acetate (5 eq., 61 µl, 0.66 mmol). The temperature of the reaction was adjusted and 
controlled at 35 °C after which the lipase enzyme was added. The reaction was allowed to 
proceed in air whilst tracking for acylation of the substrate by HPLC analysis. After 14 d there 
was no observable reaction for all active enzymes and the experiment was abandoned. The 
reaction was also attempted on a diastereomeric mixture of compound 18 and there was still 
no evidence of enzymatic acylation of the substrate.  
Synthesis of compound 20 is explained in section 4.12, after diastereomeric separation. 
4.9 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-(butylamino)-1-
oxo-4-phenylbutan-2-yl acetate 21 
N-Boc-L-phenylalaninal 15 (500 mg, 2.01 mmol), n-butyl isocyanide 9 (210 µl, 2.01 mmol) and 
acetic acid 1 (135 µl, 2.01 mmol) were dissolved in CH2Cl2 (3 ml). The experiment was carried 
out as described in 4.5 yielding compound 21 (759 mg, 96%) as a white solid. 
 
Rf = 0.31 (1:1 EtOAc/Hex); d.r. = 1.72:1.00; m.p. 125 - 126°C; 
IR νmax(cm
-1): 3341 (NH), 3030 (C=CH), 1750 (C=O), 1686 
(C=O), 1656 (C=O); 1H NMR (300 MHz, CDCl3) δ 7.35 – 7.12 
(5H, m, Ar-H), 6.57 – 6.33 (1H, m, NH), 5.44 – 5.22 (1H, m, H-
2), 5.21 – 5.07 (1H, m, NH), 4.44 – 4.24 (1H, m, H-3), 3.35 – 3.11 (2H, m, H-4), 3.04 – 2.61 (2H, 
m, H-11), 2.23 – 2.04 (3H, m, H-10), 1.58 – 1.19 (13H, m, H-12, H-13 and (CH3)3C), 0.91 (3H, q, J 
= 7.2 Hz, H-14); 13C NMR (75 MHz, CDCl3) δ 169.84, 169.32, 167.92 and 167.62 (C=O), 155.52 
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and 155.10 (Boc C=O), 137.37 (C-5), 129.28 and 129.22 (C-7 and C-7’), 128.45 and  128.41 (C-6 
and C-6’), 126.56 and 126.53 (C-8), 79.43 [(CH3)3C], 74.63 and 73.99 (C-2), 53.20 (C-3), 52.87 (C-
3), 39.14 (C-11), 39.08 (C-11), 37.23 (C-4), 28.25 [(CH3)3C], 20.84 (C-10), 20.68 (C-10), 20.02 (C-
12), 19.98 (C-13), 13.70 (C-14); HRMS (m/z), calculated for C21H33N2O5: 393.2389, found (M + 
H)+: 393.2393. 
4.10 HPLC Separation of compound 17               
 
Compound 17 (150 mg) was dissolved in HPLC grade MeCN (5 ml) and 250 µl of this solution 
was injected onto the C-18 column for each separation. The diastereomers were separated 
using gradient elution (5:5-8:2 MeCN/H2O) and collected separately. The full method is shown 
below and it was adjusted for separation of other compounds. 
  Pump  
Channel        Solvent Name   Percentage % 
                                                                    
Channel A       water                    40.0 
Channel B       acetonitrile           60.0                     
Stoptime Mode:                           Time set 
Stoptime:                                      20.00 min 
                     
Gradient Timetable 
   Time    A    B   Flow   Pressure 
    min    %    %   mL/min        bar 
----------------------------------- 
   7.00    40.0  60.0    20        --- 
  10.00   22.0  78.0    20        --- 
 
 DAD (G1315D) 
Peakwidth:        >0.013 min  (0.25 s response time) (20 Hz) 
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Slit:                                                             4 nm 
UV Lamp Required:                                    Yes 
Vis Lamp Required:                                     Yes 
 
                        
Signal table 
   Use Sig.   Signal   Wavelength   Bandwidth   Use Ref. 
                                          nm          nm            
-------------------------------------------------------- 
        Yes Signal A          217           4         No 
Prepare Mode                   
Margin for negative Absorbance:                      100  
Spectrum Range WL from:                               190 nm 
Spectrum Range WL to:                                 700 nm 
Spectrum Step:                                        2.0 nm 
Spectrum Store:                                          All 
 
Valve Position:                                  Port 1 -> 2 
Temperature:                                        20.00 °C 
Timetable                      
 
 Prep. Sampler (G2260A) 
Injection Mode:                           Standard injection 
Injection Volume:                                  100.00 µL 
 
 Fraction Collector (G1364B) 
 
Peak Detector Mode:               at least one peak detected 
Maximum fill volume:                                13.50 mL 
 
Detector type with serial number        Unit       Up Slope 
                                                      
                  G1315D:DEAAX04653    mAU       2.00 
 
 Down Slope   Threshold   Upper Threshold      Mode 
                                                     
         5.00          25.000          4000.000              Threshold 
 
Timetable                      
Time Function            Parameter                                
----------------------------------------------------------------- 
15.00 Change Trigger Mod. Trigger Mode: Peak-based with a maximum  
                         peak duration of 1.7 min       
@20.00 stop batch           
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Products were then extracted from eluent using CHCl3 and dried over MgSO4. Excess solvent 
was removed in vacuo yielding compounds 17A (66 mg) and 17B (38 mg) as white solids. 
 
(2R,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl acetate 17A. m.p. 162 – 163 °C; IR 
(solid) vmax(cm
-1): 3341 (NH), 3290 (NH), 2922 (C-H), 2851 (C-H), 
1735 (C=O), 1686 (C=O), 1652 (C=O), 1257 (C-O), 1168 (C-C); 1H 
NMR (300 MHz, CDCl3) δ 7.39 – 7.14 (5H, m, Ar-H), 5.93 – 5.75 (1H, m, NH), 5.28 – 5.02 (2H, m, 
NH and H-2), 4.38 – 4.23 (1H, m, H-3), 3.86 – 3.68 (1H, m, H-11), 2.83 (2H, d, J = 7.2 Hz, H-4), 
2.10 (3H, s, H-10), 1.98 – 1.81 (2H, m) and 1.79 – 1.52 (5H, m, cyclohexyl-CH2), 1.35 – 1.04 (12H, 
m, (CH3)3C and cyclohexyl-CH2); 
13C NMR (75 MHz, CDCl3) δ 169.15 and 166.95 (C=O), 155.03 
(Boc C=O), 137.34 (C-5), 129.28 (C-7 and C-7’), 128.51 (C-6 and C-6’), 126.61 (C-8), 79.61 
[(CH3)3C], 73.86 (C-2), 52.88 (C-3), 48.35 (C-11), 38.14 (C-4), 32.78 and 32.92 (cyclohexyl-CH2), 
28.24 [(CH3)3C], 25.46 and 24.77 (cyclohexyl-CH2), 20.69 (C-10); HRMS (m/z), calculated for 
C23H35N2O5: 419.2546, found (M + H)
+: 419.2537. 
 
(2S,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl acetate 17B. m.p. 164 - 165°C; IR (solid) 
vmax(cm
-1): 3370 (NH), 2933 (C-H), 2854 (C-H), 1749 (C=O), 1685 
(C=O), 1648 (C=O), 1222 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.38 – 
7.14 (5H, m, Ar-H), 5.99 (1H, d, J = 8.3 Hz, NH), 5.26 – 4.93 (2H, m, NH and H-2), 4.37 – 4.19 (1H, 
m, H-3), 3.88 – 3.71 (1H, m, H-11), 2.94 (2H, d, J = 7.6 Hz, H-4), 2.14 (3H, s, H-10), 1.99 – 1.82 
(2H, m) and 1.81 – 1.52 (5H, m, cyclohexyl-CH2), 1.36 – 1.01 (12H, m, (CH3)3C and cyclohexyl-
CH2); 
13C NMR (75 MHz, CDCl3) δ 169.89 and 166.65 (C=O), 155.57 (Boc C=O), 137.42 (C-5), 
129.19 (C-7 and C-7’), 128.51 (C-6 and C-6’), 126.63 (C-8), 79.56 [(CH3)3C], 74.42 (C-2), 53.38 (C-
3), 48.26 (C-11), 37.30 (C-4), 32.91 (cyclohexyl-CH2), 28.28 [(CH3)3C], 25.46 and 24.75 
(cyclohexyl-CH2), 20.89 (C-10); HRMS (m/z), calculated for C23H35N2O5: 419.2546, found (M + 
H)+: 419.2532. 
4.11 Preparation of (2R,3S)-3-acetamido-N-cyclohexyl-2-hydroxy-4-
phenylbutanamide 18A                        
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Compound 17A (90 mg, 0.22 mmol) was dissolved in CH2Cl2 (1 ml) and TFA (10 eq., 166 µl, 2.15 
mmol) was added. The reaction mixture was stirred at room temperature in air for 3 h after 
which the solvent and most of the TFA were removed in vacuo. The residue was then 
redissolved in CH2Cl2 (1 ml) and Et3N (10 eq., 298 µl, 2.15 mmol) and the reaction mixture was 
left stirring at room temperature in air for 1 h. Excess solvent and most of the Et3N were 
removed in vacuo and the product was purified by column chromatography (49:1 CHCl3/MeOH) 
affording 18A (59 mg, 84%) as a white solid. 
 
Rf = 0.53 (49:1 CHCl3/MeOH); m.p. 159-160 °C; IR (solid) vmax(cm
-
1): 3350 (OH), 3249 (NH), 2931 (C-H), 2853 (C-H), 1689 (C=O), 
1635 (C=O), 1528 (C=O); 1H NMR (300 MHz, CDCl3) δ 7.40 – 7.09 
(6H, m, Ar-H and NH), 6.98 (1H, d, J = 8.4 Hz) and 6.48 (1H, d, J = 
6.4 Hz, NH and OH), 4.21 – 3.98 (2H, m, H-2 and H-3), 3.85 – 3.63 (1H, m, H-11), 3.12 (1H, dd, J = 
13.7, 6.0 Hz, H-4a), 3.01 – 2.75 (1H, m, H-4b), 1.97 – 1.78 (4H, m, cyclohexyl-CH2), 1.77 – 1.51 
(3H, m, cyclohexyl-CH2), 1.46 – 1.01 (5H, m, cyclohexyl-CH2); 
13C NMR (75 MHz, CDCl3) δ 172.29 
and 171.94 (C=O), 138.24 (C-5), 129.15 (C-7 and C-7’), 128.46 (C-6 and C-6’), 126.54 (C-8), 73.21 
(C-2), 56.10 (C-3), 48.04 (C-11), 35.51 (C-4), 33.10, 32.57, 25.46 and 24.77 (cyclohexyl-CH2), 
22.90 (C-10); HRMS (m/z), calculated for C18H27N2O3: 319.2022, found (M + H)
+: 319.2014. 
4.12 Preparation of (2S,3S)-3-acetamido-N-cyclohexyl-2-hydroxy-4-
phenylbutanamide 18B 
Compound 18B was synthesized using the same procedure as described in 4.11. Compound 17B 
(50 mg, 0.12 mmol) was dissolved in CH2Cl2 (1 ml), followed by the addition of TFA (10 eq., 92 
µl, 1.19 mmol) and Et3N (10 eq., 165 µl, 1.19 mmol). Purification of the reaction mixture yielded 
compound 18B (36 mg, 95%) as a white precipitate.  
 
Rf = 0.47 (49:1 CHCl3/MeOH); m.p. 238 – 239 °C ; IR νmax(cm
-1): 
3386 (OH), 3277 (NH), 2918 (C-H), 2850 (C-H), 1645 (C=O), 1570 
(C=C); 1H NMR (300 MHz, CD3OD) δ 8.01 (0.16H, d, J = 8.9 Hz, 
NH), 7.74 (0.65H, d, J = 8.4 Hz, NH), 7.36 – 7.14 (5H, m, Ar-H), 
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4.56 – 4.43 (1H, m, H-3), 4.17 (1H, d, J = 3.5 Hz, H-2), 3.84 – 3.61 (1H, m, H-11), 2.76 (2H, d, J = 
7.3 Hz, H-4), 1.98 – 1.73 (6H, m, H-10 and cyclohexyl-CH2), 1.73 – 1.57 (1H, m, cyclohexyl-CH2), 
1.57 – 1.11 (6H, m, cyclohexyl-CH2); 
13C NMR (75 MHz, CD3OD) δ 174.65 and 171.53 (C=O), 
138.38 (C-5), 128.70 (C-7 and C-7’), 127.76 (C-6 and C-6’), 125.81 (C-8), (72.99 C-2), 53.93 (C-3), 
33.80 (C-4), 32.19, 25.08 and 24.60 (cyclohexyl-CH2), 20.97 (C-10); HRMS (m/z), calculated for 
C18H27N2O3: 319.2022, found (M + H)
+: 319.2015. 
4.13 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino) 
-1-oxo-4-phenylbutan-2-yl 2-chloroacetate 20                                                                                                        
N-Boc-L-phenylalaninal 15 (500 mg, 2.01 mmol), cyclohexyl isocyanide 8 (247 µl, 2.01 mmol) 
and chloroacetic acid 5 (189 mg, 2.01 mmol) were dissolved in CH2Cl2 (3 ml) and the experiment 
was carried out as described in 4.5. The reaction yielded compound 20 (776 mg, 85%) as a 
white solid being a mixture of diastereomers. Rf = 0.53 (49:1 CHCl3/MeOH); d.r. = 1.94:1.00. 
This mixture was then separated by preparative HPLC as described in 4.10 to give two clean 
separated diastereomers. 
 
 (2R,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl 2-chloroacetate 20A. m.p. 184 -185 °C; 
IR (solid) vmax(cm
-1): 3351 (NH), 3313 (NH), 2923 (C-H), 2552 (C-
H), 1767 (C=O), 1687 (C=O), 1646 (C=O), 700 (C-Cl); 1H NMR (500 
MHz, CDCl3) δ 7.32 – 7.26 (2H, m, H-7 and 7’), 7.24 – 7.16 (3H, m, 
H-6, H-6’ and H-8), 6.11 – 5.95 (1H, m, NH), 5.30 – 5.10 (2H, m, NH and H-2), 4.42 – 4.31 (1H, m, 
H-3), 4.03 (2H, s, H-10), 3.82 – 3.71 (1H, m, H-11), 2.85 (2H, d, J = 7.1 Hz, H-4), 1.97 – 1.82 (2H, 
m, cyclohexyl-CH2), 1.75 – 1.64 (2H, m, cyclohexyl-CH2), 1.64 – 1.56 (1H, m, cyclohexyl-CH2), 
1.41 – 1.09 (14H, m, (CH3)3C and cyclohexyl-CH2); 
13C NMR (126 MHz, CDCl3) δ 166.10 and 
165.59 (C=O), 154.99 (Boc C=O), 137.10 (C-5), 129.23 (C-7 and C-7’), 128.57 (C-6 and C-6’), 
126.71 (C-8), 79.73 [(CH3)3C], 75.12 (C-2), 52.71 (C-3), 48.46 (C-11), 40.46 (C-10), 38.05 (C-4), 
32.83 and 32.65 (cyclohexyl-CH2), 28.25 [(CH3)3C], 25.41 and 24.66 (cyclohexyl-CH2); HRMS 
(m/z), calculated for C23H34ClN2O5: 453.2156, found, (M + H)
+: 453.2153. 
 
Chapter 4: Experimental Procedures 
 
101 
 
 (2S,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl 2-chloroacetate 20B.   193-194 °C; IR 
(solid) vmax(cm
-1): 3373 (NH), 3330 (NH), 2931 (C-H), 2854 (C-H), 
1767 (C=O), 1682 (C=O), 1650 (C=O), 1167 (C-O), 736 (C-Cl); 1H 
NMR (500 MHz, CDCl3) δ 7.33 – 7.25 (2H, m, H-7 and 7’), 7.25 – 
7.16 (3H, m, H-6, 6’ and H-8), 6.41 (1H, d, J = 8.1 Hz, NH), 5.17 (1H, d, J = 3.5 Hz, H-2), 4.39 – 
4.24 (1H, m, H-3), 4.18 (1H, d, J = 14.7 Hz, H-10), 4.12 (1H, d, J = 14.7 Hz, H-10) 3.86 – 3.74 (1H, 
m, H-11, ), 3.05 – 2.82 (2H, m, H-4), 1.97 – 1.83 (2H, m, cyclohexyl-CH2), 1.77 – 1.66 (2H, m, 
cyclohexyl-CH2), 1.66 – 1.56 (1H, m, cyclohexyl-CH2), 1.47 – 1.02 (14H, m, (CH3)3C and 
cyclohexyl-CH2); 
13C NMR (126 MHz, CDCl3) δ 166.15 and 165.80 (C=O), 155.69 (Boc C=O), 
137.14 (C-5), 129.13 (C-7 and 7’), 128.57 (C-6 and 6’), 126.74 (C-8), 79.94 [(CH3)3C], 75.96 (C-2), 
53.09 (C-3), 48.27 (C-11), 40.72 (C-10), 36.71 (C-4), 32.80 and 29.71 (cyclohexyl-CH2), 28.26 Boc 
((CH3)3C), 25.44 and 24.64 (cyclohexyl-CH2); HRMS (m/z), calculated for C23H34ClN2O5: 453.2156, 
found, (M + H)+: 453.2156. 
4.14 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino) 
-1-oxo-4-phenylbutan-2-yl propionate 22                                                                                                         
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), cyclohexyl isocyanide 8 (148 µl, 1.20 mmol) 
and propionic acid 2 (90 µl, 1.20 mmol) were dissolved in CH2Cl2 (3 ml) and the experiment was 
carried out as described in 4.5. The reaction yielded compound 22 (360 mg, 69%) as a white 
solid, being a mixture of diastereomers. Rf = 0.55 (49:1 CHCl3/MeOH); d.r. = 1.87:1.00. The 
diastereomeric mixture of compound 22 was then separated on preparative HPLC as described 
in 4.10 to give two clean separated diastereomers. 
 
 (2R,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl propionate 22A. 1H NMR (300 MHz, 
CDCl3) δ 7.34 – 7.12 (5H, m, Ar-H), 5.91 (1H, d, J = 8.1 Hz, NH), 
5.26 – 5.07 (2H, m, NH and H-2), 4.37 – 4.25 (1H, m, H-3), 3.86 – 
3.68 (1H, m, H-12), 2.82 (2H, d, J = 7.0 Hz, H-4), 2.49 – 2.26 (2H, 
m, H-10), 1.97 – 1.81 (2H, m, cyclohexyl-CH2), 1.76 – 1.53 (3H, m, cyclohexyl-CH2), 1.46 – 1.05 
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(17H, m, (CH3)3C, H-11 and cyclohexyl-CH2); 
13C NMR (75 MHz, CDCl3) δ 172.55 and 167.03 
(C=O), 154.96 (Boc C=O), 137.34 (C-5), 129.24 (C-7 and C-7’), 128.42 (C-6 and C-6’), 126.53 (C-8), 
79.44 [(CH3)3C], 73.19 (C-2), 52.31 (C-3), 48.23 (C-12), 38.06 (C-4), 32.85 (C-10), 32.71 
(cyclohexyl-CH2), 28.19 [(CH3)3C], 27.35, 25.42 and 24.69 (cyclohexyl-CH2), 9.03 (C-11).  
 
 (2S,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl propionate 22B. 1H NMR (300 MHz, 
CDCl3) δ 7.27 – 7.07 (5H, m, Ar-H), 5.92 (1H, d, J = 8.3 Hz, NH), 
5.23 – 4.98 (1H, m, H-2), 4.94 (1H, d, J = 9.2 Hz, NH), 4.29 – 4.11 
(1H, m, H-3), 3.81 – 3.63 (1H, m, H-12), 2.87 (2H, d, J = 7.5 Hz, H-
4), 2.34 (2H, q, J = 7.5 Hz, H-10), 1.98 – 1.74 (2H, m,  cyclohexyl-CH2), 1.71 – 1.46 (3H, m, 
cyclohexyl-CH2), 1.39 – 0.93 (17H, m, (CH3)3C), H-11 and cyclohexyl-CH2); 
13C NMR (75 MHz, 
CDCl3) δ 172.14 and 165.71 (C=O), 154.47 (Boc C=O), 136.41 (C-5), 128.17 (C-7 and C-7’), 127.45 
(C-6 and C-6’), 125.57 (C-8), 78.40 [(CH3)3C], 73.63 (C-2), 52.85 (C-3), 47.13 (C-12), 36.40 (C-4), 
31.85 (cyclohexyl-CH2), 28.67 [(CH3)3C], 27.24 (cyclohexyl-CH2), 26.46 (C-10), 24.43 (cyclohexyl-
CH2), 9.93 (C-11). 
4.15 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino) 
-1-oxo-4-phenylbutan-2-yl butyrate 23 
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), cyclohexyl isocyanide 8 (148 µl, 1.20 mmol) 
and butyric acid 3 (110 µl, 1.20 mmol) were dissolved in CH2Cl2 (3 ml). The experiment was 
carried out as described in 4.5 yielding compound 23 (270 mg, 51%) as a white solid being a 
mixture of diastereomers. 
 
 Rf = 0.58 (49:1 CHCl3/MeOH); d.r. = 1.32:1.00; m.p. 156 – 157 
°C; IR vmax(cm
-1): 3350 (NH), 2933 (C-H), 2854 (C-H), 1738 (C=O), 
1686 (C=O), 1650 (C=O), 1251 (C-O); 1H NMR (300 MHz, CDCl3) δ 
7.38 – 7.12 (5H, m, Ar-H), 5.98 (0.39H, d, J = 8.2 Hz, NH), 5.82 
(0.53H, d,  J = 8.2 Hz, NH), 5.28 – 4.94 (2H, m, NH and H-2), 4.37 
– 4.20 (1H, m, H-3), 3.87 – 3.69 (1H, m, H-13), 2.94 (1H, d, J = 7.1 Hz, H-4a), 2.82 (1H, d, J = 7.1 
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Hz, H-4b), 2.46 – 2.22 (2H, m, H-10), 1.99 – 1.80 (2H, m, cyclohexyl-CH2), 1.79 – 1.54 (5H, m, H-
11 and cyclohexyl-CH2), 1.46 – 1.08 (14H, m, (CH3)3C and cyclohexyl-CH2), 1.04 – 0.92 (3H, m, H-
12); 13C NMR (75 MHz, CDCl3) δ 172.42, 171.70, 167.05 and 166.72 (C=O), 155.62 and 154.97 
(Boc C=O), 137.35 (C-5), 129.29 (C-7 and C-7’), 128.49 (C-6 and C-6’), 126.61 (C-8), 79.48 
[(CH3)3C], 74.05 and 73.48 (C-2), 53.36 and 52.90 (C-3), 48.25 and 48.16 (C-13), 38.10 and 37.41 
(C-4), 36.02 and 35.91 (C-10), 32.94 and 32.78 (cyclohexyl-CH2), 28.27 [(CH3)3C], 25.45 and 
24.72 (cyclohexyl-CH2), 18.41 and 18.33 (C-11), 13.66 and 13.63 (C-12); HRMS (m/z), calculated 
for C25H39N2O5: 447.2859, found (M + H)
+: 447.2855. 
4.16 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino) 
-1-oxo-4-phenylbutan-2-yl pivalate 24                                                                                    
N-Boc-L-phenylalaninal 15 (250 mg, 1.00 mmol), cyclohexyl isocyanide 8 (123 µl, 1.00 mmol) 
and pivalic acid 4 (102 µl, 1.00 mmol) were dissolved in CH2Cl2 (3 ml) and the experiment was 
carried out as described in 4.5. Purification of the product yielded compound 24 (450 mg, 97%), 
as a white solid, as a mixture of diastereomers. Rf = 0.36 (49:1 CHCl3/MeOH); d.r. = 2.08:1.00. 
This mixture was then separated on preparative HPLC as described in 4.10 to give two 
separated diastereomers. 
 
 (2R,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl pivalate 24A. m.p. 159 – 161 °C; IR 
(solid) vmax(cm
-1): 3341 (NH), 3265 (NH), 3030 (C=CH), 2928 (C-
H), 1653 (C=O), 1619 (C=O), 1185 (C-O); 1H NMR (500 MHz, 
CDCl3) δ 7.30 – 7.24 (2H, m, H-7 and H-7’), 7.23 – 7.12 (3H, m, H-
6, H-6’ and H-8), 5.83 (1H, d, J = 8.2 Hz, NH), 5.25 – 5.07 (2H, m, NH and H-2), 4.37 – 4.21 (1H, 
m, H-3), 3.84 – 3.71 (1H, m, H-12), 2.90 – 2.74 (2H, m, H-4), 1.96 – 1.82 (2H, m, cyclohexyl-CH2), 
1.74 – 1.52 (3H, m, cyclohexyl-CH2), 1.42 – 1.06 (23H, m, (CH3)3C, cyclohexyl-CH2 and H-11); 
13C 
NMR (126 MHz, CDCl3) δ 176.38 and 167.20 (C=O), 154.95 (Boc C=O), 137.25 (C-5), 129.30 (C-7 
and C-7’), 128.48 (C-6 and C-6’), 126.59 (C-8), 79.48 ((CH3)3C), 73.28 (C-2), 53.08 (C-3), 48.07 (C-
12), 38.87 (C-10), 37.98 (C-4), 32.87 (cyclohexyl-CH2), 28.25 ((CH3)3C), 27.07 (C-11), 25.41 and 
Chapter 4: Experimental Procedures 
 
104 
 
24.58 (cyclohexyl-CH2); HRMS (m/z), calculated for C26H41N2O5: 461.3015, found (M + H)
+: 
461.3008. 
 
 (2S,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl pivalate 24B. m.p. 180 – 181 °C; IR 
vmax(cm
-1): 3303 (NH), 3065 (C=CH), 2926 (C-H), 1644 (C=O), 
1526 (C=O); 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.25 (2H, m, H-7 
and H-7’), 7.24 – 7.13 (3H, m, H-6, H-6’, H-8), 5.97 (1H, d, J = 8.3 
Hz, NH), 5.27 – 5.01 (1H, m, H-2), 4.98 (1H, d, J = 9.4 Hz, NH), 4.34 – 4.19 (1H, m, H-3), 3.85 – 
3.70 (1H, m, H-12), 3.02 – 2.69 (2H, m, H-4), 1.97 – 1.80 (2H, m, cyclohexyl-CH2), 1.74 – 1.65 
(2H, m, cyclohexyl-CH2), 1.65 – 1.52 (1H, m, cyclohexyl-CH2), 1.44 – 1.02 (23H, s, ((CH3)3C), 
cyclohexyl-CH2 and H-11); 
13C NMR (126 MHz, CDCl3) δ 177.05 and 166.83 (C=O), 155.35 (Boc 
C=O), 137.32 (C-5), 129.31 (C-7 and C-7’), 128.49 (C-6 and C-6’), 126.62 (C-8), 79.37 [(CH3)3C], 
73.94 (C-2), 53.16 (C-3), 47.94 (C-12), 38.87 (C-10), 37.57 (C-4), 32.85 (cyclohexyl-CH2), 28.29 
[(CH3)3C], 27.08 (C-11), 25.43 and 24.58 (cyclohexyl-CH2); HRMS (m/z), calculated for 
C26H41N2O5: 461.3015, found, (M + H)
+: 461.3017. 
4.17 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino) 
-1-oxo-4-phenylbutan-2-yl 3,3-dimethylbutanoate 25                                                                                                                                               
N-Boc-L-phenylalaninal 15 (600 mg, 2.40 mmol), cyclohexyl isocyanide 8 (296 µl, 2.40 mmol) 
and tert-butyl acetic acid 5 (306 µl, 2.40 mmol) were dissolved in CH2Cl2 (3 ml). The experiment 
was carried out as described in 4.5. This yielded compound 25 (1.07 g, 94%), as white solid, 
being a mixture of diastereomers. Rf = 0.53 (49:1 CHCl3/MeOH); d.r. = 1.93:1.00. This 
diastereomeric mixture was then separated on preparative HPLC as described in 4.10 to give 
two separated diastereomers. 
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 (2R,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl 3,3-dimethylbutanoate 25A. m.p. 162-
163 °C; IR (solid) vmax(cm
-1): 3328 NH), 3032 (C=CH), 1742 (C=O), 
1682 (C=O), 1652 (C=O), 1169 (C-O); 1H NMR (500 MHz, CDCl3) δ 
7.22 – 7.16 (2H, m, H-7 and H-7’), 7.16 – 7.06 (3H, m, H-6, H-6’ 
and H-8), 5.82 (1H, d, J = 8.1 Hz, NH), 5.22 – 5.00 (2H, m, NH and 
H-2), 4.26 – 4.16 (1H, m, H-3), 3.76 – 3.63 (1H, m, H-13), 2.83 – 2.65 (2H, m, H-4), 2.28 – 2.13 
(2H, m, H-10), 1.89 – 1.75 (2H, m, cyclohexyl-CH2), 1.68 – 1.57 (2H, m, cyclohexyl-CH2), 1.57 – 
1.49 (1H, m, cyclohexyl-CH2), 1.37 – 0.93 (23H, m, (CH3)3C, cyclohexyl-CH2 and H-12); 
13C NMR 
(126 MHz, CDCl3) δ 170.33 and 167.10 (C=O), 154.95 (Boc C=O), 137.38 (C-5), 129.30 (C-7 and C-
7’), 128.45 (C-6 and C-6’), 126.53 (C-8), 79.42 [(CH3)3C], 73.43 (C-2), 52.96 (C-3), 48.25 (C-13), 
47.51 (C-12), 37.93 (C-4), 32.95 and 32.77 (cyclohexyl-CH2), 29.69 (C-12), 28.26 [(CH3)3C], 25.44 
and 24.74 (cyclohexyl-CH2); HRMS (m/z), calculated for C27H43N2O5: 475.3172, found, (M + H)
+: 
475.3163. 
 
 (2S,3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexylamino)-1-
oxo-4-phenylbutan-2-yl 3,3-dimethylbutanoate 25B. m.p. 169-
170 °C; IR vmax(cm
-1): 3290 (NH), 2930 (C-H), 1738 (C=O), 1366 
(C-O); 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.25 (2H, m, H-7 and H-
7’), 7.25 – 7.15 (3H, m, H-6, H-6’ and H-8), 6.00 (1H, d, J = 8.2 Hz, 
NH), 5.26 – 5.01 (2H, m, NH and H-2), 4.31 – 4.19 (1H, m, H-3), 
3.84 – 3.73 (1H, m, H-13), 2.99 – 2.71 (2H, m, H-4), 2.34 – 2.22 (2H, m, H-10), 1.97 – 1.83 (3H, 
m, cyclohexyl-CH2), 1.75 – 1.65 (2H, m, cyclohexyl-CH2), 1.65 – 1.57 (1H, m, cyclohexyl-CH2), 
1.41 – 1.03 (23H, m, (CH3)3C, cyclohexyl-CH2 and H-12); 
13C NMR (126 MHz, CDCl3) δ 171.18 and 
166.78 (C=O), 155.42 (Boc C=O), 137.42 (C-5), 129.18 (C-7 and C-7’), 128.51 (C-6 and C-6’), 
126.61 (C-8), 79.41 [(CH3)3C], 73.85 (C-2), 53.37 (C-3), 48.21 (C-13), 47.81 (C-10), 38.76 (C-4), 
32.89 and 30.98 (cyclohexyl-CH2), 29.70 (C-12), 28.30 ((CH3)3C), 25.45 and 24.71 (cyclohexyl-
CH2); HRMS (m/z), calculated for C27H43N2O5: 475.3172, found, (M + H)
+: 475.3161. 
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4.18 Preparation of (2S)-(3S)-3-((tert-butoxycarbonyl)amino)-1-(cyclohexyl 
amino)-1-oxo-4-phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenyl 
propanoate 26 
N-Boc-L-phenylalaninal 15 (500 mg, 2.01 mmol), cyclohexyl isocyanide 8 (246 µl, 2.01 mmol) 
and N-Boc-L-phenylalanine 7 (533 mg, 2.01 mmol) were dissolved in CH2Cl2 (5 ml). The 
experiment was carried out as described in 4.5 but product precipitated out of solution during 
the experiment. Addition of CH2Cl2 (20 ml) did not dissolve the product. Purification of the 
product was then achieved by washing with CH2Cl2 to remove the starting material. This 
afforded compound 26 (1.25 g, 100%) as a white solid which was a mixture of diastereomers. 
 
 Rf = 0.58 (49:1 CHCl3/MeOH); m.p. 190 – 192 °C; IR vmax(cm
-1): 
3348 (NH), 3029 (C=CH), 1752 (C=O), 1689 (C=O), 1653 (C=O); 1H 
NMR (500 MHz, CDCl3) δ 7.45 – 6.98 (10H, m, Ar-H), 6.97 – 6.80 
(1H, m, NH), 5.49 – 4.81 (2H, m, H-2 and NH), 4.64 – 4.12 (2H, m, 
H-3 and H-6), 3.81 – 3.64 (1H, m, H-8), 3.24 – 2.95 (2H, m, H-4), 
2.93 – 2.38 (2H, m, H-7), 1.95 – 1.79 (2H, m, cyclohexyl-CH2) 1.78 – 1.55 (3H, m, cyclohexyl-CH2), 
1.51 – 1.02 (23H, m, 2x(CH3)3C and cyclohexyl-CH2); 
13C NMR (126 MHz, CDCl3) δ 171.14, 
170.76, 167.00 and 166.17 (C=O), 155.71 and 154.77 (Boc C=O), 137.49 (Ar-C), 135.45 (Ar-C), 
129.42 (Ar-C), 129.24 (Ar-C), 129.08 (Ar C), 129.02 (Ar C), 128.43 (Ar C), 128.41 (Ar C), 128.24 
(Ar C), 127.59 (Ar C), 126.54 (Ar C), 126.35 (Ar-C), 80.75 [(CH3)3C], 79.14 ((CH3)3C), 74.11 (C-2), 
55.74, 54.87 and 52.60 (C-3 and C-8), 48.68, 37.61 and 37.15 (C-4 and C-7), 32.79, 32.64, 32.50 
(cyclohexyl-CH2), 28.39 and 28.29 Boc [(CH3)3C], 25.55, 25.51, 25.09 and 24.99 (cyclohexyl-CH2); 
HRMS (m/z), calculated for C35H50N3O7 : 624.3679, found, (M + H)
+: 624.3653. 
4.19 Preparation of (2R,3S)-N-cyclohexyl-2-hydroxy-4-phenyl-3-propion 
amidobutanamide 27A 
Compound 22A (76 mg, 0.18 mmol), TFA (136 µl, 1.77 mmol) and Et3N (245 µl, 1.77 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11 to yield compound 27A (25 mg, 42%) 
as a white solid. 
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 Rf = 0.32 (49:1 CHCl3/MeOH); m.p. = 130 – 131 °C; IR νmax(cm
-1): 
3347 (OH), 3322 (NH), 3236 (NH), 2934 (C-H), 2855 (C-H), 1730 
(C=O), 1676 (C=O); 1H NMR (300 MHz, CDCl3) δ 7.34 – 7.14 (5H, 
m, Ar-H), 7.09 – 6.92 (2H, m, NH and OH), 6.57 (1H, d, J = 6.7 Hz, 
NH), 4.18 – 4.04 (2H, m, H-2 and H-3), 3.80 – 3.63 (1H, m, H-12), 
3.11 (1H, dd, J = 13.7, 6.0 Hz, H-4a), 3.03 – 2.88 (1H, m, H-4b), 2.08 (2H, q, J = 7.6 Hz, H-10), 1.92 
– 1.54 (5H, m, cyclohexyl-CH2), 1.46 – 1.07 (5H, m, cyclohexyl-CH2), 1.01 (3H, t, J = 7.6 Hz, H-11); 
13C NMR (75 MHz, CDCl3) δ 176.08 and 171.96 (C=O), 138.27 (C-5), 129.19 (C-7 and C-7’), 128.42 
(C-6 and C-6’), 126.52 (C-8), 73.41 (C-2), 55.92 (C- 3), 48.03 (C-12), 35.45 (C-4), 33.16 
(cyclohexyl-CH2), 32.62 (cyclohexyl-CH2), 29.43 (C-10), 25.44 (cyclohexyl-CH2), 24.79 (cyclohexyl-
CH2), 9.87 (C-11); HRMS (m/z), calculated for C19H29N2O3 : 333.2178, found (M + H)
+: 333.2175. 
4.20 Preparation of (2S,3S)-N-cyclohexyl-2-hydroxy-4-phenyl-3-propion 
amidobutanamide 27B 
Compound 22B (57 mg, 0.13 mmol), TFA (101 µl, 1.31 mmol) and Et3N (181 µl, 1.31 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11 to yield compound 27B (24 mg, 56%). 
 
 Rf = 0.32 (49:1 CHCl3/MeOH); m.p. 154 – 155 °C; IR vmax(cm
-1): 
3390 (OH), 3297 (NH), 2978 (C-H), 2850 (C-H), 1634 (C=O); 1H 
NMR (300 MHz, DMSO-d6) δ 7.59 (1H, d, J = 8.8 Hz, NH or OH), 
7.44 (1H, d, J = 8.5 Hz, NH or OH) 7.25 – 7.01 (5H, m, Ar), 5.80 
(1H, d, J = 6.0 Hz, NH or OH), 4.28 – 4.16 (1H, m, H-3), 3.90 – 
3.83 (1H, m, H-2), 3.54 (1H, s, H-12), 2.68 – 2.48 (2H, m, H-4), 1.92 (2H, q, J = 7.5 Hz, H-10), 1.72 
– 1.55 (3H, m, cyclohexyl-CH2), 1.55 – 1.36 (2H, m, cyclohexyl-CH2), 1.31 – 1.13 (5H, m, 
cyclohexyl-CH2), 0.79 (3H, t, J = 7.6 Hz, H-11); 
13C NMR (75 MHz, DMSO-d6) δ 172.50 and 170.59 
(C=O), 139.20 (C-5), 128.95 (C-7 and C-7’), 127.88 (C-6 and C-6’), 125.77 (C-8), 73.24 (C-2), 53.05 
(C-3), 47.16 (C-12), 33.94 (C-4), 32.30 and 32.07 (cyclohexyl-CH2), 28.41 (C-10), 25.08 and 24.64 
(cyclohexyl-CH2), 9.83 (C-11); HRMS (m/z), calculated for C19H29N2O3: 333.2178, found, (M + 
H)+: 333.2173. 
4.21 Preparation of (3S)-3-butyramido-N-cyclohexyl-2-hydroxy-4-phenyl 
butanamide 28 
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Compound 23 (250 mg, 0.54 mmol), TFA (418 µl, 5.43 mmol) and Et3N (743 µl, 5.43 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11 to yield compound 28 (65 mg, 36%) as 
a white solid. 
 
 Rf = 0.50 (49:1 CHCl3/MeOH); m.p. 182 – 183 °C; IR vmax(cm
-1): 
3278 (OH), 2930 (C-H), 1642 (C=O), 1124 (C-O); 1H NMR (300 
MHz, CDCl3) δ 7.34 – 7.15 (5H, m, Ar-H), 7.01 (0.34H, d, J = 8.5 
Hz, NH), 6.93 (0.60H, d, J = 8.4 Hz, NH), 6.74 (0.60H, d, J = 8.0 Hz, 
NH), 6.47 (0.54H, d, J = 6.9 Hz, NH), 6.24 (0.34H, d, J = 6.7 Hz, 
OH), 6.07 (0.33H, d, J = 5.1 Hz, OH), 4.30 – 4.04 (2H, m, H-2 and H-3), 3.85 – 3.62 (1H, m, H-13), 
3.21 – 2.94 (2H, m, H-4), 2.15 – 2.00 (2H, m, H-10), 1.98 – 1.44 (7H, m, cyclohexyl-CH2 and H-
11), 1.44 – 1.08 (5H, m, cyclohexyl-CH2), 0.94 – 0.78 (3H, m, H-12); 
13C NMR (75 MHz, CDCl3) δ 
176.11, 175.28, 171.80 and 170.86 (C=O), 138.19 and 137.86 (C-5), 129.20 and 128.62 (C-7 and 
C-7’), 128.47 (C-6 and C-6’), 126.71 and 126.57 (C-8), 74.93 and 73.55 (C-2), 57.72 and 56.06 (C-
3), 48.04 and 47.96 (C-13), 38.29 and 38.13 (C-4), 35.72 and 35.57 (C-10), 33.21, 33.15, 32.80, 
32.69, 25.46 and 24.80 (cyclohexyl-CH2), 19.07 (C-11), 13.63 and 13.56 (C-12); HRMS (m/z), 
calculated for C20H31N2O3: 347.2335, found (M + H)
+: 347.2330. 
4.22 Preparation of (2R,3S)-N-cyclohexyl-2-hydroxy-4-phenyl-3-pivalamido 
butanamide 29A                      
Compound 24A (50 mg, 0.11 mmol), TFA (84 µl, 1.09 mmol) and Et3N (151 µl, 1.09 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11 to yield compound 29A (37 mg, 93%) 
as a white solid. 
 
 Rf = 0.37 (49:1 CHCl3/MeOH); m.p. 182 – 183 °C; IR vmax(cm
-1): 
3341 (OH), 3264 (NH), 3030 (C=CH), 1653 (C=O), 1619 (C=O);  1H 
NMR (500 MHz, CDCl3) δ 7.36 – 7.21 (2H, m, H-7 and H-7’), 7.21 
– 7.11 (3H, m, H-6, H-6’ and H-8), 6.97 (1H, d, J = 8.5 Hz, NH), 
6.78 (1H, d, J = 8.1 Hz, NH), 6.56 (1H, br-s, OH), 4.32 – 4.20 (1H, 
m, H-3), 4.09 (1H, s, H-2), 3.84 – 3.65 (1H, m, H-12), 3.10 (1H, dd, J = 13.8, 5.7 Hz, H-4a), 3.02 – 
2.93 (1H, m, H-4b), 1.94 – 1.78 (2H, m, cyclohexyl-CH2), 1.77 – 1.65 (2H, m, cyclohexyl-CH2), 
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1.65 – 1.52 (1H, m, cyclohexyl-CH2), 1.44 – 1.28 (3H, m, cyclohexyl-CH2), 1.25 – 1.09 (2H, m, 
cyclohexyl-CH2), 1.08 – 0.92 (9H, m, H-11); 
13C NMR (126 MHz, CDCl3) δ 180.65 and 171.82 
(C=O), 138.27 (C-5), 129.26 (C-7 and C-7’), 128.35 (C-6 and C-6’), 126.47 (C-8), 73.62 (C-2), 55.49 
(C-3), 47.96 (C-12), 38.63 (C-10), 35.28 (C-4), 33.32 and 32.77 (cyclohexyl-CH2), 27.39 C-11, 
27.18 (C-11), 25.45 and 24.84 (cyclohexyl-CH2); HRMS (m/z), calculated for C21H33N2O3: 
361.2491, found, (M + H)+: 361.2488. 
4.23 Preparation of (2S,3S)-N-cyclohexyl-2-hydroxy-4-phenyl-3-pivalamido 
butanamide 29B 
Compound 24B (50 mg, 0.11 mmol), TFA (84 µl, 1.09 mmol) and Et3N (151 µl, 1.09 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11 to yield compound 29B (26 mg, 65%) as 
a white precipitate. 
 
 Rf = 0.45 (49:1 CHCl3/MeOH); m.p. 123 – 125 °C; IR vmax(cm
-1): 
3303 (OH), 3029 (C=CH), 1644 (C=O), 1152 (C-O); 1H NMR (500 
MHz, CDCl3) δ 7.40 – 7.26 (2H, m, H-7 and H-7’), 7.24 – 7.13 (3H, 
m, H-6, H-6’ and H-8), 6.94 (1H, d, J = 8.5 Hz, NH), 6.14 (1H, br-s, 
OH), 5.97 (1H, d, J = 6.3 Hz, NH), 4.26 – 4.18 (2H, m, H-2 and H-
3), 3.84 – 3.69 (1H, m, H-12), 3.21 (1H, dd, J = 14.1, 10.5 Hz, H-4a), 3.05 (1H, dd, J = 14.0, 5.3 Hz, 
H-4b), 1.98 – 1.80 (2H, m, cyclohexyl-CH2), 1.77 – 1.65 (2H, m, cyclohexyl-CH2), 1.65 – 1.52 (1H, 
m, cyclohexyl-CH2), 1.44 – 1.09 (5H, m, cyclohexyl-CH2), 1.03 (9H, s, H-11); 
13C NMR (126 MHz, 
CDCl3) δ 181.77 and 170.74 (C=O), 137.81 (C-5), 129.16 (C-7 and C-7’), 128.66 (C-6 and C-6’), 
126.78 (C-8), 75.20 (C-2), 57.58 (C-3), 47.91 (C-12), 38.61 (C-10), 35.81 (C-4), 33.35 and 32.85 
(cyclohexyl-CH2), 27.35 (C-11), 25.47 and 24.84 (cyclohexyl-CH2); HRMS (m/z), calculated for 
C21H33N2O3: 361.2491, found, (M + H)
+: 361.2487. 
4.24 Preparation of (2R,3S)-N-cyclohexyl-3-(3,3-dimethylbutanamido)-2-
hydroxy-4-phenylbutanamide 30A                    
 Compound 25A (75 mg, 0.16 mmol), TFA (122 µl, 1.58 mmol) and Et3N (151 µl, 1.58 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11 to yield compound 30A (51 mg, 86%) 
as a white solid.  
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Rf = 0.37 (49:1 CHCl3/MeOH); m.p. 129 – 130 °C; IR vmax(cm
-1): 
3274 (OH), 3088 (C=CH), 2926 (C-H), 1729 (C=O), 1643 (C=O), 
1256 (C-O); 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.17 (5H, m, Ar-
H), 6.89 (1H, d, J = 8.3 Hz), 6.47 (0.9H, d, J = 7.8 Hz) and 6.39 (1H, 
d, J = 7.1 Hz) and 6.31 (0.1H, d, J = 7.0 Hz, 2xNH and OH) 4.27 – 
4.13 (1H, m, H-3), 4.09 – 4.02 (1H, m, H-2), 3.77 – 3.64 (1H, m, H-13), 3.21 – 3.12 (1H, m, H-4a), 
3.05 (1H, dd, J = 13.8, 9.1 Hz, H-4b), 1.98 (1H, d, J = 13.0 Hz) and 1.93 (1H, d, J = 13.0 Hz, H-10), 
1.91 – 1.77 (2H, m, cyclohexyl-CH2), 1.76 – 1.64 (3H, m, cyclohexyl-CH2), 1.47 – 1.00 (5H, m, 
cyclohexyl-CH2), 0.92 (9H, s, H-12); 
13C NMR (126 MHz, CDCl3) δ 174.26 and 171.78 (C=O), 
138.05 (C-5), 129.22 (C-7 and C-7’), 128.54 (C-6 and C-6’), 126.63 (C-8), 73.68 (C-2), 56.17 (C-3), 
50.18 (C-10), 48.13 (C-13), 35.64 (C-4), 33.03 and 32.75 (cyclohexyl-CH2), 30.71 (C-11), 29.67 (C-
12), 25.44 and 24.77 (cyclohexyl-CH2); HRMS (m/z), calculated for C22H35N2O3 : 375.2648, found, 
(M + H)+: 375.2640. 
4.25 Preparation of (2S,3S)-N-cyclohexyl-3-(3,3-dimethylbutanamido)-2-
hydroxy-4-phenylbutanamide 30B 
Compound 25B (50 mg, 0.11 mmol), TFA (81 µl, 1.05 mmol), Et3N (146 µl, 1.05 mmol) and 
CH2Cl2 (1 ml) were reacted together as described in 4.11 yielding compound 30B (30 mg, 73%) 
as a white solid.  
 
Rf = 0.37 (49:1 CHCl3/MeOH); m.p. 130 – 132 °C; IR vmax(cm
-1): 
3279 (OH), 3092 (NH), 2930 (C-H), 2859 (C-H), 1636 (C=O); 1H 
NMR (500 MHz, DMSO-d6) δ 7.59 (1H, d, J = 8.7 Hz, NH), 7.50 
(1H, d, J = 8.4 Hz, NH), 7.25 – 7.19 (2H, m, H-7 and H-7’), 7.18 – 
7.10 (3H, m, H-6, H-6’ and H-8), 5.90 (0.1H, d, J = 5.8 Hz) and 
5.83 (0.9H, d, J = 5.8 Hz, OH), 4.40 – 4.31 (1H, m, H-3), 3.98 – 3.91 (1H, m, H-2), 3.61 (1H, s, H-
13), 3.10 (2H, d, J = 7.7 Hz, H-4), 2.70 – 2.62 (1H, m, H-4a), 2.59 – 2.54 (1H, m, H-4b), 1.78 – 1.61 
- 1.49 (5H, m, cyclohexyl-CH2), 1.35 – 1.06 (5H, m, cyclohexyl-CH2), 0.79 (9H, s, H-12); 
13C NMR 
(126 MHz, DMSO-d6) δ 171.16 and 170.94 (C=O), 139.68 (C-5), 129.47 (C-7 and 7’), 128.37 (C-6 
and 6’), 126.27 (C-8), 73.86 (C-2), 53.50 (C-3), 49.15 (C-10), 47.69 (C-13), 34.28 (C-4), 32.81 and 
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32.59 (cyclohexyl-CH2), 30.74 (C-11), 30.06 (C-12), 25.59 and 25.22 (cyclohexyl-CH2); HRMS 
(m/z), calculated for C22H35N2O3: 375.2648, found, (M + H)
+: 375.2644. 
4.26 Preparation of (2R,3S)-3-(2-chloroacetamido)-N-cyclohexyl-2-hydroxy-4-
phenylbutanamide  31A                                                                                                      
Compound 20A (52 mg, 0.11 mmol), TFA (98 µl, 1.14 mmol) and Et3N (177 µl, 1.14 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 31A 
(35 mg, 88%) as a white solid. 
 
 Rf = 0.47 (49:1 CHCl3/MeOH); m.p. 169 – 170 °C; IR (solid) vmax  
(cm-1): 3404 (OH), 3298 (NH), 3032 (C=CH), 1661 (C=O), 1614 
(C=O), 892 (C-Cl); 1H NMR (500 MHz, CDCl3) δ 7.69 (1H, d, J = 9.0 
Hz, NH), 7.31 – 7.23 (2H, m, H-7 and H-7’), 7.23 – 7.15 (3H, m, H-
6, H-6’ and H-8), 6.84 (1H, d, J = 9.2 Hz, NH), 5.59 (1H, d, J = 6.0 Hz, OH), 4.39 – 4.24 (1H, m, H-
3), 4.16 – 4.07 (1H, m, H-2), 3.83 (2H, s, H-10), 3.79 – 3.69 (1H, m, H-11), 3.09 (1H, dd, J = 13.7, 
5.8 Hz, H-4a), 2.84 (1H, dd, J = 13.7, 9.3 Hz, H-4b), 1.91 – 1.80 (2H, m, cyclohexyl-CH2), 1.77 – 
1.66 (2H, m, cyclohexyl-CH2), 1.66 – 1.56 (1H, m, cyclohexyl-CH2), 1.44 – 1.27 (2H, m, 
cyclohexyl-CH2), 1.24 – 1.07 (3H, m, cyclohexyl-CH2); 
13C NMR (126 MHz, CDCl3) δ 171.25 and 
167.23 (C=O), 137.60 (C-5), 129.19 (C-7 and C-7’), 128.50 (C-6 and C-6’), 126.69 (C-8), 72.21 (C-
2), 55.38 (C-3), 48.10 (C-11), 42.30 (C-10), 35.63 (C-4), 33.11, 32.68, 25.39 and 24.78 
(cyclohexyl-CH2); HRMS (m/z), calculated for C18H26ClN2O3: 353.1632, found, (M + H)
+: 
353.1624. 
4.27 Preparation of (2S,3S)-3-(2-chloroacetamido)-N-cyclohexyl-2-hydroxy-4-
phenylbutanamide 31B 
Compound 20B (28 mg, 0.06 mmol), TFA (48 µl, 0.61 mmol) and Et3N (85 µl, 0.61 mmol) in 
CH2Cl2   (1 ml) were reacted together as described in 4.11. The reaction yielded compound 31B 
(20 mg, 90%) as a white solid.  
 
Chapter 4: Experimental Procedures 
 
112 
 
Rf = 0.50 (49:1 CHCl3/MeOH); m.p. 209 – 210 °C; IR vmax(cm
-1): 
3399 (OH), 3280 (NH), 3028 (C=CH), 1658 (C=O), 1618 (C=O), 893 
(C-Cl); 1H NMR (500 MHz, CDCl3) 7.32 – 7.26 (3H, m, Ar-H), 7.25 
– 7.10 (5H, m, Ar-H, 2xNH and OH), 4.34 – 4.25 (1H, m, H-3), 
4.25 – 4.18 (1H, m, H-2), 3.96 (1H, d, J = 15.0 Hz) and 3.90 (1H, d, J = 15.0 Hz, H-10), 3.83 – 3.71 
(1H, m, H-11), 3.00 – 2.87 (2H, m, H-4), 1.94 – 1.83 (2H, m, cyclohexyl-CH2), 1.80 – 1.68 (2H, m, 
cyclohexyl-CH2), 1.68 – 1.58 (1H, m, cyclohexyl-CH2), 1.44 – 1.32 (2H, m, cyclohexyl-CH2), 1.31 – 
1.04 (3H, m, cyclohexyl-CH2); 
13C NMR (126 MHz, CDCl3) δ 170.12 and 167.96 (C=O), 137.30 (C-
5), 129.14 (C-7 and C-7’), 128.67 (C-6 and C-6’), 126.83 (C-8), 73.23 (C-2), 56.72 (C-3), 48.27 (C-
11), 42.25 (C-10), 34.82 (C-4), 33.01, 32.85, 25.46 and 24.83 (cyclohexyl-CH2); HRMS (m/z), 
calculated for C18H26ClN2O3: 353.1632, found, (M + H)
+: 353.1628. 
4.28 Preparation of (3S)-3-((S)-2-amino-3-phenylpropanamido)-N-cyclohexyl-
2-hydroxy-4-phenylbutanamide 32 
Compound 28 (200 mg, 0.32 mmol), TFA (247 µl, 3.21 mmol) and Et3N (445 µl, 3.21 mmol) in 
CH2Cl2 (3 ml) were reacted together as described in 4.11. The reaction yielded compound 32 (92 
mg, 68%) as a white solid which was a mixture of diastereomers. 
 
 Rf = 0.41 (49:1 CHCl3/MeOH); m.p. 149 – 150 °C; IR (solid): 3269 
(OH), 3027 (C=CH), 2930 (C-H), 1671 (C=O), 1641 (C=O), 1641 
(C=O), 1198 (C-O); 1H NMR (500 MHz, DMSO-d6) δ 8.64 (0.60H, d, J 
= 8.8 Hz) and 8.48 (0.37H, d, J = 8.8 Hz) and 7.63 (0.61H, d, J = 8.4 
Hz) and 7.49 (0.37H, d, J = 8.3 Hz, 2xNH), 7.35 – 7.09 (10H, m, Ar-
H), 6.37 (0.38H, d, J = 5.7 Hz) and 6.24 (0.61H, d, J = 5.8 Hz, OH), 4.45 – 4.35 (0.62H, m) and 4.32 
– 4.21 (0.42H, m, H-3), 4.08 (0.39H, dd, J = 8.9, 4.0 Hz, H-6), 3.98 – 3.90 (1H, m, H-2), 3.85 – 3.80 
(0.40H, m, H-6), 3.67 – 3.31 (2H, m, H-4), 3.19 – 3.12 (1H, m, H-8), 2.97 – 2.57 (2H, m, H-7), 2.51 
(2H, s, NH2), 1.79 – 1.46 (5H, m, cyclohexyl-CH2), 1.37 – 1.01 (5H, m, cyclohexyl-CH2); 
13C NMR 
(126 MHz, DMSO-d6) δ 171.14, 170.90, 168.62 and 168.41 (C=O), 139.35 (Ar-C), 138.98 (Ar-C), 
135.68 (Ar-C), 135.66 (Ar-C), 130.00 (Ar-C), 129.95 (Ar-C), 129.70 (Ar-C), 129.45 (Ar-C), 128.93 
(Ar-C), 128.90 (Ar-C), 128.83 (Ar-C), 128.62 (Ar-C), 127.48 (Ar-C), 126.73 (Ar-C), 126.48 (Ar-C), 
73.40 (C-2), 70.45 (C-2), 54.23 (C-3), 54.12 (C-3), 53.83 (C-6), 47.80 (C-8), 47.76 (C-8), 37.93 (C-
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4), 37.82 (C-4), 37.34 (C-7), 34.40 (C-7), 32.77 and 32.69, 32.49, 25.56, 25.21, 25.16 and 24.97 
(cyclohexyl-CH2); HRMS (m/z), calculated for C25H34N3O3: 424.2600 found, (M + H)
+: 424.2597. 
4.29 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-((2,6-dimethyl 
phenyl)amino)-1-oxo-4-phenylbutan-2-yl acetate 33                                                                                              
N-Boc-L-phenylalaninal 15 (307 mg, 1.23 mmol), xylyl isocyanide 10 (161 mg, 1.23 mmol) and 
acetic acid 1 (83 µl, 1.23 mmol) were dissolved in CH2Cl2 (3 ml) and the experiment was carried 
out as described in 4.5. The reaction yielded compound 33 (534 mg, 99%), a yellow solid, as a 
mixture of diastereomers. Rf = 0.53 (49:1 CHCl3/MeOH); d.r. = 1.88:1.00. This diastereomeric 
mixture was then separated using preparative HPLC as described in 4.10 to give two clean 
separated diastereomers. 
 
 (2R,3S)-3-((tert-butoxycarbonyl)amino)-1-((2,6-
dimethylphenyl)amino)-1-oxo-4-phenylbutan-2-yl acetate 33A. 
m.p. 176 – 177 °C; IR vmax (cm
-1): 3314 (NH), 3256 (NH), 2918 (C-
H), 2849 (C-H), 1738 (C=O), 1692 (C=O), 1676 (C=O);  1H NMR 
(500 MHz, CDCl3) δ 7.35 – 7.14 (5H, m, Ar-H), 7.14 – 6.97 (3H, m, Ar-H), 5.40 – 5.18 (1H, m, H-2), 
5.18 – 5.05 (1H, m, NH), 4.54 – 4.38 (1H, m, H-3), 2.99 – 2.80 (2H, m, H-4), 2.26 – 2.09 (9H, m, 
H-10, H-13 and H-13’), 1.43 – 1.10 (9H, m, (CH3)3C); 
 13C NMR (126 MHz, CDCl3) δ 169.37 and 
166.42 (C=O), 154.97 (Boc C=O), 137.07 (C-11), 135.49 (C-5), 132.63 (C-12 and 12’), 129.36 (Ar-
C), 128.61 (Ar-C), 128.23 (Ar-C), 127.65 (Ar-C), 126.75 (Ar-C), 79.70 [(CH3)3C], 74.14 (C-2), 53.19 
(C-3), 38.56 (C-4), 28.26 ((CH3)3C), 20.67 (C-10), 18.38 (C-13 and 13’); HRMS (m/z), calculated 
for C25H33N2O5: 441.2389, found, (M + H)
+: 441.2380. 
 
 (2S,3S)-3-((tert-butoxycarbonyl)amino)-1-((2,6-
dimethylphenyl)amino)-1-oxo-4-phenylbutan-2-yl acetate 33B. 
m.p. 166 – 167 °C; IR vmax (cm
-1): 3317 (NH), 3030 (C=CH), 2920 
(C-H), 1744 (C=O), 1690 (C=O), 1676 (C=O); 1H NMR (500 MHz, 
CDCl3) δ 7.52 (1H, s, NH), 7.33 – 7.17 (5H, m, Ar-H), 7.15 – 7.01 (3H, m, Ar-H), 5.36 (1H, d, J = 3.9 
Hz, H-2), 4.95 (1H, d, J = 9.2 Hz, NH), 4.43 – 4.34 (1H, m, H-3), 3.13 (1H, dd, J = 14.1, 6.0 Hz, H-
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4a), 3.06 – 2.88 (1H, m, H-4b), 2.23 (6H, s, H-13 and 13’), 2.21 – 2.13 (3H, m, H-10), 1.41 – 1.17 
(9H, m, (CH3)3C); 
13C NMR (126 MHz, CDCl3) δ 169.85 and 166.29 (C=O), 155.52 Boc (C=O), 
137.31, 135.24 and 132.72 (C-5, C-12 and 12’), 129.24 (Ar-C), 128.64 (Ar-C), 128.54 (Ar-C), 
128.33 (Ar-C), 128.26 (Ar-C), 127.67 (Ar-C), 126.77 (Ar-C), 126.68 (Ar-C), 79.68 [(CH3)3C], 74.93 
(C-2), 53.44 (C-3), 37.39 (C-4), 28.25 [(CH3)3C], 20.87 (C-10), 18.53 and 18.39 (C-13 and C-13’); 
HRMS (m/z), calculated for C25H33N2O5: 441.2389, found, (M + H)
+: 441.2376. 
4.30 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-((2,6-dimethyl 
phenyl)amino)-1-oxo-4-phenylbutan-2-yl propionate 34 
N-Boc-L-phenylalaninal 15 (500 mg, 2.01 mmol), xylyl isocyanide 10 (263 mg, 2.01 mmol) and 
propionic acid 2 (150 µl, 2.01 mmol) were dissolved in of CH2Cl2 (5 ml). The experiment was 
carried out as described in 4.5 yielding compound 34 (908 mg, 99%) as a white solid which was 
a mixture of diastereomers and rotamers. 
 
 Rf = 0.62 (49:1 CHCl3/MeOH); d.r. = 1.83:1.00; m.p. 154 – 155 
°C; IR vmax(cm
-1): 3328 (NH), 3296 (NH), 2976 (C-H), 2933 (C-H), 
1736 (C=O), 1686 (C=O); 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.16 
(5H, m, Ar-H), 7.14 – 7.01 (3H, m, Ar-H), 5.43 – 5.28 (1H, m, H-2), 
5.12 (0.57H, d, J = 9.5 Hz) and 4.99 (0.40H, d, J = 9.3 Hz, NH), 
4.52 – 4.35 (1H, m, H-3), 3.18 – 3.09 (0.54H, m, H-4a), 3.05 – 2.80 (1.5H, m, H-4a and H-4b), 
2.59 – 2.40 (2H, m, H-10), 2.25 – 2.10 (6H, m, H-14 and 14’), 1.40 – 1.15 (12H, m, (CH3)3C and H-
11); 13C NMR (126 MHz, CDCl3) δ 173.25, 172.84, 166.54 and 166.41 (C=O), 155.51 and 155.00 
(Boc C=O), 137.34 (Ar-C), 137.11 (Ar-C, 135.50 (Ar-C), 135.23 (Ar-C), 132.78 (Ar-C), 132.65 (Ar-
C), 129.37 (Ar-C), 129.25 (Ar-C), 128.61 (Ar-C), 128.53 (Ar-C), 128.32 (Ar-C), 128.25 (Ar-C), 
127.66 (Ar-C), 127.64 (Ar-C), 126.75 (Ar-C), 126.66 (Ar-C), 79.74 and 79.64 [(CH3)3C], 74.77 and 
73.91 (C-2), 53.44 and 53.29 (C-3), 38.55 and 37.48 (C-4), 28.25 ((CH3)3C), 27.51 and 27.41 (C-
10), 18.54, 18.39 (C-14 and C-14’), 9.10 and 8.94 (C-11); HRMS (m/z), calculated for C26H35N2O5 : 
455.2546, found, (M + H)+: 455.2541. 
4.31 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-((2,6-dimethyl 
phenyl)amino)-1-oxo-4-phenylbutan-2-yl butyrate 35 
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N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), xylyl isocyanide 10 (158 mg, 1.20 mmol) and 
butyric acid 3 (110 µl, 1.20 mmol) were dissolved in CH2Cl2 (3 ml). The experiment was carried 
out as described in 4.5 yielding compound 35 (460 mg, 82%) as a white solid which was a 
mixture of diastereomers.  
 
Rf = 0.63 (49:1 CHCl3/MeOH); d.r. = 2.06:1.00; m.p. 170 – 171 
°C; IR vmax(cm
-1): 3339 (NH), 3257 (NH), 3029 (C=CH), 2932 (C-H), 
1712 (C=O), 1687 (C=O), 1654 (C=O) 1390 (C-O); 1H NMR (300 
MHz, CDCl3) δ 7.74 (0.29H, s, NH), 7.61 (0.16H, s, NH), 7.38 
(0.46H, s, NH), 7.33 – 7.13 (5H, m, Ar-H), 7.11 – 6.87 (3H, m, Ar-
H), 5.53 – 5.23 (1H, m, H-2), 5.21 – 5.00 (1H, m, NH), 4.54 – 4.29 (1H, m, H-3), 3.09 (0.31H, dd, J 
= 14.0, 5.4 Hz, H-4a), 2.99 – 2.52 (1.72H, m, H-4a and 4b), 2.51 – 2.32 (2H, m, H-10), 2.24 – 2.01 
(6H, m, H-15 and 15’), 1.80 – 1.60 (2H, m, H-11), 1.44 – 1.02 (9H, m, (CH3)3C), 1.05 – 0.92 (3H, 
m, H-12);  13C NMR (75 MHz, CDCl3) δ 172.49, 172.04, 166.59 and 166.46 (C=O), 155.43 and 
155.02 (Boc C=O), 137.38 (Ar-C), 137.17 (Ar-C), 135.51 (Ar-C), 135.27 (Ar-C), 132.91 (Ar-C), 
132.79 (Ar-C), 129.39 (Ar-C), 129.29 (Ar-C), 128.54 (Ar-C), 128.45 (Ar-C), 128.25 (Ar-C), 128.18 
(Ar-C), 127.56 (Ar-C), 127.54 (Ar-C), 126.67 (Ar-C), 126.57 (Ar-C), 79.60 [(CH3)3C], 74.77 and 
73.92 (C-2), 53.29 (C-3), 38.53 and 37.43 (C-4), 35.96 and 35.81 (C-10), 28.23 [(CH3)3C], 18.50, 
18.37 and 18.28 (C-15 and C-15’), 13.65 (C-12); HRMS (m/z), calculated for C27H37N2O5: 
466.2702, found, (M + H)+: 469.2702. 
4.32 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-((2,6-dimethyl 
phenyl)amino)-1-oxo-4-phenylbutan-2-yl pivalate 36 
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), xylyl isocyanide 10 (158 mg, 1.20 mmol) and 
pivalic acid 4 (123 mg, 1.20 mmol) were dissolved in CH2Cl2 (3 ml). The experiment was carried 
out as described in 4.5 yielding compound 36 (575 mg, 99%) as an off white precipitate which 
was a mixture of diastereomers. 
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 Rf = 0.65 (49:1 CHCl3/MeOH); d.r. = 1.88:1.00; m.p. 206 – 207 
°C; IR vmax(cm
-1): 3266 (NH), 2975 (C-H), 2931 (C-H), 1734 (C=O), 
1690 (C=O), 1663 (C=O); 1H NMR (300 MHz, CDCl3) δ 7.62 (0.56H, 
s) and 7.46 (0.31H, s, NH), 7.37 – 7.16 (5H, m, Ar-H), 7.15 – 6.97 
(3H, m, Ar-H), 6.45 – 6.28 (0.28H, m, NH) 5.59 – 5.26 (1H, m, H-
2), 5.20 – 5.00 (0.65H, m, NH), 4.53 – 4.32 (1H, m, H-3), 3.22 – 2.64 (2H, m, H-4), 2.32 – 2.06 
(6H, m, H-14 and 14’), 1.46 – 1.05 (18H, m, (CH3)3C and H-11); 
13C NMR (75 MHz, CDCl3) δ 
177.16, 176.76 and 166.59 (C=O), 155.40 (Boc C=O), 137.34 (Ar-C), 137.15 (Ar-C), 135.47 (Ar-C), 
135.18 (Ar-C), 132.88 (Ar-C), 132.74 (Ar-C), 129.40 (Ar-C), 129.28 (Ar-C), 128.59 (Ar-C), 128.49 
(Ar-C), 128.29 (Ar-C), 128.22 (Ar-C), 127.61 (Ar-C), 127.58 (Ar-C), 126.73 (Ar-C), 126.62 (Ar-C), 
79.68 ((CH3)3C),  79.45 [(CH3)3C],  74.57 and 73.64 (C-2), 53.55 and 53.42 (C-3), 38.96 (C-10), 
38.36 and 37.68 (C-4), 28.25 ((CH3)3C),  27.19, 27.11 and 27.08 (C-11), 18.55 and 18.39 (C-14 
and C-14’); HRMS (m/z), calculated for C28H39N2O5 : 483.2859, found, (M + H)
+: 483.2857.  
4.33 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-((2,6-dimethyl 
phenyl)amino)-1-oxo-4-phenylbutan-2-yl 3,3-dimethylbutanoate 37 
N-Boc-L-phenylalaninal 15 (500 mg, 2.01 mmol), xylyl isocyanide 10 (263 mg, 2.01 mmol) and 
tert-butyl acetic acid 5 (255 µl, 2.01 mmol) were dissolved in CH2Cl2 (5 ml). The experiment was 
carried out as described in 4.5 yielding compound 37 (936 mg, 94%) as a white solid which was 
a mixture of diastereomers. 
 Rf = 0.63 (49:1 CHCl3/MeOH); d.r. = 2.21:1.00; m.p. 213 – 214 
°C; IR vmax(cm
-1): 3337 (NH), 3275 (NH), 3030 (C=CH), 2960 (C-H), 
2868, 1737 (C=O), 1679 (C=O); 1H NMR (500 MHz, CDCl3) δ 7.59 
(0.3H, br-s, NH), 7.28 (0.2H, br-s, NH), 7.46 – 7.14 (5H, m, Ar-H), 
7.14 – 7.00 (3H, m, Ar-H), 5.49 (0.2H, br-s, NH), 5.45 – 5.27 (1H, 
m, H-2), 5.11 (0.52H, d, J = 9.4 Hz, NH), 4.97 (0.31H, d, J = 9.0 Hz, 
NH), 4.50 – 4.32 (1H, m, H-3), 3.20 – 2.68 (2H, m, H-4), 2.52 – 2.31 (2H, m, H-10), 2.28 – 2.10 
(6H, m, H-15 and H-15’), 1.47 – 1.17 (9H, m, (CH3)3C), 1.16 – 1.03 (9H, m, H-12); 
13C NMR (126 
MHz, CDCl3) δ 171.20, 170.66, 166.59 and 166.45 (C=O), 155.40 and 154.98 (Boc C=O), 137.38 
(Ar-C), 137.18 (Ar-C), 135.52 (Ar-C), 135.29 (Ar-C), 132.85 (Ar-C), 132.66 (Ar-C), 129.38 (Ar-C), 
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129.24 (Ar-C), 128.61 (Ar-C), 128.53 (Ar-C), 128.31 (Ar-C), 128.25 (Ar-C), 127.65 (Ar-C), 127.61 
(Ar-C), 126.73 (Ar-C), 126.65 (Ar-C), 79.65 [(CH3)3C], 74.53 and 73.57 (C-2), 53.57 and 53.42 (C-
3), 47.78 and 47.46 (C-10), 38.42 and 37.26 (C-4), 30.95 (C-11), 29.66 and 29.59 (C-12), 29.64 (C-
12), 28.26 ((CH3)3C), 18.57 and 18.42 (C-15 and C-15’); HRMS (m/z), calculated for C29H41N2O5: 
497.3015, found, (M + H)+: 497.3015. 
4.34 Preparation of (3S)-3-((tert-butoxycarbonyl)amino)-1-((2,6-dimethyl 
phenyl)amino)-1-oxo-4-phenylbutan-2-yl 2-chloroacetate 38 
N-Boc-L-phenylalaninal 15 (262 mg, 1.05 mmol), xylyl isocyanide 10 (138 mg, 1.05 mmol) and 
chloroacetic acid 5 (99 mg, 1.05 mmol) were dissolved in CH2Cl2 (3 ml). The experiment was 
carried out as described in 4.5 yielding compound 38 (423 mg, 85%) as a white precipitate 
which was a mixture of diastereomers. 
 
 Rf = 0.54 (49:1 CHCl3/MeOH); d.r. = 1.72:1.00; m.p. 161 – 162 
°C; IR vmax(cm
-1): 3328 (NH), 3241 (NH), 3027 (C=CH), 2978 (C-H), 
1759 (C=O), 1689 (C=O), 1663 (C=O), 762 (C-Cl); 1H NMR (500 
MHz, CDCl3) δ 7.82 (0.26H, s) and 7.53 (0.45H, s, NH), 7.41 – 
7.15 (5H, m, Ar-H), 7.14 – 6.91 (3H, m, Ar-H), 5.46 – 5.22 (1H, m, 
H-2), 5.22 – 4.88 (1H, m, NH), 4.60 – 4.35 (1H, m, H-3), 4.26 – 3.89 (2H, m, H-10), 3.23 – 2.62 
(2H, m, H-4), 2.24 – 2.06 (6H, m, H-13 and 13’), 1.43 – 1.02 (9H, m, (CH3)3C); 
13C NMR (126 MHz, 
CDCl3) δ 171.52, 171.24, 166.13, 165.98, 165.85 and 165.58 (C=O), 155.60 and 154.99 (Boc 
C=O), 137.06 (Ar-C), 136.88 (Ar-C), 135.53 (Ar-C), 135.24 (Ar-C), 135.18 (Ar-C), 132.70 (Ar-C), 
132.60 (Ar-C), 129.34 (Ar-C), 129.29 (Ar-C), 129.19 (Ar-C), 128.64 (Ar-C), 128.55 (Ar-C), 128.52 
(Ar-C), 128.32 (Ar-C), 128.24 (Ar-C), 128.10 (Ar-C), 127.72 (Ar-C), 127.69 (Ar-C), 126.82 (Ar-C), 
126.73 (Ar-C), 79.90 [(CH3)3C], 76.46 and 75.51 (C-2), 55.84 and 53.09 (C-3), 40.65 and 40.35 (C-
10), 28.24 [(CH3)3C], 18.53 and 18.37 (C-13 and 13’); HRMS (m/z), calculated for C25ClH32N2O4: 
475.2000, found, (M + H)+: 475.2006. 
4.35 Preparation of (2S)-(3S)-3-((tert-butoxycarbonyl)amino)-1-((2,6-
dimethylphenyl)amino)-1-oxo-4-phenylbutan-2-yl 2-((tert-butoxycarbonyl) 
amino)-3-phenylpropanoate 39 
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N-Boc-L-phenylalaninal 15 (500 mg, 2.01 mmol), xylyl isocyanide 10 (263 mg, 2.01 mmol) and N-
Boc-L-phenylalanine 7 (533 mg, 2.01 mmol) were dissolved in CH2Cl2 (10 ml). A white precipitate 
was formed after 1 d of stirring. The reaction product was cleaned by filtration, washing with 
CH2Cl2 and drying in vacuo yielding compound 39 (630 mg, 49%) which was a mixture of 
diastereomers. 
 
 d.r. = 1.75:1.00; m.p. 197 – 199 °C; IR vmax(cm
-1): 3354 (NH), 2980 
(C-H), 1748 (C=O), 1688 (C=O), 1366 (C-O); 1H NMR (500 MHz, 
DMSO-d6) δ 9.39 (0.48H, s, NH), 9.25 (0.55H, s, NH), 7.52 (0.52H, d, 
J = 8.4 Hz, NH), 7.46 (0.50H, d, J = 8.2 Hz, NH), 7.39 – 7.27 (5H, m, 
Ar-H), 7.27 – 7.16 (5H, m, Ar-H), 7.14 – 6.99 (3H, m, Ar-H), 6.86 
(0.56H, d, J = 9.4 Hz, NH), 6.67 (0.51H, d, J = 9.7 Hz, NH), 5.22 – 5.12 
(0.64H, m) and 5.06 – 4.94 (0.65H, m, H-2), 4.63 – 4.55 (0.61H, m), 4.55 – 4.46 (0.65H, m) and 
4.43 – 4.23 (1H, m, H-3 and H-6), 3.32 – 3.19 (1H, m, H-7a), 3.07 – 2.79 (2H, m, H-4), 2.76 – 2.65 
(1H, m, H-7b), 2.16 (3H, s) and 2.14 – 2.03 (3H, m, 2xCH3), 1.39 – 1.24 (18H, m, 2x(CH3)3C); 
13C 
NMR (126 MHz, DMSO-d6) δ 172.04, 171.90, 166.28 and 166.23 (C=O), 156.25, 156.23 and 
155.31 (Boc C=O), 138.56 (Ar-C), 138.25 (Ar-C), 138.16 (Ar-C), 137.95 (Ar-C), 136.06 (Ar-C), 
135.86 (Ar-C), 134.66 (Ar-C), 134.60 (Ar-C), 129.72 (Ar-C), 129.70 (Ar-C), 129.68 (Ar-C), 129.60 
(Ar-C), 128.66 (Ar-C), 128.56 (Ar-C), 128.21 (Ar-C), 128.08 (Ar-C), 127.31 (Ar-C), 127.25 (Ar-C), 
126.96 (Ar-C), 126.89 (Ar-C), 126.76 (Ar-C), 126.62 (Ar-C), 79.06, 78.97 and 78.54 [(CH3)3C], 
76.19 and 74.98 (C-2), 55.74, 55.50, 53.50 and 53.23 (C-2 and C-6), 38.50, 36.98, 36.64 and 
35.72 (C-4 and C-7), 28.59 and 28.48 [(CH3)3C], 18.56 and 18.44 (CH3x2 ); HRMS (m/z), 
calculated for C37H38N3O7: 646.3492, found (M + H)
+: 646.3482. 
4.36 Preparation of (2R,3S)-3-acetamido-N-(2,6-dimethylphenyl)-2-hydroxy-
4-phenylbutanamide 40A 
Compound 33A (100 mg, 0.23 mmol), TFA (175 µl, 2.27 mmol) and Et3N (315 µl, 2.27 mmol) in 
CH2Cl2 (1.5 ml) were reacted together as described in 4.11. The reaction yielded compound 40A 
(63 mg, 81%) as a white solid. 
 
Chapter 4: Experimental Procedures 
 
119 
 
 Rf = 0.35 (49:1 CHCl3/MeOH); m.p. 238 – 248 °C; IR vmax(cm
-1): 
3064 (NH), 2924 (C-H), 2854 (C-H), 1658 (C=O), 1617 (C=O); 1H 
NMR (500 MHz, CD3OD) δ 7.25 – 7.17 (4H, m, Ar-H), 7.13 – 7.08 
(1H, m, Ar-H), 7.00 – 6.93 (3H, m, Ar-H), 4.52 – 4.46 (2H, m, NH 
and H-3), 4.06 (1H, d, J = 2.2 Hz, H-2), 2.89 (1H, dd, J = 13.4, 8.1 Hz, H-4a), 2.82 (1H, dd, J = 13.3, 
7.4 Hz, H-4b), 2.06 (6H, s, H-13 and 13’), 1.80 (3H, s, H-10); 13C NMR (126 MHz, CD3OD) δ 172.74 
and 171.44 (C=O), 138.12, 135.45 and 133.65 (C-5, C-12 and 12’), 129.13 (Ar-C), 128.07 (Ar-C), 
127.63 (Ar-C), 127.01 (Ar-C), 126.14 (Ar-C), 71.31 (C-2), 53.74 (C-3), 37.64 (C-4), 21.39 (C-10), 
17.09 (C-13 and 13’); HRMS (m/z), calculated for C20H25N2O3: 341.1865, found, (M + H)
+: 
341.1854. 
4.37 Preparation of (2S,3S)-3-acetamido-N-(2,6-dimethylphenyl)-2-hydroxy-
4-phenylbutanamide 40B 
Compound 33B (40 mg, 0.091 mmol), TFA (70 µl, 0.91 mmol) and Et3N (126 µl, 0.91 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 40B 
(21 mg, 70%) as a white solid. 
 
 Rf = 0.37 (49:1 CHCl3/MeOH); m.p. 223 – 224 °C; IR vmax(cm
-1): 
3316 (OH), 2909 (C-H), 2851 (C-H), 1745 (C=O); 1H NMR (500 
MHz, CD3OD) δ 7.34 – 7.15 (5H, m, Ar-H), 7.13 – 7.03 (3H, m, Ar-
H), 4.64 – 4.56 (3H, m, 2xNH and H-3), 4.39 (1H, d, J = 3.5 Hz, H-
2), 3.02 – 2.88 (2H, m, H-4), 2.25 (6H, s, H-13 and 13’), 2.18 – 2.14 (3H, m, H-10); 13C NMR (126 
MHz, CD3OD) δ 172.74, 172.11, 171.76 and 171.44 (C=O), 138.44 (Ar-C), 138.12 (Ar-C), 135.45 
(Ar-C), 135.41 (Ar-C), 133.66 (Ar-C), 128.80 (Ar-C), 127.91 (Ar-C), 127.74 (Ar-C), 127.63 (Ar-C), 
127.04 (Ar-C), 126.14 (Ar-C), 125.97 (Ar-C), 73.58 (C-2), 54.11 and 53.75 (C-3), 34.17 (C-4), 21.39 
and 21.09 (C-10), 17.29 and 17.09 (C-13 and C-13’); HRMS (m/z), calculated for C20H25N2O5: 
341.1865 found, (M + H)+: 341.1856. 
4.38 Preparation of (3S)-N-(2,6-dimethylphenyl)-2-hydroxy-4-phenyl-3-
propionamidobutanamide 41 
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Compound 34 (450 mg, 0.99 mmol), TFA (763 µl, 9.90 mmol) and Et3N (1.37 ml, 9.90 mmol) in 
CH2Cl2 (3 ml) were reacted together as described in 4.11. The reaction yielded compound 41 
(351 mg, 98%) as an off white solid which was a mixture of diastereomers. 
 
 Rf = 0.48 (49:1 CHCl3/MeOH); m.p. 150 – 151 °C; IR vmax(cm
-1): 
3318 (OH), 3245 (NH), 3027 (C-H), 1664 (C=O), 1619 (C=O); 1H 
NMR (500 MHz, DMSO-d6) δ 9.29 (0.24H, s, NH), 9.10 (0.66H, s, 
NH), 7.77 (0.23H, d, J = 8.7 Hz, NH), 7.55 (0.71H, d, J = 8.9 Hz, 
NH), 7.38 – 7.14 (5H, m, Ar-H), 7.13 – 6.98 (3H, m, Ar-H), 6.29 
(0.66H, br-s, OH), 6.24 – 6.14 (0.29H, m, OH), 4.45 – 4.30 (1H, m, H-3), 4.23 – 4.17 (0.27H, m, H-
2), 4.07 – 3.97 (0.74H, m, H-2), 2.96 – 2.74 (2H, m, H-4), 2.12 –  1.99 (8H, m, H-10, H-14 and H-
14’), 0.96 – 0.84 (3H, m, H-11); 13C NMR (126 MHz, DMSO-d6) δ 173.18, 173.02, 171.21 and 
171.10 (C=O), 139.79 (Ar-C), 139.29 (Ar-C), 135.77 (Ar-C), 135.73 (Ar-C), 129.77 (Ar-C), 129.46 
(Ar-C), 128.65 (Ar-C), 128.46 (Ar-C), 128.07 (Ar-C), 127.98 (Ar-C), 126.84 (Ar-C), 126.57 (Ar-C), 
74.30 and 71.94 (C-2), 53.70 (C-3), 46.23 (C-10), 37.96 and 34.68 (C-4), 28.96 and 28.93 (C-10), 
18.71 and 18.52 (C-14 and C-14’), 10.35 and 10.14 (C-11); HRMS (m/z), calculated for 
C21H27N2O3 : 355.2022, found, (M + H)
+: 355.2019. 
4.39 Preparation of (3S)-3-butyramido-N-(2,6-dimethylphenyl)-2-hydroxy-4-
phenylbutanamide 42 
Compound 35 (100 mg, 0.21 mmol), TFA (164 µl, 2.13 mmol) and Et3N (295 µl, 2.13 mmol) in 
CH2Cl2 (2 ml) were reacted together as described in 4.11. The reaction yielded compound 42 (58 
mg, 74%) as a white solid which was a mixture of diastereomers. 
 
 Rf = 0.42 (49:1 CHCl3/MeOH); m.p. 242 – 244 °C; IR vmax(cm
-1): 
3264 (NH), 3028 (C=CH), 2960 (NH), 1662 (C=O), 1649 (C=O), 
1375 (C-O); 1H NMR (500 MHz, DMSO-d6) δ 9.30 (0.79H, s, NH), 
9.11 (0.26H, s, NH), 7.79 (0.72H, d, J = 8.8 Hz, NH), 7.56 (0.26H, 
d, J = 8.9 Hz, NH), 7.36 – 7.13 (5H, m, Ar-H), 7.12 – 7.00 (3H, m, 
Ar-H), 6.25 (1H, s, OH), 4.49 – 4.32 (1H, m, H-3), 4.20 (0.72H, d, J = 3.3 Hz, H-2), 4.03 (0.26H, d, J 
= 2.5 Hz, H-2), 2.96 – 2.75 (2H, m, H-4), 2.18 and 2.10 (6H, 2xs, H-15 and H-15’), 2.08 – 1.96 (2H, 
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m, H-10), 1.50 – 1.35 (2H, m, H-11), 0.79 and 0.72 (3H, 2t, J = 7.4 Hz, H-12); 13C NMR (126 MHz, 
DMSO-d6) δ 172.22, 172.18, 171.20 and 171.12 (C=O), 139.78 (Ar-C), 139.28 (Ar-C), 135.76 (Ar-
C), 135.73 (Ar-C), 135.50 (Ar-C), 135.35 (Ar-C), 129.75 (Ar-C), 129.44 (Ar-C), 128.64 (Ar-C), 
128.44 (Ar-C), 128.07 (Ar-C), 127.98 (Ar-C), 126.84 (Ar-C), 126.82 (Ar-C), 126.55 (Ar-C), 126.33 
(Ar-C), 74.46 and 71.96 (C-2), 53.72 and 53.67 (C-3), 37.92 and 37.80 (C-4), 34.60 (C-10), 19.07 
and 18.96 (C-11), 18.71 and 18.55 (C-15 and C-15’), 14.10 and 13.94 (C-12); HRMS (m/z), 
calculated for C22H29N2O3: 369.2178, found (M + H)
+: 369.2171. 
4.40 Preparation of (3S)-N-(2,6-dimethylphenyl)-2-hydroxy-4-phenyl-3-
pivalamidobutanamide 43 
Compound 36 (150 mg, 0.31 mmol), TFA (240 µl, 3.12 mmol) and Et3N (432 µl, 3.12 mmol) in 
CH2Cl2 (2 ml) were reacted together as described in 4.11. The reaction yielded compound 43 
(114 mg, 96%) as an off white solid which was a mixture of diastereomers. 
 
 Rf = 0.50 (49:1 CHCl3/MeOH); m.p. 196 – 197 °C; IR vmax(cm
-1): 
3352 (OH), 3238 (NH), 3028 (C=C-H), 2968 (C-H), 1654 (C=O), 
1637 (C=O); 1H NMR (500 MHz, CDCl3) δ 8.54 (0.47H, s, NH), 8.49 
(0.53H, s, NH), 7.45 – 7.15 (5H, m, Ar-H), 7.15 – 6.87 (3H, m, Ar-
H), 6.70 – 6.50, 6.35 – 6.20 and 5.53 – 5.02 (2H, m) NH and OH, 
4.56 – 4.22 (2H, m, H-2 and H-3), 3.38 – 3.13 (1H, m, H-4a), 3.12 – 2.81 (1H, m, H-4b), 2.30 – 
2.03 (6H, m, H-14 and 14’), 1.09 – 0.73 (9H, m, H-11); 13C NMR (126 MHz, CDCl3) δ 181.86, 
180.97, 171.48 and 170.31 (C=O), 138.10  (Ar-C), 137.92 (Ar-C), 134.98 (Ar-C), 134.96 (Ar-C), 
133.23 (Ar-C), 133.18 (Ar-C), 129.34 (Ar-C), 129.28 (Ar-C), 129.16 (Ar-C), 128.60 (Ar-C), 128.58 
(Ar-C), 128.40 (Ar-C), 128.23 (Ar-C), 128.21 (Ar-C), 128.18 (Ar-C), 128.16 (Ar-C), 128.10 (Ar-C), 
127.57 (Ar-C), 126.74 (Ar-C), 126.71 (Ar-C), 75.54 and 73.84 (C-2), 57.58 and 55.57 (C-3), 38.68 
and 38.66 (C-10), 35.42 and 34.90 (C-4), 27.36 and 27.31 (C-11), 18.62 and 18.58 (C-14 and C-
14’); HRMS (m/z), calculated for C23H31N2O3: 383.2335, found, (M + H)
+: 383.2331. 
4.41 Preparation of (3S)-3-(3,3-dimethylbutanamido)-N-(2,6-dimethyl 
phenyl)-2-hydroxy-4-phenylbutanamide 44 
Chapter 4: Experimental Procedures 
 
122 
 
Compound 37 (450 mg, 0.90 mmol), TFA (694 µl, 9.01 mmol) and Et3N (1.25ml, 9.01mmol) in 
CH2Cl2 (3 ml) were reacted together as described in 4.11. The reaction yielded compound 44 
(325 mg, 91%) as a white solid which was a mixture of diastereomers. 
 
 Rf = 0.55 (49:1 CHCl3/MeOH); m.p. 183 – 184 °C; IR vmax(cm
-1): 
3256 (NH), 3062 (C=C-H), 2954 (C-H), 1660 (C=O), 1640 (C=O), 
1365 (C-O); 1H NMR (300 MHz, CDCl3) δ 8.45 (0.72H, s, NH), 8.25 
(0.28H, s, NH), 7.47 – 7.15 (5H, m, Ar-H), 7.14 – 6.94 (3H, m, Ar-
H), 4.29 – 4.10 (1H, m, H-2 and H-3), 3.68 – 3.50 (0.28H, m) and 
3.38 (0.74H, dd, J = 13.7, 7.8 Hz) and 3.23 – 3.08 (0.46H, m) and 2.96 (0.76H, dd, J = 13.8, 7.8 
Hz) and 2.62 (0.29H, dd, J = 13.6, 10.1 Hz, H-4),  2.29 – 2.08 (6H, m, H-15 and H-15’), 1.84 (1H, d, 
J = 12.8 Hz, H-10a), 1.76 (1H, d, J = 12.8 Hz, H-10b), 1.10 and 0.85 (9H, 2 x s, H-12); 13C NMR (75 
MHz, CDCl3) δ 174.89, 171.91 and 171.28 (C=O), 137.96 (Ar-C), 135.25 (Ar-C), 135.13 (Ar-C), 
133.24 (Ar-C), 129.34 (Ar-C), 129.26 (Ar-C), 128.75 (Ar-C), 128.58 (Ar-C), 128.25 (Ar-C), 128.16 
(Ar-C), 127.43 (Ar-C), 127.28 (Ar-C), 126.76 (Ar-C), 126.67 (Ar-C), 75.87 and 73.67 (C-2), 56.59 
and 53.86 (C-3), 49.82 and 47.80 (C-10), 39.71 and 35.57 (C-4), 30.99 and 30.80 (C-11), 29.69, 
29.64 and 29.52 (C-12), 18.74, 18.53 and 18.41 (C-15 and C-15’); HRMS (m/z), calculated for 
C24H33N2O3: 399.2491, found, (M + H)
+: 399.2486. 
4.42 Preparation of (3S)-3-(2-chloroacetamido)-N-(2,6-dimethylphenyl)-2-
hydroxy-4-phenylbutanamide 45 
Compound 38 (150 mg, 0.32 mmol), TFA (243 µl, 3.16 mmol) and Et3N (438 µl, 3.16 mmol) in 
CH2Cl2 (3 ml) were reacted together as described in 4.11. The reaction yielded compound 45 (78 
mg, 76%) as a mixture of oil and white precipitate which was a mixture of diastereomers. 
 
 Rf = 0.42 (49:1 CHCl3/MeOH); m.p. 216 – 217 °C; IR vmax(cm
-1): 
3333 (OH), 3068 (C=CH), 2973 (C-H), 1657 (C=O), 768 (C-Cl); 1H 
NMR (500 MHz, DMSO-d6) δ 9.31 (0.21H, s), 9.08 (0.46H, s), 8.23 
– 8.17 (0.10H, m) and 7.94 (0.31H, d, J = 9.3 Hz) NH and OH, 7.31 
– 7.07 (5H, m, Ar-H), 7.05 – 6.91 (3H, m, Ar-H), 6.40 (0.48H, d, J = 6.0 Hz) and 6.24 (0.21H, d, J = 
6.1 Hz) NH, 4.38 – 4.29 (1H, m, H-3), 4.18 – 4.13 and 4.01 – 3.88 (3H, 2xm, H-2 and H-10), 2.85 
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(0.70H, dd, J = 13.2, 7.8 Hz, H-4a), 2.78 – 2.74 (0.54H, m, H-4b), 2.69 (0.66H, dd, J = 13.2, 7.1 Hz, 
H-4b 2.10 and 2.02 (4H, 2xs, H-13 and 13’); 13C NMR (126 MHz, DMSO-d6) δ 170.94, 170.91, 
170.87, 165.78, 165.61 and 165.54 (C=O), 139.27 (Ar-C), 138.79 (Ar-C), 135.81 (Ar-C), 135.74 
(Ar-C), 129.77 (Ar-C), 129.39 (Ar-C), 128.78 (Ar-C), 128.63 (Ar-C), 128.11 (Ar-C), 128.01 (Ar-C), 
126.95 (Ar-C), 126.92 (Ar-C), 126.76 (Ar-C), 126.56 (Ar-C), 73.72, 71.21 and 71.12 (C-2), 54.20, 
54.09 and 54.06 (C-3), 43.13 and 43.09 (C-10), 37.87 and 34.53 (C-4), 18.73 and 18.58 (C-13 and 
C-13’); HRMS (m/z), calculated for C20ClH24N2O3: 375.1475, found (M + H)
+: 375.1469. 
4.43 Preparation of (3S)-3-((S)-2-amino-3-phenylpropanamido)-N-(2,6-
dimethylphenyl)-2-hydroxy-4-phenylbutanamide 46 
Compound 39 (500 mg, 0.78 mmol), TFA (600 µl, 7.77 mmol) and Et3N (1.08 ml, 7.77 mmol) in 
CH2Cl2 (3 ml) were reacted together as described in 4.11. The reaction yielded compound 46 
(320 mg, 92%) as a white precipitate which was a mixture of diastereomers. 
 
 Rf = 0.49 (49:1 CHCl3/MeOH); m.p. 167 – 168 °C; IR vmax(cm
-1): 
3308 (OH), 3031 (C=C-H), 1654 (C=O), 1359 (C-O); 1H NMR (300 
MHz, DMSO-d6) δ 9.37 (0.55H, s, NH), 9.20 (0.49H, s, NH), 8.03 
(0.39H, d, J = 9.4 Hz, NH), 7.94 (0.56H, d, J = 9.2 Hz, NH), 7.43 – 7.11 
(10H, m, Ar-H), 7.10 – 6.98 (3H, m, Ar-H), 6.47 (0.48H, d, J = 5.6 Hz, 
OH), 6.27 (0.57H, d, J = 5.8 Hz, OH), 4.57 – 4.32 (1H, m, H-3), 4.27 – 4.13 and 4.09 – 3.99 (1H, 
2xm, H-2), 3.01 – 2.66  and 2.48 – 2.30 (4H, 2xm) H-4 and H-7, 2.18 (3H, s, CH3), 2.08 (3H, s, 
CH3), 1.63 (2H,br-s, NH2); 
13C NMR (75 MHz, DMSO-d6) δ 173.83, 173.31, 170.68 and 170.43 
(C=O), 138.75 (Ar-C), 138.51 (Ar-C), 135.30 (Ar-C), 135.22 (Ar-C), 134.89 (Ar-C), 129.34 (Ar-C), 
129.29 (Ar-C), 129.17 (Ar-C), 129.09 (Ar-C), 128.22 (Ar-C), 128.12 (Ar-C), 128.08 (Ar-C), 128.04 
(Ar-C), 127.59 (Ar-C), 127.44 (Ar-C), 126.39 (Ar-C), 126.00 (Ar-C), 73.46 and 70.72 (C-2), 56.21, 
55.99 and 52.64 (C-3 and C-6), 37.61 and 34.48 (C-4 and C-7), 18.21 (CH3), 18.04 (CH3); HRMS 
(m/z), calculated for C27H32N3O3: 446.2444, found (M + H)
+: 446.2441. 
4.44 Preparation of 1-isocyanoadamantane 11 
Commercially available adamantylamine (1.00 g, 6.61 mmol), excess formic acid (5 ml) and 
excess acetic anhydride (5 ml) were added together and left to stir under N2 overnight. The 
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reaction was then worked up in brine (200 ml) and solid Na2CO3 (≈ 50 g) was added in small 
portions waiting for effervescence to stop before each addition. The product was then 
extracted with EtOAc (2 x 100 ml) and dried over MgSO4. After filtration the solvent was 
removed in vacuo yielding a white precipitate (crude – 1.38 g).  
Crude adamantyl formamide (1.38 g, ≈7.14 mmol) was dissolved in anhydrous CH2Cl2 (40 ml) 
and cooled to 0 °C whilst stirring under N2. Excess POCl3 (5 ml) was then added gradually 
followed by excess Et3N (15 ml). After 30 min of stirring the reaction was allowed to warm to 
room temperature and was left to stir overnight. The reaction was then quenched by slowly 
adding a saturated aqueous solution of NaHCO3 (150 ml) in ice and solid Na2CO3 (≈ 20 g) until 
effervescence had stopped. The product was then extracted using CH2Cl2 (100 ml) and dried 
over Na2SO4. Excess solvent was removed in vacuo. Column chromatography (3:7 EtOAc/Hex) 
afforded 11 as a light yellow precipitate (805 mg, 75%) with a distinct isocyanide smell.42 
 
Rf = 0.33 (3:7 EtOAc/Hex) visualised using iodine; 
1H NMR (300 MHz, CDCl3) δ 2.16 
– 2.06 (3H, m, H-4, 4’ and 4’’), 2.06 – 1.98 (6H, m, H-3, 3’ and 3’’), 1.76 – 1.60 (6H, 
m, H-5, 5’ and 5’’); 13C NMR (75 MHz, CDCl3) δ 151.59 (t, JC-N = 5.2 Hz, C-1), 54.22 (t, 
JC-N = 11.3 Hz, C-2), 43.58 (C-3, 3’ and 3’), 35.50 (C-5, 5’ and 5’), 28.73 (C-4, 4’ and 4’). 
4.45 Preparation of (3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl acetate 47                                                                                                                     
N-Boc-L-phenylalaninal 15 (500 mg, 2.01 mmol), adamantyl isocyanide 11 (220 mg, 2.01 mmol) 
and acetic acid 1 (162 µl, 2.01 mmol) were dissolved in CH2Cl2 (5 ml) and the experiment was 
carried out as described in 4.5. The reaction yielded compound 47 (637 mg, 100%) as a white 
flaky solid, as a mixture of diastereomers. Rf = 0.54 (49:1 CHCl3/MeOH); d.r. = 1.96:1.00. This 
diastereomeric mixture was then separated using preparative HPLC as detailed in 4.10 to give 
two clean separated diastereomers. 
 
 (2R,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl acetate 47A. 
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m.p. 156 – 157 °C; IR vmax (cm
-1): 3284 (NH), 3085 (C=C-H), 2908 (C-H), 1756 (C=O), 1719 (C=O), 
1655 (C=O), 1365 (C-O); 1H NMR (500 MHz, CDCl3) δ  7.31 – 7.25 (2H, m, H-7 and H-7’), 7.24 – 
7.15 (3H, m, H-6, H-6’ and H-8), 5.60 (1H, s, NH), 5.20 (1H, d, J = 9.6 Hz, NH), 5.08 – 4.97 (1H, m, 
H-2), 4.34 – 4.23 (1H, m, H-3), 2.82 (2H, d, J = 7.3 Hz, H-4), 2.19 – 2.03 (6H, m, H-10 and H-13), 
1.99 (6H, s, H-12), 1.72 – 1.60 (6H, m, H-14), 1.40 – 1.19 (9H, m, (CH3)3C); 
13C NMR (126 MHz, 
CDCl3) δ 169.09 and 166.76 (C=O), 154.97 (Boc C=O), 137.38 (C-5), 129.24 (C-7 and C-7’), 128.47 
(C-6 and C-6’), 126.56 (C-8), 79.45 [(CH3)3C], 73.77 (C-2), 52.91 (C-3), 52.35 (C-11), 41.36 (C-12), 
38.16 (C-14), 36.24 (C-4), 29.38 (C-13), 28.29 [(CH3)3C], 20.70 (C-10); HRMS (m/z), calculated for 
C27H39N2O5: 471.2859, found (M + H)
+: 471.2856. 
 
  
(2S,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl acetate 47B. 
m.p. 156 – 157 °C; IR (solid) vmax (cm
-1): 3299 (NH), 2915 (C-H), 
1748 (C=O), 1696 (C=O), 1669 (C=O); 1H NMR (500 MHz, CDCl3) 
δ 7.32 – 7.25 (2H, m, H-7 and H-7’), 7.24 – 7.16 (3H, m, H-6, H-6’ and H-8), 5.77 (1H, s, NH), 5.22 
– 5.04 (1H, m, H-2), 4.97 – 4.82 (1H, m, NH), 4.33 – 4.18 (1H, m, H-3), 2.93 (2H, d, J = 7.8 Hz, H-
4), 2.20 – 2.05 (6H, m, H-13 and H-10), 2.04 – 2.00 (6H, m, H-12), 1.73 – 1.60 (6H, m, H-14), 1.42 
– 1.20 (9H, m, (CH3)3C); 
13C NMR (126 MHz, CDCl3) δ 169.90 and 166.59 (C=O), 155.56 (Boc 
C=O), 137.44 (C-5), 129.17 (C-7 and C-7’), 128.49 (C-6 and C-6’,) 126.60 (C-8), 79.45  [(CH3)3C], 
74.48 (C-2), 53.36 (C-3), 52.38 (C-11), 41.43 (C-12), 37.34 (C-4), 36.26 (C-14), 29.70 (C-13), 28.32 
[(CH3)3C], 20.91 (C-10); HRMS (m/z), calculated for C27H39N2O5: 471.2859, found (M + H)
+: 
471.2854. 
4.46 Synthesis of (3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl propionate 48                                                                                             
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), adamantyl isocyanide 11 (193 mg, 1.20 mmol) 
and propionic acid 3 (90 µl, 1.20 mmol) were dissolved in CH2Cl2 (3 ml) and the experiment was 
carried out as described in 4.5. The reaction yielded compound 48 (594 mg, 100%) as a white 
flaky solid being a mixture of diastereomers. Rf = 0.61 (5:5 EtOAc/Hex); d.r. = 1.75:1.00. This 
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diastereomeric mixture was then separated using preparative HPLC as detailed in 4.10 to give 
two clean separated diastereomers. 
 (2R,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl propionate 
48A. m.p. 117 – 118 °C; IR vmax (cm
-1): 3386 (NH), 3290 (NH), 
2977 (C-H), 1718 (C=O), 1685 (C=O), 1656 (C=O), 1364 (C-O); 1H 
NMR (500 MHz, CDCl3) δ 7.33 – 7.24 (2H, m, Ar-H), 7.24 – 7.11 
(3H, m, Ar-H), 5.62 (1H, s, NH), 5.22 (1H, d, J = 9.6 Hz, NH), 5.11 
– 5.00 (1H, m, H-2), 4.35 – 4.23 (1H, m, H-3), 2.82 (2H, d, J = 7.3 Hz, H-4), 2.47 – 2.26 (2H, m, H-
10), 2.07 (3H, s, H-14), 1.99 (6H, s, H-13), 1.67 (6H, s, H-15), 1.40 – 1.04 (12H, m, (CH3)3C and H-
11); 13C NMR (126 MHz, CDCl3) δ 172.40 and 166.95 (C=O), 154.95 (Boc C=O), 137.44 (C-5), 
129.25 (C-7 and C-7’), 128.44 (C-6 and C-6’), 126.52 (C-8), 79.40 [(CH3)3C], 73.54 (C-2), 52.96 (C-
3), 52.29 (C-12), 41.39 (C-13), 38.11 (C-4), 36.24 (C-15), 29.69 (C-14), 28.29 [(CH3)3C], 27.38 (C-
10), 9.05 (C-11); HRMS (m/z), calculated for C28H41N2O5: 485.3015, found (M + H)
+:  485.3007.  
 
 (2S,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl propionate 
48B. m.p. 125 – 126 °C; IR vmax (cm
-1): 3333 (NH), 2916 (C-H), 
1747 (C=O), 1692 (C=O), 1664 (C=O), 1365 (C-O); 1H NMR (500 
MHz, CDCl3) δ 7.32 – 7.25 (2H, m, Ar-H), 7.25 – 7.17 (3H, m, Ar-
H), 5.75 (1H, s, NH), 5.06 (1H, d, J = 9.1 Hz, NH), 5.00 – 4.92 (1H, 
m, H-2), 4.30 – 4.19 (1H, m, H-3), 2.94 (2H, d, J = 7.6 Hz, H-4), 2.50 – 2.35 (2H, m, H-10), 2.14 – 
2.05 (3H, m, H-14), 2.05 – 1.94 (6H, m, H-13), 1.73 – 1.61 (6H, m, H-15), 1.45 – 1.10 (14H, m, 
(CH3)3C and H-11); 
13C NMR (126 MHz, CDCl3) δ 173.19 and 166.70 (C=O), 155.52 (Boc C=O), 
137.46 (C-5), 129.19 (C-7 and C-7’), 128.48 (C-6 and C-6’), 126.59 (C-8), 79.38 [(CH3)3C], 74.27 
(C-2), 53.38 (C-3), 52.32 (C-12), 41.45 (C-13), 37.49 (C-4), 36.26 (C-15), 29.38 (C-14), 28.32 
[(CH3)3C], 27.50 (C-10), 8.94 (C-11); HRMS (m/z), calculated for C28H41N2O5: 485.3015, found (M 
+ H)+: 485.3011. 
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4.47 Synthesis of (3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl butyrate 49                                                                                                      
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), adamantyl isocyanide 11 (193 mg, 1.20 mmol) 
and butyric acid 3 (110 µl, 1.20 mmol) were dissolved in CH2Cl2 (3 ml) and the experiment was 
carried out as described in 4.5. The reaction yielded compound 49 (522 mg, 87%) as a mixture 
of diastereomers. Rf = 0.65 (3:7 EtOAc/Hex); d.r. = 1.95:1.00. This diastereomeric mixture was 
then separated using preparative HPLC as detailed in 4.10 to give two clean separated 
diastereomers. 
 
 (2R,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl butyrate 
49A. m.p. 108 – 109 °C; IR vmax (cm
-1): 3286 (NH), 3067 (C=CH), 
1710 (C=O), 1691 (C=O); 1H NMR (500 MHz, CDCl3) δ 7.31 – 7.24 
(2H, m, Ar-H), 7.23 – 7.13 (3H, m, Ar-H), 5.62 (1H, s, NH), 5.21 
(1H, d, J = 9.6 Hz, NH), 5.11 – 5.02 (1H, m, H-2), 4.33 – 4.22 (1H, 
m, H-3), 2.82 (2H, d, J = 7.4 Hz, H-4), 2.42 – 2.23 (2H, m, H-10), 2.07 (3H, s, H-15), 1.99 (6H, s, H-
14), 1.76 – 1.60 (8H, m, H-11 and H-16), 1.41 – 1.18 (9H, m, (CH3)3C), 1.06 – 0.92 (3H, m, H-12);
 
13C NMR (126 MHz, CDCl3) δ 171.57 and 166.99 (C=O), 154.93 (Boc C=O), 137.45 (C-5), 129.27 
(C-7 and C-7’), 128.44 (C-6 and C-6’), 126.51 (C-8), 79.38 [(CH3)3C], 73.48 (C-2), 52.98 (C-3), 
52.28 (C-13), 41.40 (C-14), 38.10 (C-4), 36.25 (C-16), 35.91 (C-10), 29.38 (C-15), 28.29 [(CH3)3C], 
18.38 (C-11), 13.70 (C-12); HRMS (m/z), calculated for C29H43N2O5: 499.3172, found (M + H)
+: 
499.3169. 
 
 (2S,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl butyrate 
49B. m.p. 139 – 140 °C; IR vmax (cm
-1): 3316 (NH), 2908 (C-H), 
1745 (C=O), 1693 (C=O), 1665 (C=O); 1H NMR (500 MHz, CDCl3) 
δ 7.32 – 7.25 (2H, m, Ar-H), 7.25 – 7.16 (3H, m, Ar-H), 5.73 (1H, 
s, NH), 5.07 (1H, d, J = 9.4 Hz, NH), 5.00 – 4.93 (1H, m, H-2), 4.31 
– 4.19 (1H, m, H-3), 2.93 (2H, d, J = 7.5 Hz, H-4), 2.45 – 2.27 (2H, m, H-10), 2.12 – 2.05 (3H, m, H-
15), 2.05 – 1.95 (6H, m, H-14), 1.75 – 1.60 (8H, m, H-11 and H-16), 1.44 – 1.15 (9H, m, (CH3)3C), 
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1.04 – 0.93 (3H, m, H-12); 13C NMR (126 MHz, CDCl3) δ 172.42 and 166.70 (C=O), 155.48 (Boc 
C=O), 137.45 (C-5), 129.19 (C-7 and C-7’), 128.49 (C-6 and C-6’), 126.60 (C-8), 79.36 [(CH3)3C], 
74.14 (C-2), 53.36 (C-3), 52.32 (C-13), 41.44 (C-14), 37.49 (C-4), 36.26 (C-16), 36.03 (C-10), 29.70 
(C-15), 28.32 [(CH3)3C], 18.32 (C-11), 13.65 (C-12); HRMS (m/z), calculated for C29H43N2O5: 
499.3172, found (M + H)+: 499.3169 
4.48 Preparation of (3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl pivalate 50                                                                                                      
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), adamantyl isocyanide 11 (193 mg, 1.20 mmol) 
and pivalic acid 4 (123 mg, 1.20 mmol) were dissolved in CH2Cl2 (3 ml) and the experiment was 
carried out as described in 4.5. The experiment yielded compound 50 (564 mg, 92%) as a white 
solid, being a mixture of diastereomers. Rf = 0.67 (49:1 CHCl3/MeOH); d.r. = 2.12:1.00. This 
mixture was then separated using preparative HPLC as detailed in 4.10 to give two clean 
separated diastereomers. 
 
 (2R,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl pivalate 
50A. m.p. 147 – 148 °C; IR vmax (cm
-1): 3417 (NH), 3351 (NH), 
2964 (C-H), 1742 (C=O), 1717 (C=O), 1677 (C=O), 1530 (C=C); 
1H NMR (500 MHz, CDCl3) δ 7.31 – 7.11 (5H, m, Ar-H), 5.63 
(1H, s, NH), 5.24 (1H, d, J = 9.7 Hz, NH), 5.18 – 5.03 (1H, m, H-
2), 4.37 – 4.18 (1H, m, H-3), 2.89 – 2.73 (2H, m, H-4), 2.07 (3H, s, H-14), 1.99 (6H, s, H-13), 1.67 
(6H, s, H-15), 1.40 – 1.15 (18H, m, H-11 and (CH3)3C); 
13C NMR (126 MHz, CDCl3) δ 176.09 and 
167.27 (C=O), 154.91 (Boc C=O), 137.43 (C-5), 129.32 (C-7 and C-7’), 128.45 (C-6 and C-6’), 
126.53 (C-8), 79.36 [(CH3)3C], 73.29 (C-2), 53.18 (C-3), 52.22 (C-12), 41.48 (C-13), 38.79 (C-10), 
37.96 (C-4), 36.24 (C-15), 29.69 (C-14), 28.29 [(CH3)3C], 27.05 (C-11); HRMS (m/z), calculated for 
C30H45N2O5: 513.3328, found (M + H)
+: 513.3326. 
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 (2S,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl pivalate 
50B. m.p. 132 – 133 °C; IR vmax (cm
-1): 3342 (NH), 3306 (NH), 
2912 (C-H), 2852 (C-H), 1734 (C=O), 1691 (C=O), 1663 (C=O), 
1547 (C=C); 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.16 (5H, m, Ar-
H), 5.74 (1H, s, NH), 4.99 (1H, d, J = 9.4 Hz, NH), 4.97 – 4.90 
(1H, m, H-2), 4.32 – 4.18 (1H, m, H-3), 3.02 – 2.87 (2H, m, H-4), 2.09 (3H, s, H-14), 2.00 (6H, s, H-
13), 1.69 (6H, s, H-15), 1.42 – 1.13 (18H, m, H-11 and (CH3)3C); 
13C NMR (126 MHz, CDCl3) δ 
176.93 and 166.79 (C=O), 155.35 (Boc C=O), 137.43 (C-5), 129.23 (C-7 and C-7’), 128.49 (C-6 and 
C-6’), 126.60 (C-8), 79.29 [(CH3)3C], 74.07 (C-2), 53.27 (C-3), 52.21 (C-12), 41.51 (C-13), 38.82 (C-
10), 37.73 (C-4), 36.26 (C-15), 29.39 (C-14), 28.34 [(CH3)3C], 27.04 (C-11); HRMS (m/z), 
calculated for C30H45N2O5: 513.3328, found (M + H)
+: 513.3322. 
4.49 Synthesis of (3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl 3,3-dimethylbutanoate 51                                                                                                     
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), adamantyl isocyanide 11 (193 mg, 1.20 mmol) 
and tert-butyl acetic acid 5 (153 µl, 1.20 mmol) were dissolved in CH2Cl2 (3 ml) and the 
experiment proceeded as described in 4.5. Purification of the product yielded compound 51 
(588 mg, 93%) as a mixture of diastereomers. Rf = 0.47 (49:1 CHCl3/MeOH); d.r. = 2.01:1.00. The 
diastereomeric mixture was then separated using preparative HPLC as detailed in 4.10 to give 
two clean separated diastereomers. 
 
 (2R,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl 3,3-
dimethylbutanoate 51A. m.p. 150 – 151 °C; IR vmax (cm
-1): 3405 
(NH), 3302 (NH), 2909 (C-H), 2850 (C-H), 1735 (C=O), 1720 
(C=O), 1677 (C=O), 1535 (C=C); 1H NMR (500 MHz, CDCl3) δ 7.30 
– 7.24 (2H, m, Ar-H), 7.23 – 7.14 (3H, m, Ar-H), 5.66 (1H, s, NH), 
5.22 (1H, d, J = 9.6 Hz, NH), 5.14 – 5.03 (1H, m, H-2), 4.34 – 4.18 
(1H, m, H-3), 2.90 – 2.74 (2H, m, H-4), 2.21 (2H, s, H-10), 2.07 (3H, s, H-15), 2.03 – 1.91 (6H, m, 
H-14), 1.74 – 1.61 (6H, m, H-16), 1.41 – 1.18 (9H, m, (CH3)3C), 1.07 (9H, s, H-12); 
13C NMR (126 
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MHz, CDCl3) δ 170.17 and 167.12 (C=O), 154.90 (Boc C=O), 137.53 (C-5), 129.31 (C-7 and C-7’), 
128.43 (C-6 and C-6’), 126.49 (C-8), 79.33 [(CH3)3C], 73.50 (C-2), 53.04 (C-3), 52.32 (C-13), 47.57 
(C-10), 41.44 (C-14), 37.88 (C-4), 36.26 (C-16), 30.96 (C-11), 29.69 (C-12), 29.40 (C-15), 28.30 
[(CH3)3C]; HRMS (m/z), calculated for C31H47N2O5: 527.3485, found (M + H)
+: 527.3484. 
 
 (2S,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl 3,3-
dimethylbutanoate 51B. m.p. 144 – 145 °C; IR vmax (cm
-1): 3267 
(NH), 3087 (C=CH), 2908 (C-H), 1735 (C=O), 1668 (C=O), 1653 
(C=O); 1H NMR (500 MHz, CDCl3) δ 7.31 – 7.25 (2H, m, Ar-H), 
7.25 – 7.16 (3H, m, Ar-H), 5.72 (1H, s, NH), 5.17 (1H, d, J = 9.0 
Hz, NH), 4.99 – 4.88 (1H, m, H-2), 4.29 – 4.17 (1H, m, H-3), 2.93 
(2H, d, J = 7.6 Hz, H-4), 2.35 – 2.19 (2H, m, H-10), 2.12 – 2.05 (3H, m, H-15), 2.05 – 1.94 (6H, m, 
H-14), 1.74 – 1.60 (6H, m, H-16), 1.44 – 1.19 (9H, m, (CH3)3C), 1.05 (9H, s, H-12); 
13C NMR (126 
MHz, CDCl3) δ 171.23 and 166.77 (C=O), 155.44 (Boc C=O), 137.50 (C-5), 129.18 (C-7 and C-7’), 
128.52 (C- and C-6’), 126.61 (C-8), 79.29 [(CH3)3C], 73.92 (C-2), 53.42 (C-3), 52.37 (C-13), 47.88 
(C-10), 41.44 (C-14), 37.61 (C-4), 36.27 (C-16), 31.00 (C-11), 29.70 (C-12), 29.39 (C-15), 28.35 
[(CH3)3C]; HRMS (m/z), calculated for C31H47N2O5: 527.3485, found (M + H)
+: 527.3484.  
4.50 Synthesis of (3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl 2-chloroacetate 52                                                                                                        
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), adamantyl isocyanide 11 (193 mg, 1.20 mmol) 
and chloro-acetic acid 6 (113 mg, 1.20 mmol) were dissolved in CH2Cl2 (3 ml) and the 
experiment proceeded as described in 4.5. The reaction yielded compound 52 (495 mg, 82%) as 
a mixture of diastereomers. Rf = 0.27 (1:1 EtOAc/Hex); d.r. = 1.97:1.00. This diastereomeric 
mixture was then separated using preparative HPLC as detailed in 4.10 to give two clean 
separated diastereomers. 
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 (2R,3S)-1-adamantan-1-ylamino-3-((tert-
butoxycarbonyl)amino)-1-oxo-4-phenylbutan-2-yl 2-chloro 
acetate 52A. m.p. 143 – 144 °C; IR vmax (cm
-1): 3281 (NH), 3064 
(C=CH), 1777 (C=O), 1725 (C=O), 745 (C-Cl); 1H NMR (500 MHz, 
CDCl3) δ 7.33 – 7.26 (2H, m, Ar-H), 7.25 – 7.14 (3H, m, Ar-H), 
5.73 (1H, s, NH), 5.29 – 5.17 (1H, m, NH), 5.16 – 5.06 (1H, m, H-
2), 4.39 – 4.30 (1H, m, H-3), 4.00 (2H, s, H-10), 2.85 (2H, d, J = 7.3 Hz, H-4), 2.07 (3H, s, H-13), 
2.03 – 1.93 (6H, m, H-12), 1.72 – 1.62 (6H, m, H-14), 1.45 – 1.27 (9H, m, (CH3)3C); 
13C NMR (126 
MHz, CDCl3) δ 165.94 and 165.43 (C=O), 154.95 (Boc C=O), 137.20 (C-5), 129.23 (C-7 and C-7’), 
128.55 (C-6 and C-6’), 126.67 (C-8), 79.66 [(CH3)3C], 75.01 (C-2), 52.77 (C-3), 52.58 (C-11), 41.35 
(C-10), 40.43 (C-12), 38.09 (C-4), 36.23 (C-14), 29.38 (C-13), 28.29 [(CH3)3C]; HRMS (m/z), 
calculated for C27H38ClN2O5: 505.2469, found (M + H)
+: 505.2461.  
 
 (2S,3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl-2-chloroacetate 52B. m.p. 
80 – 81 °C; IR vmax (cm
-1): 3285 (NH), 3064 (C=C-H), 1770 (C=O), 
1725 (C=O), 745 (C-Cl);  1H NMR (500 MHz, CDCl3) δ  7.34 – 7.17 
(5H, m, Ar-H), 5.87 (1H, s, NH), 5.14 – 5.01 (1H, m, H-2), 4.90 
(1H, d, J = 9.1 Hz, NH), 4.35 – 4.25 (1H, m, H-3), 4.15 (1H, d, J = 
14.8 Hz, H-10a), 4.09 (1H, d, J = 14.8 Hz, H-10b), 3.05 – 2.89 (2H, m, H-4), 2.13 – 2.06 (3H, m, H-
13), 2.06 – 1.97 (6H, m, H-12), 1.74 – 1.65 (6H, m, H-14), 1.38 (9H, s, (CH3)3C); 
13C NMR (126 
MHz, CDCl3) δ 165.96 and 165.67 (C=O), 155.53 (Boc C=O), 137.18 (C-5), 129.17 (C-7 and C-7’), 
128.55 (C-6 and C-6’), 126.72 (C-8), 79.68 [(CH3)3C], 75.94 (C-2), 53.20 (C-3), 52.53 (C-11), 41.44 
(C-12), 40.70 (C-10), 37.10 (C-4), 36.24 (C-14), 29.39 (C-13), 28.32 ((CH3)3C); HRMS (m/z), 
calculated for C27H38ClN2O5: 505.2469, found (M + H)
+: 505.2469.  
4.51 Synthesis of (2S)-(3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenyl 
propanoate 53                                                                                                                
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N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), adamantyl isocyanide 11 (193 mg, 1.20 mmol) 
and N-Boc-phenylalanine 7 (318 mg, 1.20 mmol) were dissolved in CH2Cl2 (3 ml) and the 
experiment was carried out as described in 4.5. The reaction yielded compound 53 (632 mg, 
78%) as a mixture of diastereomers. Rf = 0.27 (1:1 EtOAc/Hex); d.r. = 2.49:1.00. This mixture 
was then separated using preparative HPLC as detailed in 4.10 to give two clean separated 
diastereomers. 
 
 (2S)-(2R,3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl-2-((tert-butoxycarbonyl) 
amino)-3-phenylpropanoate 53A. m.p. 80 – 81 °C; IR vmax (cm
-1): 
3342 (NH), 2977 (C-H), 2909 (C-H), 1743 (C=O), 1692 (C=O), 1365 
(C-O); 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.00 (10H, m, Ar-H), 
6.42 – 6.27 (1H, m, NH), 5.22 (1H, d, J = 9.9 Hz, NH), 5.14 – 5.02 
(1H, m, H-2), 5.02 – 4.94 (1H, m, NH), 4.37 – 4.25 and 4.25 – 4.12 (2H, 2xm, H-3 and H-6), 3.13 – 
2.95 (2H, m, H-4), 2.61 – 2.47 and 2.35 – 2.25 (2H, 2xm, H-7) 2.12 – 1.94 (9H, m, H-9 and H-10), 
1.66 (6H, s, H-11), 1.49 – 1.10 (18H, m, 2x(CH3)3C); 
13C NMR (126 MHz, CDCl3) δ 171.08 and 
166.94 (C=O), 155.50 and 154.74 (Boc C=O), 137.51 (Ar-C), 135.51 (Ar-C), 129.39 (Ar-C), 129.15 
(Ar-C), 129.09 (Ar-C), 128.96 (Ar-C), 128.26 (Ar-C), 127.51 (Ar-C), 126.37 (Ar-C), 80.55 [(CH3)3C], 
79.15 [(CH3)3C], 74.27 (C-2), 55.50 and 52.80  (C-3 and C-6), 52.52 (C-8), 41.17 (C-9), 37.73 and 
37.27 (C-4 and C-7), 36.37 (C-11), 29.44 (C-10), 28.32 and 28.25 [(CH3)3C]; HRMS (m/z), 
calculated for C39H54N3O7: 676.3962, found (M + H)
+: 676.3954.   
 
(2S)-(2S,3S)-1-adamantan-1-ylamino-3-((tert-butoxycarbonyl) 
amino)-1-oxo-4-phenylbutan-2-yl-2-((tert-butoxycarbonyl) 
amino)-3-phenylpropanoate 53B. m.p. 132 – 133 °C; IR vmax (cm
-
1): 3343 (NH), 2908 (C-H), 1690 (C=O), 1657 (C=O), 1518 (C=C); 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.09 (10H, m, Ar-H), 6.45 – 
6.27 (m) and 5.98 (1H, s, NH), 5.20 – 5.07 (1H, m, H-2), 5.02 – 
4.76 (2H, m, 2xNH), 4.61 – 4.49 (1H, m) and 4.41 – 4.21 (1H, m) H-3 and H-6, 3.27 – 3.16 (1H, m, 
H-4a), 3.16 – 2.99 (1H, m, H-4b), 2.97 – 2.85 (1H, m, H-7a), 2.85 – 2.71 (1H, m, H-7b), 2.14 – 
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1.91 (9H, m, H-9 and H-10), 1.74 – 1.60 (6H, m, H-11), 1.47 – 1.17 (18H, m, 2x(CH3)3C); 
13C NMR 
(126 MHz, CDCl3) δ 170.72 and 166.07 (C=O), 155.35 (Boc C=O), 137.45 (Ar-C), 135.89 (Ar-C), 
129.32 (Ar-C), 129.23 (Ar-C), 128.99 (Ar-C), 128.78 (Ar-C), 128.45 (Ar-C), 128.28 (Ar-C), 127.20 
(Ar-C), 126.56 (Ar-C), 80.29 [(CH3)3C], 79.50 [(CH3)3C], 75.74 (C-2), 54.70 and 53.45 (C-3 and C-
6), 52.43 (C-8), 41.30 (C-9), 37.50 and 36.64 (C-4 and C-7), 36.31 (C-11), 29.42 (C-10), 28.37 and 
28.26 [(CH3)3C], HRMS (m/z), calculated for C39H54N3O7: 676.3962, found (M + H)
+: 676.3962.  
4.52 Synthesis of (2R,3S)-3-acetamido-N-adamantan-1-yl-2-hydroxy-4-phenyl 
butanamide 54A 
Compound 47A (70 mg, 0.15 mmol), TFA (115 µl, 1.49 mmol) and Et3N (207 µl, 1.49 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 54A 
(51 mg, 93%) as a white solid. 
 
 Rf = 0.39 (49:1 CHCl3/MeOH); m.p. 196 – 197 °C; IR vmax(cm
-1): 
3345 (OH), 3314 (NH), 3031 (C=CH), 1748 (C=O), 1312 (C-O); 1H 
NMR (300 MHz, CDCl3) δ 7.34 – 7.15 (5H, m, Ar-H), 7.05 (1H, d, J 
= 8.2 Hz, NH), 6.72 (1H, s, OH), 6.34 (1H, d, J = 6.8 Hz, NH), 4.14 
– 4.01 (1H, m, H-3), 3.97 (1H, dd, J = 6.8, 3.4 Hz, H-2), 3.10 (1H, dd, J = 13.7, 6.2 Hz, H-4a), 2.92 
(1H, dd, J = 13.7, 9.2 Hz, H-4b), 2.07 (3H, s, H-13), 2.02 – 1.95 (6H, m, H-12), 1.87 (3H, s, H-10), 
1.67 (6H, s, H-14); 13C NMR (75 MHz, CDCl3) δ 172.08 and 171.87 (C=O),138.26 (C-5), 129.15 (C-
7 and C-7’), 128.44 (C-6 and C-6’), 126.52 (C-8), 73.22 (C-2), 55.91 (C-3), 51.76 (C-11), 41.42 (C-
12), 36.29 (C-4), 35.58 (C-14), 29.38 (C-13), 23.00 (C-10); HRMS (m/z), calculated for 
C22H31N2O3: 371.2335, found (M + H)
+: 371.2331. 
4.53 Synthesis of (2S,3S)-3-acetamido-N-adamantan-1-yl-2-hydroxy-4-phenyl 
butanamide 54B 
Compound 47B (60 mg, 0.13 mmol), TFA (98 µl, 1.27 mmol) and Et3N (176 µl, 1.27 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 54B 
(47 mg, 99%) as a white solid. 
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 Rf = 0.33 (49:1 CHCl3/MeOH); m.p. 217 – 218 °C; IR vmax(cm
-1): 
3357 (OH), 3324 (NH), 3103 (NH), 2902 (C-H), 1606 (C=O), 1344 
(C-O); 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.15 (6H, m, Ar-H and 
NH), 6.73 (0.56H, s, NH), 6.61 (0.44H, s) and 5.91 – 5.82 (2H, m) 
NH and OH, 4.26 – 4.13 (1H, m, H-3), 4.13 – 4.06 (1H, m, H-2), 3.10 – 2.99 (1H, m, H-4a), 2.99 – 
2.88 (1H, m, H-4b), 2.13 – 1.96 (9H, m, H-12 and H-13), 1.93 – 1.86 (3H, m, H-10), 1.70 (6H, s, H-
14); 13C NMR (126 MHz, CDCl3) δ 172.59, 172.51,170.75 and 170.69 (C=O), 138.36 (C-5), 129.28 
(C-7 and C-7’), 128.51 and 128.41 (C-6 and C-6’), 126.52 (C-8), 74.78 and 74.68 (C-2), 57.39, 
57.29 and 57.24 (C-3), 51.62 and 51.40 (C-11), 41.64 and 41.61 (C-12), 36.39 (C-14), 35.33 35.29 
and 35.24 (C-4), 29.46 (C-13), 22.88 and 22.83 (C-10); HRMS (m/z), calculated for C22H31N2O3: 
371.2335, found (M + H)+: 371.2331. 
4.54 Preparation of (2R,3S)-N-adamantan-1-yl-2-hydroxy-4-phenyl-3-
propionamidobutanamide 55A 
Compound 48A (60 mg, 0.12 mmol), TFA (96 µl, 1.24 mmol) and Et3N (172 µl, 1.24 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 55A 
(47 mg, 99%) as a white solid. 
 
 Rf = 0.46 (49:1 CHCl3/MeOH); m.p. 185 – 186 °C; IR vmax(cm
-1): 
3342 (OH), 3292 (NH), 2906 (C-H), 1750 (C=O), 1360 (C-O); 1H 
NMR (500 MHz, CDCl3) δ 7.28 – 7.22 (2H, m, Ar-H), 7.21 – 7.16 
(3H, m, Ar-H), 6.74 (1H, d, J = 8.1 Hz), 6.65 (1H, s) and 6.22 (1H, 
s) 2xNH and OH, 4.19 – 4.09 (1H, m, H-3), 4.01 – 3.92 (1H, m, H-
2), 3.08 (1H, dd, J = 13.8, 6.2 Hz, H-4a), 2.97 (1H, dd, J = 13.8, 9.3 Hz, H-4b), 2.15 – 2.03 (5H, m, 
H-10 and H-14), 1.98 (6H, s, H-13), 1.67 (6H, s, H-15), 1.02 (3H, t, J = 7.6 Hz, H-11); 13C NMR (126 
MHz, CDCl3) δ 175.82 and 171.84 (C=O), 138.35 (C-5), 129.23 (C-7 and C-7’), 128.44 (C-6 and C-
6’), 126.53 (C-8), 73.52 (C-2), 55.74 (C-3), 51.81 (C-12), 41.57 (C-13), 36.38 (C-15), 35.76 (C-4), 
29.54 (C-10), 29.49 (C-14), 9.91 (C-11); HRMS (m/z), calculated for C23H33N2O3: 385.2491, found 
(M + H)+: 385.2487. 
Chapter 4: Experimental Procedures 
 
135 
 
4.55 Preparation of (2S,3S)-N-adamantan-1-yl-2-hydroxy-4-phenyl-3-propion 
amidobutanamide 55B 
Compound 48B (40 mg, 0.083 mmol), TFA (56 µl, 0.91 mmol) and Et3N (114 µl, 0.91 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 55B 
(28 mg, 88%) as a white solid. 
 
 Rf = 0.49 (49:1 CHCl3/MeOH); m.p. 214 – 215 °C; IR vmax(cm
-1): 
3362 (OH), 3264 (NH), 2908 (C-H), 1760 (C=O); 1H NMR (500 
MHz, CDCl3) δ 7.31 – 7.24 (2H, m, Ar-H), 7.24 – 7.16 (3H, m, Ar-
H), 6.71 (1H, s), 5.95 (1H, d, J = 6.8 Hz) and 5.86 (1H, d, J = 5.2 
Hz) 2xNH and OH, 4.21 – 4.14 (1H, m, H-3), 4.14 – 4.09 (1H, m, 
H-2), 3.11 (1H, dd, J = 14.1, 10.0 Hz, H-4a), 2.99 (1H, dd, J = 14.1, 5.6 Hz, H-4b), 2.18 – 1.94 (11H, 
m, H-10, H-13 and H-14), 1.69 (6H, s, H-15), 1.06 (3H, t, J = 7.6 Hz, H-10); 13C NMR (126 MHz, 
CDCl3) δ 176.66 and 170.78 (C=O), 138.01 (C-5), 129.19 (C-7 and C-7’), 128.66 (C-6 and C-6’), 
126.73 (C-8), 75.13 (C-2), 57.91 (C-3), 51.75 (C-12), 41.68 (C-13), 36.41 (C-15), 35.72 (C-4), 29.52 
(C-14), 29.46 (C-10), 9.76 (C-11); HRMS (m/z), calculated for C23H33N2O3: 385.2491, found (M + 
H)+: 385.2486. 
4.56 Preparation of (2R,3S)-N-adamantan-1-yl-3-butyramido-2-hydroxy-4-
phenylbutanamide 56A                                                                                              
 Compound 49A (80 mg, 0.16 mmol), TFA (123 µl, 1.60 mmol) and Et3N (222 µl, 1.60 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 56A 
(60 mg, 94%) as a white solid. 
 
 Rf = 0.44 (49:1 CHCl3/MeOH); m.p. 109 – 110 °C; IR vmax(cm
-1): 
3374 (OH), 3284 (NH), 3064 (C=C-H), 2907 (C-H), 1645 (C=O), 
1360 (C-O); 1H NMR (500 MHz, CDCl3) δ 7.28 – 7.21 (2H, m, Ar-
H), 7.21 – 7.15 (3H, m, Ar-H), 6.95 (1H, s, OH), 6.78 – 6.70 (1H, 
m, NH), 6.50 – 6.38 (1H, m, NH), 4.20 – 4.09 (1H, m, H-3), 4.01 – 
3.93 (1H, m, H-2), 3.11 (1H, dd, J = 13.8, 6.2 Hz, H-4a), 2.99 – 2.90 (1H, m, H-4b), 2.14 – 2.02 
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(5H, m, H-10 and H-15), 1.99 (6H, s, H-14), 1.67 (6H, s, H-16), 1.58 – 1.45 (2H, m, H-11), 0.84 
(3H, t, J = 7.3 Hz, H-12); 13C NMR (126 MHz, CDCl3) δ 175.06 and 171.89 (C=O), 138.29 (C-5), 
129.17 (C-7 and C-7’), 128.40 (C-6 and C-6’), 126.47 (C-8), 73.49 (C-2), 55.73 (C-3), 51.71 (C-13), 
41.44 (C-14), 38.24 (C-4), 36.30 (C-16), 35.53 (C-10), 29.38 (C-15), 19.08 (C-11), 13.69 (C-12); 
HRMS (m/z), calculated for C24H35N2O3: 399.2648, found (M + H)
+:  399.2645. 
4.57 Preparation of (2S,3S)-N-adamantan-1-yl-3-butyramido-2-hydroxy-4-
phenylbutanamide 56B 
Compound 49B (70 mg, 0.14 mmol), TFA (108 µl, 1.40 mmol) and Et3N (194 µl, 1.40 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 56B 
(57 mg, 100%) as a white solid. 
 
 Rf = 0.49 (49:1 CHCl3/MeOH); m.p. 151 – 152 °C; IR vmax(cm
-1): 
3360 (OH), 3266 (NH), 3064 (C-H), 2924 (C-H), 1660 (C=O), 1603 
(C=C), 1370 (C-O);  ; 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.25 (2H, 
m, Ar-H), 7.21 – 7.13 (3H, m, Ar-H) , 5.73 (1H, s, NH), 4.96 (1H, d, 
J = 3.9 Hz, NH), 4.26 – 4.15 (1H, m, H-3), 3.99 (1H, d, J = 6.5 Hz, 
H-2), δ 3.13 (1H, dd, J = 13.8, 6.2 Hz, H-4a), 2.98 – 1.97 (1H ,m , H-4b), 2.36 (2H, t, J = 7.4 Hz, H-
10), 2.12 – 2.05 (3H, m, H-15), 2.01 (6H, m, H-14), 1.71 – 1.68 (8H, m, H-11 and H-16), 0.97 (3H, 
q, J = 7.1 Hz, H-12); 13C NMR (126 MHz, CDCl3) δ 172.42 and 166.70 (C=O), 137.45 (C-5), 129.19 
(C-7 and C-7’), 128.49 (C-6 and C-6’), 126.60 (C-8), 74.24 (C-2), 56.48 (C-3), 52.32 (C-13), 41.44 
(C-14), 37.49 (C-4), 36.26 (C-16), 36.03 (C-10), 29.70 (C-15), 18.32 (C-11), 13.65 (C-12); HRMS 
(m/z), calculated for C24H35N2O3: 399.2648, found (M + H)
+: 399.2643. 
4.58 Preparation of (2R,3S)-N-adamantan-1-yl-2-hydroxy-4-phenyl-3-
pivalamidobutanamide 57A                                                                                                                    
Compound 50A (90 mg, 0.18 mmol), TFA (136 µl, 1.76 mmol) and Et3N (244 µl, 1.76 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The experiment yielded compound 
57A (51 mg, 70%) as a white solid. 
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 Rf = 0.62 (49:1 CHCl3/MeOH); m.p. 239 – 240 °C; IR vmax(cm
-1): 
3301 (OH), 2907 (C-H), 1737 (C=O), 1651 (C-O), 1345 (C-O); 1H 
NMR (500 MHz, CDCl3) δ 7.28 – 7.22 (2H, m, Ar-H), 7.21 – 7.15 
(3H, m, Ar-H), 6.75 – 6.67 (1H, m), 6.67 – 6.54 (1H, m) and 6.48 
– 6.39 (1H, m, 2xNH and OH), 4.27 – 4.16 (1H, m, H-3), 4.02 – 
3.95 (1H, m, H-2), 3.12 – 2.96 (2H, m, H-4), 2.07 (3H, s, H-14), 1.99 (6H, s, H-13), 1.67 (6H, s, H-
15), 1.05 (9H, s, H-11); 13C NMR (126 MHz, CDCl3) δ 180.67 and 171.73 (C=O), 138.26 (C-5), 
129.25 (C-7 and C-7’), 128.37 (C- and C-6’), 126.49 (C-8), 73.85 (C-2), 55.46 (C-3), 51.69 (C-12), 
41.52 (C-13), 38.65 (C-10) 36.30 (C-15), 35.52 (C-4), 29.38 (C-14), 27.48 (C-11); HRMS (m/z), 
calculated for C25H37N2O3: 413.2804, found (M + H)
+: 413.2798. 
4.59 Preparation of (2S,3S)-N-adamantan-1-yl-2-hydroxy-4-phenyl-3-pival 
amidobutanamide of 57B 
Compound 50B (45 mg, 0.087 mmol), TFA (67 µl, 0.87 mmol) and Et3N (121 µl, 0.87 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 57B 
(26 mg, 70%) as a white solid.  
 
 Rf = 0.54 (49:1 CHCl3/MeOH); m.p. 61 – 63 °C; IR vmax(cm
-1): 
3318 (OH), 3248 (NH), 2961 (C-H), 1664 (C=O), 1636 (C=O), 
1358 (C-O); 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.17 (5H, m, Ar-
H), 6.75 (1H, s, NH), 5.97 (1H, d, J = 6.6 Hz, NH), 4.24 – 4.15 (1H, 
m, H-3), 4.14 – 4.09 (1H, m, H-2), 3.18 (1H, dd, J = 14.2, 10.5 Hz, 
H-4a), 3.05 (1H, dd,  J = 14.1, 5.4 Hz, H-4b), 2.13 – 2.05 (3H, m, H-14), 2.05 – 1.91 (6H, m, H-13), 
1.73 – 1.60 (6H, m, H-15), 1.05 (9H, s, H-11); 13C NMR (126 MHz, CDCl3) δ 181.67 and 170.79 
(C=O), 137.89 (C-5), 129.36 (C-7 and C-7’), 128.65 (C-6 and C-6’), 126.75 (C-8), 75.28 (C-2), 57.59 
(C-3), 51.65 (C-12), 41.62 (C-13), 38.62 (C-10), 36.27 (C-15), 35.97 (C-4), 29.41 (C-14), 27.40 (C-
11); HRMS (m/z), calculated for C25H37N2O3: 413.2804, found (M + H)
+: 413.2802. 
4.60 Preparation of (2R,3S)-N-adamantan-1-yl-3-(3,3-dimethylbutanamido)-2-
hydroxy-4-phenylbutanamide 58A                                                                                                                     
Chapter 4: Experimental Procedures 
 
138 
 
Compound 51A (75 mg, 0.14 mmol), TFA (110 µl, 1.42 mmol) and Et3N (197 µl, 1.42 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 58A 
(50 mg, 82%) as a white solid.  
 
Rf = 0.44 (49:1 CHCl3/MeOH); m.p. 172 – 173 °C; IR vmax(cm
-1): 
3346 (OH), 3290 (NH), 3088 (C=CH), 2906 (C-H), 1660 (C=O), 
1360 (C-O); 1H NMR (500 MHz, CDCl3) δ  7.28 – 7.13 (5H, m, Ar-
H), 6.97 (1H, d, J = 8.2 Hz), 6.77 (1H, s) and 6.57 (1H, d, J = 6.5 
Hz, 2xNH and OH), 4.24 – 4.15 (1H, m, H-3), 4.00 – 3.92 (1H, m, 
H-2), 3.16 (1H, dd, J = 13.8, 6.4 Hz, H-4a), 2.92 (1H, dd, J = 13.8, 9.3 Hz, H-4b), 2.11 – 2.04 (3H, 
m, H-15), 2.04 – 1.91 (8H, m, H-10 and H-14), 1.70 – 1.63 (6H, m, H-16), 0.90 (9H, s, H-12), 13C 
NMR (126 MHz, CDCl3) δ 173.84 and 171.96 (C=O), 138.25 (C-5), 129.19 (C-7 and C-7’), 128.41 
(C-6 and C-6’), 126.45 (C-8), 73.43 (C-2), 55.59 (C-3), 51.73 (C-13), 50.02 (C-10), 41.47 (C-14), 
36.30 (C-16), 35.49 (C-4), 30.74 (C-11), 29.73 (C-12), 29.38 (C-15); HRMS (m/z), calculated for 
C26H39N2O3: 427.2961, found (M + H)
+: 427.2955.  
4.61 Preparation of (2S,3S)-N-adamantan-1-yl-3-(3,3-dimethylbutanamido)-2-
hydroxy-4-phenylbutanamide 58B 
Compound 51B (31 mg, 0.059 mmol), TFA (45 µl, 0.59 mmol) and Et3N (82 µl, 0.59 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 58B 
(27 mg, 100%) as a white solid. 
 
 Rf = 0.46 (49:1 CHCl3/MeOH); m.p. 195 – 196 °C; IR vmax(cm
-1): 
3301 (OH), 3285 (NH), 2906 (C-H), 2851 (C-H), 1654 (C=O), 1638 
(C=O), 1360 (C-O); 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.14 (5H, 
m, Ar-H), 6.76 (1H, s) and 6.07 – 5.95 (2H, m, 2xNH and OH), 
4.27 – 4.15 (1H, m, H-3), 4.15 – 4.08 (1H, m, H-2), 3.14 (1H, dd, J 
= 14.3, 10.3 Hz. H-4a), 3.04 (1H, dd, J = 14.2, 5.3 Hz, H-4b), 2.04 (3H, m, H-15), 2.04 – 1.89 (8H, 
m, H-10 and H-14), 1.73 – 1.63 (6H, m, H-16), 0.88 (9H, s, H-12); 13C NMR (126 MHz, CDCl3) δ 
174.87 and 170.82 (C=O), 137.91 (C-5), 129.11 (C-7 and C-7’), 128.67 (C-6 and C-6’), 126.71 (C-
8), 75.36 (C-2), 57.77 (C-3), 51.68 (C-13), 50.07 (C-10), 41.53 (C-14), 36.32 (C-16), 35.94 (C-4), 
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30.81 (C-11), 29.63 (C-12), 29.40 (C-15); HRMS (m/z), calculated for C26H39N2O3: 427.2961, 
found (M + H)+: 427.2962.  
4.62 Preparation of (2R,3S)-N-adamantan-1-yl-3-(2-chloroacetamido)-2-
hydroxy-4-phenylbutanamide 59A                                                                                                             
Compound 52A (60 mg, 0.12 mmol), TFA (92 µl, 1.19 mmol) and Et3N (165 µl, 1.19 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 59A 
(42 mg, 88%) as a white solid.  
 
Rf = 0.44 (49:1 CHCl3/MeOH); m.p. 141 – 142 °C; IR vmax(cm
-1): 
3320 (OH), 3280 (NH), 3064 (C=C-H), 2907 (C-H), 1649 (C=O), 
1360 (C-O), 749 (C-Cl); 1H NMR (500 MHz, CDCl3) δ 7.51 (1H, d, J 
= 8.7 Hz, NH), 7.31 – 7.24 (2H, m, Ar-H), 7.24 – 7.17 (3H, m, Ar-
H), 6.50 (1H, s, NH), 5.37 (1H, s, OH), 4.36 – 4.24 (1H, m, H-3), 4.01 (1H, s, H-2), 3.86 (2H, s, H-
10), 3.08 (1H, dd, J = 13.7, 6.1 Hz, H-4a), 2.87 (1H, dd, J = 13.5, 8.9 Hz, H-4b), 2.13 – 2.05 (3H, m, 
H-13), 1.99 (6H, s, H-12), 1.68 (6H, s, H-14); 13C NMR (126 MHz, CDCl3) δ 171.06 and 167.15 
(C=O), 137.61 (C-5), 129.22 (C-7 and C-7’), 128.52 (C-6 and C-6’), 126.69 (C-8), 72.26 (C-2), 55.35 
(C-3), 52.00 (C-11), 42.34( C-10), 41.40 (C-12), 36.23 (C-14), 35.87 (C-4), 29.36 (C-13); HRMS 
(m/z), calculated for C22H30ClN2O3: 405.1945, found (M + H)
+: 405.1945.  
4.63 Preparation of (2S,3S)-N-adamantan-1-yl-3-(2-chloroacetamido)-2-
hydroxy-4-phenylbutanamide 59B 
Compound 52B (42 mg, 0.083 mmol), TFA (64 µl, 0.83 mmol) and Et3N (115 µl, 0.83 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 59B 
(25 mg, 77%) as a white solid. 
 
 Rf = 0.47 (49:1 CHCl3/MeOH); m.p. 223 – 224 °C; IR (solid) 
vmax(cm
-1): 3313 (OH), 2906 (C-H), 1648 (C=C), 1361 (C-O), 794 
(C-Cl); 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.25 (2H, m, Ar-H), 
7.25 – 7.17 (3H, m, Ar-H), 6.97 (1H, d, J = 7.5 Hz), 6.64 (1H, s) 
and 5.07 (1H, d, J = 5.2 Hz, 2xNH and OH), 4.34 – 4.24 (1H, m, H-3), 4.21 – 4.14 (1H, m, H-2), 
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3.98 – 3.88 (2H, m, H-10), 3.09 – 2.95 (2H, m, H-4), 2.13 – 2.06 (3H, m, H-13), 2.06 – 1.98 (6H, 
m, H-12), 1.77 – 1.66 (6H, m, H-14); 13C NMR (126 MHz, CDCl3) δ 170.07 and 168.05 (C=O), 
137.39 (C-5), 129.18 (C-7 and C-7’), 128.67 (C-6 and C-6’), 126.82 (C-8), 73.97 (C-2), 57.41 (C-3), 
51.94 (C-11), 42.29 (C-10), 41.51 (C-12), 36.27 (C-14), 35.40 (C-4), 29.39 (C-13); HRMS (m/z), 
calculated for C22H30ClN2O3: 405.1945, found  (M + H)
+: 405.1945. 
4.64 Preparation of (2R,3S)-N-adamantan-1-yl-3-((S)-2-amino-3-phenyl 
propanamido)-2-hydroxy-4-phenylbutanamide 60A                                                                                                               
Compound 53A (100 mg, 0.15 mmol), TFA (114 µl, 1.48 mmol) and Et3N (205 µl, 1.48 mmol) in 
CH2Cl2 (2 ml) were reacted together as described in 4.11. The reaction yielded compound 60A 
(59 mg, 84%) as a white solid. 
 
 Rf = 0.29 (49:1 CHCl3/MeOH); m.p. 65 – 66 °C; IR vmax(cm
-1): 
3311 (OH), 3028 (C=CH), 2907 (C-H), 1648 (C=O), 1345 (C-O); 1H 
NMR (500 MHz, CDCl3) δ 7.96 (0.83H, d, J = 8.3 Hz, NH), 7.67 
(0.13H, d, J = 8.9 Hz, NH), 7.34 – 7.11 (10H, m, Ar-H), 6.60 (0.89H, 
s, NH), 6.53 (0.13H, s, NH), 6.10 (1H, br-s, OH), 4.34 – 4.23 (1H, 
m, H-3), 4.05 – 3.99 (0.89H, m, H-2), 3.94 – 3.90 (0.13H, m, H-2), 3.49 (1H, dd, J = 10.4, 3.7 Hz, 
H-6), 3.24 – 3.04 (2H, m, H-4a and H-7a), 3.04 – 2.91 (1H, m, H-4b), 2.36 (1H, dd, J = 13.8, 10.3 
Hz, H-7b), 2.11 – 2.03 (3H, m, H-10), 2.03 – 1.93 (6H, m, H-9), 1.71 – 1.61 (6H, m, H-11); 13C 
NMR (126 MHz, CDCl3) δ 176.31 and 171.40 (C=O), 138.19 (Ar-C), 137.75 (Ar-C), 129.35 (Ar-C), 
129.29 (Ar-C), 129.10 (Ar-C), 128.77 (Ar-C), 128.66 (Ar-C), 128.44 (Ar-C), 128.40 (Ar-C), 126.89 
(Ar-C), 126.86 (Ar-C), 126.57 (Ar-C), 126.54 (Ar-C), 73.38 (C-2), 56.51 and 55.20 (C-3 and C-6), 
51.79 (C-8), 41.50 (C-9), 41.01 (C-7), 36.29 (C-11), 35.95 (C-4), 29.39 (C-10); HRMS (m/z), 
calculated for C29H38N3O3: 476.2913, found (M + H)
+: 476.2918.   
4.65 Preparation of (2S,3S)-N-adamantan-1-yl-3-((S)-2-amino-3-
phenylpropanamido)-2-hydroxy-4-phenylbutanamide 60B 
Compound 53A (40 mg, 0.059 mmol), TFA (46 µl, 0.59 mmol) and Et3N (82 µl, 0.59 mmol) in 
CH2Cl2 (1 ml) were reacted described together as in 4.11. The reaction yielded compound 60B 
(25 mg, 89%) as a white solid. 
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 Rf = 0.31 (49:1 CHCl3/MeOH); m.p. 60 – 62 °C; IR vmax(cm
-1): 
3313 (OH), 3028 (C=C-H), 2906 (C-H), 1654 (C=O), 1603 (C=O), 
1360 (C-O); 1H NMR (500 MHz, CDCl3) δ 7.74 (1H, d, J = 7.1 Hz, 
NH), 7.33 – 7.09 (10H, m, Ar-H), 6.74 (1H, s, NH), 4.24 – 4.13 (2H, 
m, H-2 and H-3), 3.57 – 3.49 (1H, m, H-6), 3.14 – 3.05 (2H, m, H-
4a and H-7a), 2.97 (1H, dd, J = 14.0, 5.1 Hz, H-4b), 2.49 (1H, dd, J = 13.8, 9.2 Hz, H-7b), 2.12 – 
1.96 (9H, m, H-9 and H-10), 1.75 – 1.63 (6H, m, H-11); 13C NMR (126 MHz, CDCl3) δ 176.95 and 
170.48 (C=O), 138.17 (Ar-C), 137.22 (Ar-C), 129.22 (Ar-C), 129.18 (Ar-C), 128.77 (Ar-C), 128.53 
(Ar-C), 126.99 (Ar-C), 126.60 (Ar-C), 74.93 (C-2), 57.51 (C-3), 56.08 (C-6), 51.63 (C-8), 41.56 (C-
9), 40.77 (C-7) 36.32 (C-11), 35.03 (C-4), 29.42 (C-10); HRMS (m/z), calculated for C29H38N3O3: 
476.2913, found (M + H)+: 476.2917.  
4.66 Preparation of (S)-2-isocyano-N-methoxy-N-methyl-3-phenyl 
propanamide 12 
 
Excess formic acid (20 ml) and excess acetic anhydride (5 ml) were added to compound 14 
(3.15 g, 15.10 mmol) and left to stir under N2. TFA (4 eq., 464 µl, 60.4 mmol) was added 
dropwise and the reaction was left stirring at room temperature for 4 h whilst being monitored 
by TLC. The reaction was worked up as described in 4.44 yielding a crude formylated product as 
a viscous colourless oil (2.76 g, 78%). Crude product (2.76 g, ≈ 11.66 mmol) was dissolved in 
anhydrous CH2Cl2 (10 ml) under N2 at 0°C, followed by slow addition of excess POCl3 (5 ml) and 
excess Et3N (15 ml). The experiment was completed using the same procedure as that 
described in 4.2 yielding 12 (2.06 g, 81%), as a brown oil with a slight distinct smell. 
 
 Rf = 0.29 (3:7 EtOAc/Hex); [αD]
20
589 +2.13 (c 2, CHCl3); IR: νmax(cm
-1): 3033 
(C=C-H), 2940 (C-H), 2143 (CΞN), 1676 (C=O); 1H NMR (500 MHz, CDCl3) δ 
7.32 – 7.29 (5H, m, Ar-H), 4.85 – 4.77 (1H, m, H-2), 3.66 (3H, s, H-6), 3.25 – 
3.22 (4H, m, H-5 and H-3a), 3.10 (1H, q, J = 8.5Hz, H-3b); 13C NMR (126 MHz, CDCl3) δ 165.88 C-
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1), 159.28 (C-4), 135.26 (Ar-C), 129.33 (Ar-C), 129.00 (Ar-C), 128.27 (Ar-C), 61.66 (C-6), 55.45 (C-
2), 38.70 (C-3), 32.53 (C-5).  
4.67 Synthesis (5S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-
dioxa-3,6,10-triazatetradecan-8-yl acetate 61 
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), phenylalanine isocyanide 12 (250 mg, 1.20 
mmol) and acetic acid 1 (81 µl, 1.20 mmol) were dissolved in CH2Cl2 (3 ml). The experiment 
proceeded as described in 4.5 yielding compound 61 (283 mg, 45%) as a white solid which was 
a mixture of diastereomers 
. 
 Rf = 0.54 (49:1 CHCl3/MeOH); d.r. = 1.52:1.00; m.p. 124 – 
125 °C; IR vmax(cm
-1): 3354 (NH), 2917 (C-H), 1747 (C=O), 
1690 (C=O), 1605 (C=C), 1366 (C-O); 1H NMR (300 MHz, 
CDCl3) δ 7.40 – 6.99 (10H, m, Ar-H), 6.92 – 6.57 (1H, m, NH), 
5.43 – 4.95 (2H, m, NH and H-2), 4.46 – 4.15 (2H, m, H-3 and H-8), 3.83 – 3.58 (3H, m, H-11), 
3.33 – 3.14 (3H, m, H-10), 3.14 – 2.39 (4H, m H-4 and H-9), 2.22 – 1.95 (3H, m, H-6), 1.44 – 1.20 
(9H, m, (CH3)3C); 
13C NMR (126 MHz, CDCl3) δ 171.23, 170.88, 169.35, 168.92, 167.55 and 
166.77 (C=O), 155.40 and 154.84 (Boc C=O), 137.28 (Ar-C), 135.82 (Ar-C), 129.54 (Ar-C), 129.49 
(Ar-C), 129.33 (Ar-C), 129.24 (Ar-C), 129.17 (Ar-C), 128.77 (Ar-C), 128.58 (Ar-C), 128.46 (Ar-C), 
128.43 (Ar-C), 128.36 (Ar-C), 127.14 (Ar-C), 127.04 (Ar-C), 126.53 (Ar-C), 126.48 (Ar-C), 79.42 
[(CH3)3C], 74.35 and 73.68 (C-2), 61.77 and 61.66 (C-11), 52.66 (C-3), 52.54, 50.08 and 49.83 (C-
8), 38.69, 38.53, 37.91 and 36.96 (C-4 and C-9), 32.16 (C-10), 28.44 and 28.25 [(CH3)3C], 20.86 
and 20.55 (C-6); HRMS (m/z), calculated for C28H38N3O7: 528.2710, found (M + H)
+: 528.2710. 
4.68 Synthesis of (5S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-
dioxa-3,6,10-triazatetradecan-8-yl propionate 62 
N-Boc-L-phenylalaninal 15 (250 mg, 1.00 mmol), phenylalanine isocyanide 12 (218 mg, 1.00 
mmol) and propionic acid 2 (83 µl, 1.00 mmol) were dissolved in of CH2Cl2 (3 ml). The 
experiment proceeded as in 4.5 yielding 62 (544 mg, 100%) as a white solid which was a 
mixture of diastereomers.  
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Rf = 0.55 (1:1 EtOAc/Hex); d.r. = 1.34:1.00; m.p. 159 – 160 
°C; IR vmax(cm
-1): 3372 (NH), 3064 (C-H), 1738 (C=O), 1691 
(C=O), 1656 (C=O), 1523 (C=C); 1H NMR (300 MHz, CDCl3) δ 
7.48 – 6.69 (11H, m, Ar-H and NH), 5.49 – 4.98 (3H, m, NH, 
H-2 and H-9), 4.58 – 4.15 (1H, m, H-3), 3.84 – 3.52 (3H, m, H-
12), 3.41 – 2.10 (9H, m, H-4, H-6, H-10 and H-11), 1.60 – 0.99 (12H, m, (CH3)3C and H-7); 
13C 
NMR (75 MHz, CDCl3) δ 172.67, 172.37, 170.99, 167.75 and 166.95 (C=O), 155.34 and 154.90 
(Boc C=O), 137.35 (Ar-C), 136.30 (Ar-C), 135.86 (Ar-C), 135.27 (Ar-C), 129.52 (Ar-C), 129.48 (Ar-
C), 129.31 (Ar-C), 129.26 (Ar-C), 129.19 (Ar-C), 128.74 (Ar-C), 128.54 (Ar-C), 128.45 (Ar-C), 
128.39 (Ar-C), 128.31 (Ar-C), 127.09 (Ar-C), 126.96 (Ar-C), 126.48 (Ar-C), 126.43 (Ar-C), 79.36 
[(CH3)3C], 74.19 and 73.51 (C-2), 61.60 (C-12), 52.74 and 50.18 (C-3), 49.87 (C-9), 38.69, 38.50, 
37.98, 37.77 and 37.01 (C-4 and C-10), 32.16 (C-11), 28.23 [(CH3)3C], 27.44 and 27.25 (C-6), 8.93 
and 8.83 (C-7); HRMS (m/z), calculated for C29H40N3O7: 542.2866, found (M + H)
+: 542.2868. 
4.69 Synthesis of (5S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-
dioxa-3,6,10-triazatetradecan-8-yl 3,3-dimethylbutanoate 63 
N-Boc-L-phenylalaninal 15 (400 mg, 1.60 mmol), phenylalanine isocyanide 13 (349 µl, 1.60 
mmol) and tert-butyl isocyanide 4 (204 µl, 1.60 mmol) were dissolved in CH2Cl2 (3 ml). The 
experiment proceeded as described in 4.5 yielding compound 63 (239 mg, 26%) as a white solid 
that appeared as a single diastereomer. 
  
Rf = 0.54 (49:1 CHCl3/MeOH); d.r. = 1 peak; m.p. 106 – 107 
°C; IR (solid) vmax(cm
-1): 3309 (NH), 3029 (C-H), 1649 (C=O), 
1604 (C=C), 1365 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.38 – 
7.02 (10H, m, Ar-H), 6.87 – 6.70 (1H, m, NH), 5.42 – 4.91 (3H, 
m, NH, H-2 and H-10), 4.40 – 4.17 (1H, m, H-3), 3.78 – 3.59 
(3H, m, H-13), 3.22 – 2.59 (7H, m, H-4, H-11 and H-12), 2.26 
(2H, s, H-6), 1.32 (9H, s, (CH3)3C), 1.13 – 0.70 (9H, m, H-8); 
13C NMR (75 MHz, CDCl3) δ 171.00, 
170.58, 170.15 and 167.78 (C=O), 154.83 (Boc C=O), 137.37 (Ar-C), 135.89 (Ar-C), 129.45 (Ar-C), 
129.28 (Ar-C), 128.44 (Ar-C), 128.40 (Ar-C), 126.99 (Ar-C), 126.46 (Ar-C), 79.34 [(CH3)3C], 73.21 
(C-2), 61.62 (C-13), 52.86 and 50.15 (C-3 and C-10), 47.32 (C-6), 38.57 and 37.96 (C-4 and C-11), 
Chapter 4: Experimental Procedures 
 
144 
 
32.15 (C-12), 30.80 (C-7), 29.72 (C-8), 29.57 (C-8), 28.24 [(CH3)3C]; HRMS (m/z), calculated for 
C32H44N3O7: 584.3336, found (M + H)
+: 584.3338. 
4.70 Synthesis of (5S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-
dioxa-3,6,10-triazatetradecan-8-yl butyrate 64 
N-Boc-L-phenylalaninal 15 (150 mg, 0.60 mmol), phenylalanine isocyanide 12 (131 mg, 0.60 
mmol) and butyric acid 3 (55 µl, 0.60 mmol) were combined and the reaction was heated under 
microwave conditions at 120 °C, at 60 W for 7 min. The reaction was repeated 3 times and the 
product from all the reactions was combined and purified by column chromatography as 
detailed in 4.5. The experiment yielded compound 64 (832 mg, 83%) as a white solid which was 
a mixture of diastereomers. 
 
 Rf = 0.54 (49:1 CHCl3/MeOH); d.r. = 1.00:0.93; m.p. 135 – 
136 °C; IR vmax(cm
-1): 3384 (NH), 2966 (C-H), 1736 (C=O), 
1689 (C=O), 1654 (C=O); 1H NMR (300 MHz, CDCl3) δ 7.37 – 
7.00 (10H, m, Ar-H), 6.96 – 6.64 (1H, m, NH), 5.44 – 5.03 (3H, 
m, NH, H-2 and H-10), 4.60 – 4.16 (1H, m, H-3), 3.81 – 3.61 
(3H, m, H-13), 3.30 – 2.12 (9H, m,H-4, H-6, H-11 and H-12), 1.76 – 1.50 (2H, m, H-7), 1.45 – 1.11 
(9H, m, (CH3)3C), 1.03 – 0.81 (3H, m, H-8); 
13C NMR (75 MHz, CDCl3) δ 171.87, 171.53, 167.74 
and 166.94 (C=O), 155.30 (Boc C=O), 154.85 (Boc C=O), 137.33 (Ar-C), 136.27 (Ar-C), 135.84 (Ar-
C), 129.53 (Ar-C), 129.47 (Ar-C), 129.27 (Ar-C), 129.20 (Ar-C), 128.55 (Ar-C), 128.42 (Ar-C), 
128.40 (Ar-C), 128.33 (Ar-C), 127.10 (Ar-C), 126.98 (Ar-C), 126.46 (Ar-C), 79.39 [(CH3)3C], 74.05 
and 73.36 (C-2), 61.72 and 61.63 (C-13), 52.73, 50.15 and 49.84 (C-3 and C-10), 38.52, 37.87 and 
37.05 (C-4 and C-11), 35.96 and 35.76 (C-6), 32.16 (C-12), 28.25 [(CH3)3C], 18.25 and  18.15 (C-
7), 13.64 (C-8); HRMS (m/z), calculated for C30H42N3O7 : 556.3023, found (M + H)
+: 556.3030. 
4.71 Synthesis of (2R,3S)-3-acetamido-2-hydroxy-N-(S)-1-(methoxy 
(methyl)amino)-1-oxo-3-phenylpropan-2-yl)-4-phenylbutanamide 65 
Compound 61 (100 mg, 0.19 mmol), TFA (146 µl, 1.89 mmol) and Et3N (262 µl, 1.89 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 65 (43 
mg, 53%) as a yellow oil which appeared as a single diastereomer. 
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 Rf = 0.43 (49:1 CHCl3/MeOH); IR vmax(cm
-1): 3332 (OH), 3029 
(C=C-H), 1642 (C=O), 1518 (C=C), 1374 (C-O); 1H NMR (500 
MHz, CDCl3) δ 7.37 (1H, d, J = 8.3 Hz, NH), 7.32 – 7.13 (10H, 
m, Ar-H), 6.27 (1H, d, J = 8.1 Hz, NH), 5.77 (1H, s, OH), 5.14 
(1H, s, H-8), 4.23 – 4.09 (1H, m, H-3), 4.05 (1H, s, H-2), 3.65 (3H, s, H-11), 3.23 – 2.98 (6H, m, H-
4a, H-9a and H-10), 2.91 (1H, dd, J = 13.7, 7.7 Hz, H-9b), 1.87 (3H, s, H-6); 13C NMR (126 MHz, 
CDCl3) δ 172.70, 172.36 and 171.54 (C=O), 138.04 (Ar-C), 136.30 (Ar-C), 129.26 (Ar-C), 129.19 
(Ar-C), 128.56 (Ar-C), 128.53 (Ar-C), 127.01 (Ar-C), 126.60 (Ar-C), 73.40 (C-2), 61.47 (C-11), 55.95 
(C-3), 50.48 (C-8), 38.02 (C-9), 35.90 (C-4), 32.16 (C-10), 23.12 (C-6). HRMS (m/z), calculated for 
C23H30N3O5: 428.2185, found (M + H)
+: 428.2177. 
4.72 Synthesis of (2R,3S)-2-hydroxy-N-(S)-1-(methoxy(methyl)amino)-1-oxo-
3-phenylpropan-2-yl)-4-phenyl-3-propionamidobutanamide 66 
Compound 62 (100 mg, 0.18 mmol), TFA (142 µl, 1.85 mmol) and Et3N (256 µl, 1.85 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The reaction yielded compound 66 (44 
mg, 54%) as a light brown oil which appeared as a single diastereomer. 
 
 Rf = 0.33 (49:1 CHCl3/MeOH); IR vmax(cm
-1): 3346 (OH), 3028 
(C=C-H), 2974 (C-H), 1643 (C=O), 1389 (C-O); 1H NMR (500 
MHz, CDCl3) δ 7.48 (1H, d, J = 8.4 Hz, NH), 7.32 – 7.12 (10H, 
m, Ar-H), 6.39 (1H, d, J = 8.2 Hz) and 6.08 (1H, d, J = 6.6 Hz) 
NH and OH, 5.24 – 5.10 (1H, m, H-9), 4.25 – 4.13 (1H, m, H-
3), 4.09 – 4.00 (1H, m, H-2), 3.61 (3H, s, H-12), 3.21 – 2.85 (7H, m, H-4, H-10 and H-11), 2.13 – 
2.02 (2H, m, H-6), 1.00 (3H, t, J = 7.6 Hz, H-7); 13C NMR (126 MHz, CDCl3) δ 175.79 (C=O), 172.66 
(C=O), 171.47 (C=O), 138.09 (Ar-C), 136.30 (Ar-C), 129.27 (Ar-C), 129.19 (Ar-C), 128.51 (Ar-C), 
128.42 (Ar-C), 126.97 (Ar-C), 126.49 (Ar-C), 73.35 (C-2), 61.45 (C-12), 55.56 (C-3), 50.30 (C-9), 
38.15 and 35.75 (C-4 and C-10), 32.08 (C-11), 29.47 (C-6), 9.70 (C-7); HRMS (m/z), calculated for 
C24H32N3O5: 442.2342, found (M + H)
+: 442.2342. 
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4.73 Synthesis of (3S)-3-butyramido-2-hydroxy-N-(S)-1-(methoxy(methyl) 
amino)-1-oxo-3-phenylpropan-2-yl)-4-phenylbutanamide 67 
Compound 64 (130 mg, 0.23 mmol), TFA (234 µl, 2.33 mmol) and Et3N (323 µl, 2.33 mmol) in 
CH2Cl2 (1 ml) were reacted together as described in 4.11. The procedure yielded compound 67 
(62 mg, 59%) as a light brown oil that appeared as predominantly one diastereomer. 
 
 Rf = 0.50 (49:1 CHCl3/MeOH); IR (oil) vmax(cm
-1): 3328 (OH), 
3063 (C=C-H), 2963 (C-H), 1643 (C=O), 1517 (C=C), 1389 (C-
O); 1H NMR (500 MHz, CDCl3) δ 7.68 – 7.49 (1H, m, NH), 7.31 
– 7.11 (10H, m, Ar-H), 6.56 – 6.41 (1H, m) and 6.12 – 5.88 
(1H, m) NH and OH, 5.35 – 5.13 (1H, m, H-10), 4.34 – 4.17 
(1H, m, H-3), 4.10 – 4.01 (1H, m, H-2), 3.59 (3H, s, H-13), 3.25 – 2.79 (7H, m, H-4, H-11 and H-
12), (2H, t, J = 7.4 Hz, H-6), 1.56 – 1.40 (2H, m, H-7), 0.80 (3H, t, J = 7.4 Hz, H-8); 13C NMR (126 
MHz, CDCl3) δ 174.66, 172.56, 171.51 and 171.44 (C=O), 138.09 (Ar-C), 136.29 (Ar-C), 129.30 
(Ar-C), 129.27 (Ar-C), 129.23 (Ar-C), 129.20 (Ar-C), 129.18 (Ar-C), 129.16 (Ar-C), 128.48 (Ar-C), 
128.40 (Ar-C), 126.95 (Ar-C), 126.45 (Ar-C), 74.65 and 73.14 (C-2), 61.45 (C-13), 55.22 (C-3), 
50.21 (C-10), 38.30, 38.28, 38.18 (C-4 and C-11), 35.80 (C-6), 32.06 (C-12), 18.95 (C-7), 13.59 
and 13.52 (C-8); HRMS (m/z), calculated for C25H34N3O5: 456.2498, found (M + H)
+: 456.2500. 
4.74 Preparation of 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-isocyano-D-
glucopyranose 13 68 
4.74.1 Formylation of glucosamine 
 
                                
Na metal (0.533 g, 23.19 mmol) was dissolved in MeOH (49 ml) and glucosamine hydrochloride 
(5.00 g, 23.186 mmol) was added to the solution ensuring complete dissolution by rigorous 
stirring. Methyl formate (4 eq., 5.14 ml, 83.469 mmol) was added and the reaction was left to 
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stir under reflux at 40 °C overnight. Excess solvent and methyl formate were removed in vacuo 
and crude formylated glucosamine (4.80 g) was used in the next step. 
4.74.2 Acyl protection of hydroxyl groups 
 
                             
Crude formylated glucosamine (4.80 g, 23.186 mmol) was dissolved in pyridine (25 ml) and 
acetic anhydride (25 ml) was added. The reaction was allowed to proceed for 4 h after which 
the acetic anhydride was quenched using MeOH and removed in vacuo. Excess pyridine was 
then removed as an azeotropic mixture with toluene, yielding a white precipitate. 1H NMR 
spectroscopy showed the expected acylated product Rf 0.29 (3:7 EtOAc/Hex) and the crude 
mixture was used in the next step. 
4.74.3 Dehydration of glucose formamide 
 
                             
Crude acylated glucose formamide (8.69 g, 23.19 mmol) was dissolved in anhydrous CH2Cl2 (40 
ml) under N2 and cooled down to 0 °C. POCl3 (3 eq., 6.48 ml, 69.56 mmol) was slowly added 
followed by Et3N (8 eq., 58.0 ml, 0.42 mol) and the experiment was completed as described in 
4.4. Column chromatography yielded 13 as a white solid being an anomeric mixture (4.79 g, 
59%).  
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Rf =  0.29 (3:7 EtOAc/Hex); [αD]
20
589 +420.7 (c 0.375, CHCl3) (lit +149 (c 
0.375, CHCl3))
68; m.p. 114 – 115 °C (lit m.p. 113 °C)68, IR (solid): 
vmax(cm
-1): 2961 (C-H), 2915 (C-H), 2153 (CΞN), 1750 (C=O), 1738 (C=O); 
1H NMR (300 MHz, CDCl3) δ 6.41 (0.79H, d, J = 3.6 Hz, H-1), 5.81 
(0.26H, d, J = 8.5 Hz, H-1), 5.55 (0.75H, dd, J = 10.6, 9.4 Hz, H-3), 5.40 (0.28H, dd, J = 10.5, 9.4 
Hz, H-3), 5.91 – 4.95 (1H, m, H-4), 4.38 – 4.25 (1H, m, H-6a), 4.19 – 4.08 (1H, m, H-5), 4.07 
(0.55H, d, J = 2.3 Hz) and 4.05 – 4.00 (0.69H, m, H-6b), 3.99 (0.34H, d, J = 3.6 Hz, H-2), 3.90 
(0.23H, ddd, J = 10.1, 4.4, 2.1 Hz, H-2), 3.82 (0.24H, dd, J = 10.5, 8.5 Hz, H-2), 2.25 (3H, s, CH3), 
2.13 (3H, s, CH3), 2.10 – 2.06 (3H, m, CH3), 2.06 – 2.01 (3H, m, CH3); 
13C NMR (75 MHz, CDCl3) δ 
170.39, 169.68, 169.44, 169.42, 169.35, 168.37 and 168.29 (C=O), 162.19 and 162.00 (C-7), 
91.23 and 88.37 (C-1), 73.00 , 71.98, 70.07, 69.87(C-3, C-4 and C-5) , 67.19 and 61.19 (C-6), 
56.10 and 54.79 (C-2), 20.61, 20.49 and 20.41 (CH3x3). 
4.75 Synthesis of (2S,3R,4R,5S,6R)-4-(3S)-2-acetoxy-3-((tert-
butoxycarbonyl)amino)-4-phenylbutanamido)-6-(acetoxymethyl)tetrahydro-
2H-pyran-2,3,5-triyl triacetate 68A 
N-Boc-L-phenylalaninal 15 (335 mg, 1.34 mmol), glucose isocyanide 13 (400 mg, 1.34 mmol) 
and acetic acid 1 (91 µl, 1.34 mmol) were dissolved in CH2Cl2 (5 ml). The experiment proceeded 
as described in 4.5 yielding compound 68A (207 mg, 28%) as a white solid as a mixture of at 
least 3 diastereomers.  
 
Rf = 0.42 (49:1 CHCl3/MeOH); m.p. 202 – 204 °C; IR (solid) 
vmax(cm
-1): 3370 (NH), 2982 (C-H), 1744 (C=O), 1691 (C=O), 
1674 (C=O), 1520 (C=C), 1367 (C-O); 1H NMR (500 MHz, 
CDCl3) δ 7.32 – 7.24 (2H, m, Ar-H), 7.24 – 7.10 (3H, m, Ar-H), 
6.60 – 6.44 (0.5H, m, NH), 6.44 – 6.12 (1.5H, m, NH and H-
15), 5.32 – 4.70 (4H, m, NH, H-2, H-12 and H-16), 4.48 – 4.15 (3H, m, H-3, H-11 and H-14a), 4.15 
– 3.93 (2H, m, H-13 and H-14b), 3.00 – 2.60 (2H, m, H-4), 2.26 – 1.97 (15H, m, H-10 and CH3x4), 
1.33 (9H, s, (CH3)3C); 
13C NMR (126 MHz, CDCl3) δ 172.20 (C=O)), 170.63, 170.61, 169.68, 
169.38, 169.25, 169.08, 169.06, 169.02, 168.62, 168.37, 167.99 and 167.91 (C=O), 155.49 and 
154.98 (Boc C=O), 137.01 (C-5), 136.96 (C-5), 129.25 (Ar-C), 129.19 (Ar-C), 129.13 (Ar-C), 129.10 
Chapter 4: Experimental Procedures 
 
149 
 
(Ar-C), 128.59 (Ar-C), 128.55 (Ar-C), 128.48 (Ar-C), 126.75 (Ar-C), 126.70 (Ar-C), 126.65 (Ar-C), 
92.24 (C-15), 90.09 (C-15), 89.84 (C-15), 79.77 [(CH3)3C], 74.36 (C-2), 73.81 (C-2), 72.96 (C-O), 
72.87 (C-O), 71.84 (C-O), 70.33 (C-O), 70.13 (C-O), 69.90 (C-O), 69.77 (C-O), 67.25 (C-O), 61.55 
(C-O), 53.00, 52.66, 52.06 and 51.49 (C-3 and C-11), 37.50 (C-4), 36.87 (C-4), 28.22 [(CH3)3C], 
20.98 (CH3), 20.71 (CH3), 20.68 (CH3), 20.66 (CH3), 20.54 (CH3), 20.50 (CH3); HRMS (m/z), 
calculated for C31H43N2O14: 667.2714, found (M + H)
+: 667.2714. 
4.76 Synthesis of (2S,3R,4R,5S,6R)-4-((3R)-2-acetoxy-3-((tert-butoxycarbonyl) 
amino)-4-phenylbutanamido)-6-(acetoxymethyl)tetrahydro-2H-pyran-2,3,5-
triyl triacetate 68B 
N-Boc-D-phenylalaninal 16 (335 mg, 1.34 mmol), glucose isocyanide 13 (400 mg, 1.34 mmol) 
and acetic acid 1 (91 µl, 1.34 mmol) were dissolved in CH2Cl2 (5 ml). The experiment proceeded 
as described in 4.5 yielding compound 68B (900 mg, 100%) as a white precipitate. 
  
Rf = 0.59 (49:1 CHCl3/MeOH); d.r. = 1.00:1.28; m.p. 209 – 
210 °C; IR (solid) vmax(cm
-1): 3365 (NH), 2982 (C-H), 1741 
(C=O), 1688 (C=O), 1676 (C=O), 1518 (C=C), 1366 (C-O), 702; 
1H NMR (500 MHz, CDCl3) δ 7.40 – 7.08 (5H, m, Ar-H), 6.94 – 
6.83 and 6.51 – 6.34 (1H, m, NH), 6.31 – 6.09 (1H, m, H-15), 
5.40 – 4.82 (4H, m, H-2, H-12, H-16 and NH), 4.51 – 3.92 (5H, m, H-3, H-11, H-13 and H-14), 3.19 
– 2.61 (2H, m, H-4), 2.28 – 1.91 (15H, m, H-10 and CH3x4), 1.55 – 1.16 (9H, m, (CH3)3C);
 13C NMR 
(126 MHz, CDCl3) δ 172.45, 170.65, 170.63, 169.44, 169.15, 169.06, 168.67, 168.52, 168.42 and 
168.01 (C=O), 155.53, 155.41 and 155.01 (Boc C=O), 136.85 and 135.97 (C-5), 129.30 (Ar-C), 
129.24 (Ar-C), 129.14 (Ar-C), 129.07 (Ar-C), 128.70 (Ar-C), 128.57 (Ar-C), 128.53 (Ar-C), 128.50 
(Ar-C), 128.45 (Ar-C), 127.00 (Ar-C), 126.73 (Ar-C), 126.70 (Ar-C), 126.66 (Ar-C), 90.27 (C-15), 
89.84 (C-15), 80.09 [(CH3)3C], 79.79 ((CH3)3C), 74.51 (C-2), 73.86 (C-2), 70.27 (C-O), 70.05 (C-O), 
69.85 (C-O), 69.74 (C-O), 69.69 (C-O), 67.55 (C-O), 67.20 (C-O), 61.58 (C-14), 60.79 (C-O), 52.68 
and 51.88 (C-3), 35.32 (C-4), 28.26 [(CH3)3C], 28.20 [(CH3)3C], 20.67 (CH3), 20.64 (CH3), 20.62 
(CH3), 20.60 (CH3), 20.51 (CH3); HRMS (m/z), calculated for C31H43N2O14: 667.2714, found (M + 
H)+: 667.2714. 
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4.77 Synthesis of (2S,3R,4R,5S,6R)-6-(acetoxymethyl)-4-((3S)-3-((tert-butoxy 
carbonyl)amino)-4-phenyl-2-(propionyloxy)butanamido)tetrahydro-2H-
pyran-2,3,5-triyl triacetate 69 
N-Boc-L-phenylalaninal 15 (250 mg, 1.00 mmol), glucose isocyanide 13 (357 mg, 1.00 mmol) 
and propionic acid 2 (83 µl, 1.00 mmol) were dissolved in CH2Cl2 (5 ml). The experiment 
proceeded as described in 4.5 yielding compound 69 (680 mg, 99%) as a white solid. 
  
Rf = 0.42 (49:1 CHCl3/MeOH); d.r. = 2.04:1.00; m.p. 181-
182°C; IR vmax(cm
-1): 3370 (NH), 2982 (C-H), 1748 (C=O), 
1688 (C=O), 1673 (C=O), 1521 (C=C), 1367 (C-O); 1H NMR 
(300 MHz, CDCl3) δ 7.37 – 7.09 (5H, m, Ar-H), 6.62 – 6.12 
(2H, m, NH and H-16), 5.39 – 4.61 (4H, m, NH, H-2 H-13 and 
H-17), 4.53 – 3.94 (5H, m, H-3 H-12, H-14 and H-15), 3.01 – 2.60 (2H, m, H-4), 2.60 – 2.31 (2H, 
m, H-10), 2.24 – 1.91 (12H, m, CH3x4), 1.33 (9H, s, (CH3)3C), 1.25 – 1.03 (3H, m, H-11); 
13C NMR 
(75 MHz, CDCl3) δ 173.01, 172.82, 170.61, 169.12, 169.07, 168.56 and 168.09 (C=O), 155.46 and 
154.98 (Boc C=O), 137.02 (C-5), 129.21 (Ar-C), 129.16 (Ar-C), 128.58 (Ar-C), 128.48 (Ar-C), 
126.75 (Ar-C), 126.65 (Ar-C), 90.13 (C-16), 79.93 [(CH3)3C], 74.21, 73.67 and 73.00 (C-2), 71.89 
(C-O), 70.35 (C-O), 70.18 (C-O), 69.92 (C-O), 69.79 (C-O), 67.35 (C-O), 61.59 (C-15), 53.03, 51.89 
and 51.56 (C-3 and C-9), 36.97 (C-4), 28.22 [(CH3)3C], 27.28 (C-10), 27.23 (C-10), 20.93 (CH3), 
20.67 (CH3), 20.64 (CH3), 20.52 (CH3), 8.97 (C-11), 8.66 (C-11); HRMS (m/z), calculated for 
C32H45N2O14: 681.2871, found (M + H)
+: 681.2874. 
4.78 Synthesis of (2S,3R,4R,5S,6R)-6-(acetoxymethyl)-4-((3S)-3-((tert-butoxy 
carbonyl)amino)-2-((3,3-dimethylbutanoyl)oxy)-4-phenylbutanamido) 
tetrahydro-2H-pyran-2,3,5-triyl triacetate 70  
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), glucose isocyanide 13 (429 mg, 1.20 mmol) 
and tert-butyl acetic acid 5 (153 µl, 1.20 mmol) were dissolved in CH2Cl2 (5 ml). The experiment 
proceeded as described in 4.5 yielding compound 70 (427 mg, 50%) as a white solid as a 
mixture of at least 3 diastereomers.  
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Rf = 0.55 (49:1 CHCl3/MeOH); m.p 186 – 187 °C; IR vmax(cm
-1): 
3371 (NH), 2967 (C-H), 1743 (C=O), 1689 (C=O), 1518 (C=C), 
1321 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.10 (5H, m, 
Ar-H), 6.65 – 6.16 (2H, m, NH and H-17), 5.60 – 4.73 (4H, m, 
NH, H-2, H-14 and H-18), 4.59 – 3.78 (5H, m, H-3, H-13, H-15 
and H-16), 3.00 – 2.51 (2H, m, H-4), 2.47 – 1.88 (14H, m, H-10 
and CH3x4), 1.56 – 1.19 (9H, m, (CH3)3C), 1.19 – 0.81 (9H, m, H-12); 
13C NMR (75 MHz, CDCl3) δ 
175.88, 170.90, 170.65, 170.64, 169.29, 169.10, 168.65 and 168.18 (C=O), 155.35 and 155.09 
(Boc C=O), 137.08 (C-5), 129.32 Ar C, 129.22 (Ar-C), 129.15 (Ar-C), 128.54 (Ar-C), 128.47 (Ar-C), 
126.70 (Ar-C), 126.42 (Ar-C), 90.11 (C-17), 79.85 and 79.64 [(CH3)3C], 73.44 and 72.87 (C-2), 
70.27 (C-O), 69.73 (C-O), 67.98 (C-O), 67.37 (C-O), 61.56 (C-16), 52.99 and 51.57(C-3 and C-13), 
47.68 (C-10), 47.52 (C-10), 47.28 (C-10), 37.42 (C-4), 30.89 (C-11), 30.72 (C-11), 30.52 (C-11), 
29.66 (C-12), 29.58 (C-12), 28.35 [(CH3)3C], 28.19 ((CH3)3C), 20.80 (CH3), 20.67 (CH3), 20.65 
(CH3), 20.52 (CH3); HRMS (m/z), calculated for C35H51N2O14: 723.3340, found (M + H
+): 
723.3340. 
4.79 Synthesis of (2S,3R,4R,5S,6R)-6-(acetoxymethyl)-4-((3S)-3-((tert-Butoxy 
carbonyl)amino)-2-(((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropanoyl) 
oxy)-4-phenylbutanamido)tetrahydro-2H-pyran-2,3,5-triyl triacetate 71 
 
N-Boc-L-phenylalaninal 15 (300 mg, 1.20 mmol), glucose isocyanide 13 (429 mg, 1.20 mmol) 
and N-Boc-L-phenylalanine 7 (318 mg, 1.20 mmol) were dissolved in CH2Cl2 (5 ml). The 
experiment was carried out as described in 4.5 yielding compound 71 (743 mg, 71%) as a white 
solid as a mixture of at least 3 diastereomers. 
 Rf = 0.42 (49:1 CHCl3/MeOH); d.r. = 1.77:1.00:1.00; m.p. 202 
– 203 °C; IR vmax(cm
-1): 3371 (NH), 2967 (C-H), 1743 (C=O), 
1689 (C=O), 1518 (C=C), 1366 (C-O); 1H NMR (300 MHz, CDCl3) 
δ 7.54 – 6.87 (10H, m, Ar-H), 6.88 – 6.60 (1H, m, NH), 6.44 – 
6.18 (1H, m, H-12), 5.58 – 4.72 (5H, m, NHx2 , H-2 H-9and H-
13), 4.70 – 3.45 (6H, m, H-3, H-6, H-8, H-10 and H-11), 3.34 – 
3.09 and 3.09 – 2.27 (4H, 2xm, H-4 and H-7), 2.24 – 1.79 (12H, m, CH3x4), 1.63 – 1.13 (18H, m, 
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(CH3)3Cx2); 
13C NMR (75 MHz, CDCl3) δ 170.91, 170.61, 169.38, 169.22, 169.18, 168.70 and 
167.86 (C=O), 155.59 (Boc C=O), 154.72 (Boc C=O), 136.92 (Ar-C), 135.58 (Ar-C), 129.34 (Ar-C), 
129.26 (Ar-C), 129.19 (Ar-C), 129.14 (Ar-C), 129.01 (Ar-C), 128.88 (Ar-C), 128.76 (Ar-C), 128.45 
(Ar-C), 127.44 (Ar-C), 127.15 (Ar-C), 126.64 (Ar-C), 126.38 (Ar-C), 91.92 and 90.08 (C-12), 80.63 
[(CH3)3C], 80.24 [(CH3)3C], 79.78 [(CH3)3C], 72.64 (C-O), 70.52 (C-O), 70.25 (C-O), 69.68 (C-O), 
69.48 (C-O), 68.35 (C-O), 67.72 (C-O), 61.60 (C-11), 52.70, 52.30, 51.73 and 51.52 (C-3 and C-8), 
37.73 (C-4), 28.51 and 28.36 [(CH3)3C], 20.94 (CH3), 20.76 (CH3), 20.73 (CH3), 20.72 (CH3), 20.65 
(CH3), 20.57 (CH3), 20.54 (CH3); HRMS (m/z), calculated for C43H58N3O16: 872.3817, found (M + 
H)+: 872.3842. 
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APPENDIX I-CRYSTALLOGRAPHIC DATA 
1. X-ray crystallography data for (2S,3S)-3-acetamido-N-cyclohexyl-2-hydroxy-
4-phenylbutanamide 18B 
 
Table 1.  Crystal data and structure refinement. 
______________________________________________________________________________ 
Identification code  14a_mzz113b_p 
Empirical formula  C19 H30 N2 O4 
Formula weight  350.45 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 6.4416(4) Å a= 90°. 
 b = 13.1342(11) Å b= 90°. 
 c = 23.4165(18) Å g = 90°. 
Volume 1981.2(3) Å3 
Z 4 
Density (calculated) 1.175 Mg/m3 
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Absorption coefficient 0.082 mm-1 
F(000) 760 
Crystal size 0.61 x 0.12 x 0.07 mm3 
Theta range for data collection 3.28 to 28.00°. 
Index ranges -8<=h<=8, -15<=k<=17, -30<=l<=26 
Reflections collected 14036 
Independent reflections 2750 [R(int) = 0.0434] 
Completeness to theta = 28.00° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9943 and 0.9516 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2750 / 0 / 241 
Goodness-of-fit on F2 1.029 
Final R indices [I>2sigma(I)] R1 = 0.0428, wR2 = 0.0914 
R indices (all data) R1 = 0.0622, wR2 = 0.0988 
Absolute structure parameter 10(10) 
Largest diff. peak and hole 0.216 and -0.168 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103).  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________ 
 x y z U(eq) 
______________________________________________________________________________ 
C(1) 14716(3) 5476(2) 167(1) 27(1) 
C(2) 13207(3) 6139(2) -38(1) 34(1) 
C(3) 13646(4) 6818(2) -474(1) 40(1) 
C(4) 15607(4) 6843(2) -714(1) 41(1) 
C(5) 17119(4) 6193(2) -514(1) 42(1) 
C(6) 16685(3) 5515(2) -75(1) 34(1) 
C(7) 14217(3) 4753(1) 648(1) 28(1) 
C(8) 13679(3) 5304(1) 1205(1) 23(1) 
C(9) 12794(3) 4576(2) 1656(1) 26(1) 
C(10) 10703(3) 4166(2) 1458(1) 27(1) 
C(11) 8580(3) 2607(2) 1363(1) 29(1) 
C(12) 8452(4) 2190(2) 759(1) 49(1) 
C(13) 6394(4) 1627(2) 677(1) 59(1) 
C(14) 6122(5) 786(2) 1107(1) 62(1) 
C(15) 6294(4) 1198(2) 1713(1) 49(1) 
C(16) 8328(4) 1772(2) 1802(1) 42(1) 
C(17) 15415(3) 6705(2) 1698(1) 26(1) 
C(18) 17427(3) 7125(2) 1922(1) 36(1) 
N(1) 15512(2) 5814(1) 1426(1) 25(1) 
N(2) 10513(3) 3155(1) 1469(1) 32(1) 
O(1) 13750(2) 7160(1) 1768(1) 38(1) 
O(2) 14177(2) 3762(1) 1769(1) 31(1) 
O(3) 9329(2) 4750(1) 1305(1) 38(1) 
C(1M) 18140(4) 4470(2) 2833(1) 48(1) 
O(1M) 16225(3) 3982(1) 2743(1) 48(1) 
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Table 3.   Bond lengths [Å] and angles [°]. 
______________________________________________________________________________ 
 
C(1)-C(6)  1.391(3) 
C(1)-C(2)  1.391(3) 
C(1)-C(7)  1.506(3) 
C(2)-C(3)  1.384(3) 
C(2)-H(2A)  0.9500 
C(3)-C(4)  1.384(3) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.378(3) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.387(3) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.532(2) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-N(1)  1.453(2) 
C(8)-C(9)  1.535(3) 
C(8)-H(8)  1.0000 
C(9)-O(2)  1.416(2) 
C(9)-C(10)  1.523(3) 
C(9)-H(9)  1.0000 
C(10)-O(3)  1.225(2) 
C(10)-N(2)  1.334(3) 
C(11)-N(2)  1.459(2) 
C(11)-C(16)  1.511(3) 
C(11)-C(12)  1.520(3) 
C(11)-H(11)  1.0000 
C(12)-C(13)  1.530(3) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-C(14)  1.503(4) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
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C(14)-C(15)  1.524(4) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-C(16)  1.525(3) 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-H(16A)  0.9900 
C(16)-H(16B)  0.9900 
C(17)-O(1)  1.239(2) 
C(17)-N(1)  1.333(2) 
C(17)-C(18)  1.503(3) 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
N(1)-H(1)  0.84(2) 
N(2)-H(2)  0.84(2) 
O(2)-H(2B)  0.86(3) 
C(1M)-O(1M)  1.406(3) 
C(1M)-H(1M1)  0.9800 
C(1M)-H(1M2)  0.9800 
C(1M)-H(1M3)  0.9800 
O(1M)-H(1M)  0.8400 
 
C(6)-C(1)-C(2) 118.20(18) 
C(6)-C(1)-C(7) 121.55(18) 
C(2)-C(1)-C(7) 120.24(17) 
C(3)-C(2)-C(1) 121.02(19) 
C(3)-C(2)-H(2A) 119.5 
C(1)-C(2)-H(2A) 119.5 
C(4)-C(3)-C(2) 120.1(2) 
C(4)-C(3)-H(3) 119.9 
C(2)-C(3)-H(3) 119.9 
C(5)-C(4)-C(3) 119.5(2) 
C(5)-C(4)-H(4) 120.3 
C(3)-C(4)-H(4) 120.3 
C(4)-C(5)-C(6) 120.5(2) 
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C(4)-C(5)-H(5) 119.8 
C(6)-C(5)-H(5) 119.8 
C(5)-C(6)-C(1) 120.7(2) 
C(5)-C(6)-H(6) 119.7 
C(1)-C(6)-H(6) 119.7 
C(1)-C(7)-C(8) 112.70(15) 
C(1)-C(7)-H(7A) 109.1 
C(8)-C(7)-H(7A) 109.1 
C(1)-C(7)-H(7B) 109.1 
C(8)-C(7)-H(7B) 109.1 
H(7A)-C(7)-H(7B) 107.8 
N(1)-C(8)-C(7) 109.68(14) 
N(1)-C(8)-C(9) 110.15(14) 
C(7)-C(8)-C(9) 112.02(15) 
N(1)-C(8)-H(8) 108.3 
C(7)-C(8)-H(8) 108.3 
C(9)-C(8)-H(8) 108.3 
O(2)-C(9)-C(10) 110.29(15) 
O(2)-C(9)-C(8) 111.44(14) 
C(10)-C(9)-C(8) 109.85(15) 
O(2)-C(9)-H(9) 108.4 
C(10)-C(9)-H(9) 108.4 
C(8)-C(9)-H(9) 108.4 
O(3)-C(10)-N(2) 124.31(18) 
O(3)-C(10)-C(9) 120.41(17) 
N(2)-C(10)-C(9) 115.28(16) 
N(2)-C(11)-C(16) 109.54(17) 
N(2)-C(11)-C(12) 112.48(17) 
C(16)-C(11)-C(12) 111.39(19) 
N(2)-C(11)-H(11) 107.7 
C(16)-C(11)-H(11) 107.7 
C(12)-C(11)-H(11) 107.7 
C(11)-C(12)-C(13) 109.72(18) 
C(11)-C(12)-H(12A) 109.7 
C(13)-C(12)-H(12A) 109.7 
C(11)-C(12)-H(12B) 109.7 
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C(13)-C(12)-H(12B) 109.7 
H(12A)-C(12)-H(12B) 108.2 
C(14)-C(13)-C(12) 111.9(2) 
C(14)-C(13)-H(13A) 109.2 
C(12)-C(13)-H(13A) 109.2 
C(14)-C(13)-H(13B) 109.2 
C(12)-C(13)-H(13B) 109.2 
H(13A)-C(13)-H(13B) 107.9 
C(13)-C(14)-C(15) 110.7(2) 
C(13)-C(14)-H(14A) 109.5 
C(15)-C(14)-H(14A) 109.5 
C(13)-C(14)-H(14B) 109.5 
C(15)-C(14)-H(14B) 109.5 
H(14A)-C(14)-H(14B) 108.1 
C(14)-C(15)-C(16) 111.4(2) 
C(14)-C(15)-H(15A) 109.3 
C(16)-C(15)-H(15A) 109.3 
C(14)-C(15)-H(15B) 109.3 
C(16)-C(15)-H(15B) 109.3 
H(15A)-C(15)-H(15B) 108.0 
C(11)-C(16)-C(15) 111.02(18) 
C(11)-C(16)-H(16A) 109.4 
C(15)-C(16)-H(16A) 109.4 
C(11)-C(16)-H(16B) 109.4 
C(15)-C(16)-H(16B) 109.4 
H(16A)-C(16)-H(16B) 108.0 
O(1)-C(17)-N(1) 121.88(17) 
O(1)-C(17)-C(18) 121.49(17) 
N(1)-C(17)-C(18) 116.62(17) 
C(17)-C(18)-H(18A) 109.5 
C(17)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
C(17)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
C(17)-N(1)-C(8) 122.42(16) 
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C(17)-N(1)-H(1) 117.6(14) 
C(8)-N(1)-H(1) 119.9(14) 
C(10)-N(2)-C(11) 124.45(17) 
C(10)-N(2)-H(2) 114.4(16) 
C(11)-N(2)-H(2) 121.0(16) 
C(9)-O(2)-H(2B) 110.0(17) 
O(1M)-C(1M)-H(1M1) 109.5 
O(1M)-C(1M)-H(1M2) 109.5 
H(1M1)-C(1M)-H(1M2) 109.5 
O(1M)-C(1M)-H(1M3) 109.5 
H(1M1)-C(1M)-H(1M3) 109.5 
H(1M2)-C(1M)-H(1M3) 109.5 
C(1M)-O(1M)-H(1M) 109.5 
 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103).  The anisotropic 
displacement factor exponent takes the form: -2p2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 32(1)  26(1) 22(1)  -4(1) -2(1)  -1(1) 
C(2) 31(1)  40(1) 30(1)  1(1) 2(1)  4(1) 
C(3) 50(1)  39(1) 31(1)  6(1) -4(1)  8(1) 
C(4) 56(1)  37(1) 30(1)  2(1) 4(1)  -10(1) 
C(5) 40(1)  45(1) 39(1)  -2(1) 12(1)  -7(1) 
C(6) 32(1)  35(1) 35(1)  -1(1) 2(1)  3(1) 
C(7) 32(1)  24(1) 27(1)  -3(1) 0(1)  1(1) 
C(8) 21(1)  23(1) 26(1)  -1(1) -1(1)  2(1) 
C(9) 23(1)  27(1) 28(1)  2(1) 1(1)  4(1) 
C(10) 21(1)  31(1) 29(1)  3(1) 4(1)  4(1) 
C(11) 23(1)  30(1) 35(1)  1(1) 3(1)  2(1) 
C(12) 42(1)  70(2) 35(1)  -6(1) 6(1)  -5(1) 
C(13) 55(2)  85(2) 37(1)  -22(1) -2(1)  -13(2) 
C(14) 63(2)  46(2) 77(2)  -23(1) 0(2)  -16(1) 
C(15) 55(1)  37(1) 54(2)  4(1) -1(1)  -20(1) 
C(16) 45(1)  36(1) 44(1)  4(1) -6(1)  -7(1) 
C(17) 29(1)  28(1) 22(1)  2(1) -3(1)  1(1) 
C(18) 33(1)  41(1) 34(1)  -1(1) -5(1)  -8(1) 
N(1) 19(1)  26(1) 30(1)  -2(1) 0(1)  4(1) 
N(2) 21(1)  30(1) 47(1)  4(1) -1(1)  3(1) 
O(1) 34(1)  36(1) 45(1)  -16(1) -8(1)  10(1) 
O(2) 24(1)  31(1) 37(1)  5(1) -5(1)  6(1) 
O(3) 22(1)  33(1) 58(1)  7(1) -1(1)  6(1) 
C(1M) 55(1)  44(1) 44(1)  11(1) -7(1)  -13(1) 
O(1M) 59(1)  31(1) 55(1)  12(1) -23(1)  -7(1) 
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Table 5.  Torsion angles [°]. 
________________________________________________________________ 
C(6)-C(1)-C(2)-C(3) 0.3(3) 
C(7)-C(1)-C(2)-C(3) 179.07(18) 
C(1)-C(2)-C(3)-C(4) 0.3(3) 
C(2)-C(3)-C(4)-C(5) -0.6(3) 
C(3)-C(4)-C(5)-C(6) 0.2(3) 
C(4)-C(5)-C(6)-C(1) 0.3(3) 
C(2)-C(1)-C(6)-C(5) -0.6(3) 
C(7)-C(1)-C(6)-C(5) -179.39(18) 
C(6)-C(1)-C(7)-C(8) 115.2(2) 
C(2)-C(1)-C(7)-C(8) -63.6(2) 
C(1)-C(7)-C(8)-N(1) -67.79(19) 
C(1)-C(7)-C(8)-C(9) 169.58(15) 
N(1)-C(8)-C(9)-O(2) -65.96(19) 
C(7)-C(8)-C(9)-O(2) 56.41(19) 
N(1)-C(8)-C(9)-C(10) 171.50(14) 
C(7)-C(8)-C(9)-C(10) -66.13(18) 
O(2)-C(9)-C(10)-O(3) -175.49(17) 
C(8)-C(9)-C(10)-O(3) -52.3(2) 
O(2)-C(9)-C(10)-N(2) 4.7(2) 
C(8)-C(9)-C(10)-N(2) 127.96(18) 
N(2)-C(11)-C(12)-C(13) -180.0(2) 
C(16)-C(11)-C(12)-C(13) 56.6(3) 
C(11)-C(12)-C(13)-C(14) -56.9(3) 
C(12)-C(13)-C(14)-C(15) 56.2(3) 
C(13)-C(14)-C(15)-C(16) -54.9(3) 
N(2)-C(11)-C(16)-C(15) 178.62(18) 
C(12)-C(11)-C(16)-C(15) -56.3(2) 
C(14)-C(15)-C(16)-C(11) 55.0(3) 
O(1)-C(17)-N(1)-C(8) -1.5(3) 
C(18)-C(17)-N(1)-C(8) 177.80(17) 
C(7)-C(8)-N(1)-C(17) 145.11(17) 
C(9)-C(8)-N(1)-C(17) -91.2(2) 
O(3)-C(10)-N(2)-C(11) -7.3(3) 
C(9)-C(10)-N(2)-C(11) 172.47(17) 
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C(16)-C(11)-N(2)-C(10) -135.7(2) 
C(12)-C(11)-N(2)-C(10) 99.8(2) 
 
Symmetry transformations used to generate equivalent atoms:  
  
Table 6.  Hydrogen bonds [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(1)-H(1)...O(3)#1 0.84(2) 2.00(2) 2.843(2) 175(2) 
 N(2)-H(2)...O(2) 0.84(2) 2.11(2) 2.588(2) 116.0(19) 
 O(2)-H(2B)...O(1M) 0.86(3) 1.79(3) 2.650(2) 174(2) 
 O(1M)-H(1M)...O(1)#2 0.84 1.82 2.653(2) 174.9 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z    #2 -x+3,y-1/2,-z+1/2  
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2. X-ray crystallographic data for (2R,3S)-N-adamantanyl-3-butyramido-2-hydroxy-4-
phenylbutanamide 55A 
 
 
Table 1.  Crystal data and structure refinement. 
Identification code  14a_mzz155a_p 
Empirical formula  C23 H32 N2 O3 
Formula weight  384.51 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 7.3110(4) Å = 90°. 
 b = 10.8229(6) Å = 90°. 
 c = 26.0551(15) Å  = 90°. 
Volume 2061.6(2) Å3 
Z 4 
Density (calculated) 1.239 Mg/m3 
Absorption coefficient 0.082 mm-1 
F(000) 832 
Crystal size 0.47 x 0.11 x 0.09 mm3 
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Theta range for data collection 3.36 to 28.00°. 
Index ranges -9<=h<=7, -13<=k<=14, -34<=l<=28 
Reflections collected 13871 
Independent reflections 2842 [R(int) = 0.0375] 
Completeness to theta = 28.00° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9927 and 0.9626 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2842 / 0 / 266 
Goodness-of-fit on F2 1.069 
Final R indices [I>2sigma(I)] R1 = 0.0507, wR2 = 0.1307 
R indices (all data) R1 = 0.0571, wR2 = 0.1343 
Absolute structure parameter 10(10) 
Largest diff. peak and hole 0.326 and -0.204 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103).  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 1897(4) 2279(3) 4141(1) 23(1) 
C(2) 916(5) 3350(3) 4214(1) 34(1) 
C(3) -815(5) 3326(4) 4434(1) 44(1) 
C(4) -1566(5) 2220(4) 4592(1) 40(1) 
C(5) -592(5) 1144(3) 4521(1) 42(1) 
C(6) 1137(5) 1180(3) 4302(1) 35(1) 
C(7) 3763(4) 2323(3) 3892(1) 25(1) 
C(8) 3665(4) 2401(2) 3302(1) 18(1) 
C(9) 5578(4) 2582(2) 3074(1) 19(1) 
C(10) 5386(4) 3015(2) 2514(1) 21(1) 
C(11) 5093(4) 2240(2) 1609(1) 21(1) 
C(12) 3284(4) 2912(3) 1511(1) 28(1) 
C(13) 2895(5) 2953(3) 934(1) 36(1) 
C(14) 4464(6) 3633(3) 662(1) 41(1) 
C(15) 6265(5) 2960(3) 760(1) 36(1) 
C(16) 6645(4) 2919(3) 1339(1) 26(1) 
C(17) 6113(6) 1648(3) 546(1) 39(1) 
C(18) 4569(5) 960(3) 816(1) 33(1) 
C(19) 4970(4) 921(2) 1395(1) 26(1) 
C(20) 2771(5) 1625(3) 728(1) 38(1) 
C(21) 1094(4) 1207(3) 2949(1) 22(1) 
C(22) 464(4) -1(3) 2715(1) 28(1) 
C(23) -25(6) 173(3) 2154(1) 43(1) 
N(1) 2865(3) 1284(2) 3083(1) 19(1) 
N(2) 5463(3) 2118(2) 2165(1) 23(1) 
O(1) 25(3) 2076(2) 3007(1) 29(1) 
O(2) 6520(3) 1456(2) 3123(1) 23(1) 
O(3) 5161(3) 4117(2) 2423(1) 27(1)
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Table 3.   Bond lengths [Å] and angles [°]. 
 
C(1)-C(2)  1.376(4) 
C(1)-C(6)  1.378(4) 
C(1)-C(7)  1.511(4) 
C(2)-C(3)  1.390(5) 
C(2)-H(2A)  0.9500 
C(3)-C(4)  1.380(5) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.377(5) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.387(5) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.541(3) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-N(1)  1.460(3) 
C(8)-C(9)  1.533(4) 
C(8)-H(8)  1.0000 
C(9)-O(2)  1.405(3) 
C(9)-C(10)  1.538(4) 
C(9)-H(9)  1.0000 
C(10)-O(3)  1.228(3) 
C(10)-N(2)  1.332(3) 
C(11)-N(2)  1.478(3) 
C(11)-C(16)  1.524(4) 
C(11)-C(12)  1.530(4) 
C(11)-C(19)  1.535(3) 
C(12)-C(13)  1.533(4) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-C(14)  1.536(5) 
C(13)-C(20)  1.536(4) 
C(13)-H(13)  1.0000 
C(14)-C(15)  1.526(5) 
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C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-C(17)  1.530(4) 
C(15)-C(16)  1.536(4) 
C(15)-H(15)  1.0000 
C(16)-H(16A)  0.9900 
C(16)-H(16B)  0.9900 
C(17)-C(18)  1.524(5) 
C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
C(18)-C(20)  1.516(5) 
C(18)-C(19)  1.537(4) 
C(18)-H(18)  1.0000 
C(19)-H(19A)  0.9900 
C(19)-H(19B)  0.9900 
C(20)-H(20A)  0.9900 
C(20)-H(20B)  0.9900 
C(21)-O(1)  1.231(3) 
C(21)-N(1)  1.343(3) 
C(21)-C(22)  1.515(4) 
C(22)-C(23)  1.518(4) 
C(22)-H(22A)  0.9900 
C(22)-H(22B)  0.9900 
C(23)-H(23A)  0.9800 
C(23)-H(23B)  0.9800 
C(23)-H(23C)  0.9800 
N(1)-H(1)  0.86(3) 
N(2)-H(2)  0.84(4) 
O(2)-H(2B)  0.77(4) 
 
C(2)-C(1)-C(6) 118.3(3) 
C(2)-C(1)-C(7) 120.2(3) 
C(6)-C(1)-C(7) 121.4(3) 
C(1)-C(2)-C(3) 121.0(3) 
C(1)-C(2)-H(2A) 119.5 
C(3)-C(2)-H(2A) 119.5 
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C(4)-C(3)-C(2) 120.1(3) 
C(4)-C(3)-H(3) 119.9 
C(2)-C(3)-H(3) 119.9 
C(5)-C(4)-C(3) 119.2(3) 
C(5)-C(4)-H(4) 120.4 
C(3)-C(4)-H(4) 120.4 
C(4)-C(5)-C(6) 120.2(3) 
C(4)-C(5)-H(5) 119.9 
C(6)-C(5)-H(5) 119.9 
C(1)-C(6)-C(5) 121.1(3) 
C(1)-C(6)-H(6) 119.4 
C(5)-C(6)-H(6) 119.4 
C(1)-C(7)-C(8) 112.8(2) 
C(1)-C(7)-H(7A) 109.0 
C(8)-C(7)-H(7A) 109.0 
C(1)-C(7)-H(7B) 109.0 
C(8)-C(7)-H(7B) 109.0 
H(7A)-C(7)-H(7B) 107.8 
N(1)-C(8)-C(9) 108.6(2) 
N(1)-C(8)-C(7) 111.3(2) 
C(9)-C(8)-C(7) 110.6(2) 
N(1)-C(8)-H(8) 108.8 
C(9)-C(8)-H(8) 108.8 
C(7)-C(8)-H(8) 108.8 
O(2)-C(9)-C(8) 107.5(2) 
O(2)-C(9)-C(10) 113.3(2) 
C(8)-C(9)-C(10) 108.9(2) 
O(2)-C(9)-H(9) 109.0 
C(8)-C(9)-H(9) 109.0 
C(10)-C(9)-H(9) 109.0 
O(3)-C(10)-N(2) 125.5(2) 
O(3)-C(10)-C(9) 119.5(2) 
N(2)-C(10)-C(9) 115.0(2) 
N(2)-C(11)-C(16) 111.0(2) 
N(2)-C(11)-C(12) 111.3(2) 
C(16)-C(11)-C(12) 109.7(2) 
Chapter 4: Experimental Procedures 
 
174 
 
N(2)-C(11)-C(19) 106.4(2) 
C(16)-C(11)-C(19) 109.0(2) 
C(12)-C(11)-C(19) 109.3(2) 
C(11)-C(12)-C(13) 109.7(3) 
C(11)-C(12)-H(12A) 109.7 
C(13)-C(12)-H(12A) 109.7 
C(11)-C(12)-H(12B) 109.7 
C(13)-C(12)-H(12B) 109.7 
H(12A)-C(12)-H(12B) 108.2 
C(12)-C(13)-C(14) 109.1(3) 
C(12)-C(13)-C(20) 109.0(2) 
C(14)-C(13)-C(20) 109.4(3) 
C(12)-C(13)-H(13) 109.8 
C(14)-C(13)-H(13) 109.8 
C(20)-C(13)-H(13) 109.8 
C(15)-C(14)-C(13) 109.8(2) 
C(15)-C(14)-H(14A) 109.7 
C(13)-C(14)-H(14A) 109.7 
C(15)-C(14)-H(14B) 109.7 
C(13)-C(14)-H(14B) 109.7 
H(14A)-C(14)-H(14B) 108.2 
C(14)-C(15)-C(17) 108.7(3) 
C(14)-C(15)-C(16) 109.5(3) 
C(17)-C(15)-C(16) 110.1(3) 
C(14)-C(15)-H(15) 109.5 
C(17)-C(15)-H(15) 109.5 
C(16)-C(15)-H(15) 109.5 
C(11)-C(16)-C(15) 109.4(2) 
C(11)-C(16)-H(16A) 109.8 
C(15)-C(16)-H(16A) 109.8 
C(11)-C(16)-H(16B) 109.8 
C(15)-C(16)-H(16B) 109.8 
H(16A)-C(16)-H(16B) 108.2 
C(18)-C(17)-C(15) 109.8(3) 
C(18)-C(17)-H(17A) 109.7 
C(15)-C(17)-H(17A) 109.7 
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C(18)-C(17)-H(17B) 109.7 
C(15)-C(17)-H(17B) 109.7 
H(17A)-C(17)-H(17B) 108.2 
C(20)-C(18)-C(17) 109.9(3) 
C(20)-C(18)-C(19) 109.1(3) 
C(17)-C(18)-C(19) 109.0(3) 
C(20)-C(18)-H(18) 109.6 
C(17)-C(18)-H(18) 109.6 
C(19)-C(18)-H(18) 109.6 
C(11)-C(19)-C(18) 110.0(2) 
C(11)-C(19)-H(19A) 109.7 
C(18)-C(19)-H(19A) 109.7 
C(11)-C(19)-H(19B) 109.7 
C(18)-C(19)-H(19B) 109.7 
H(19A)-C(19)-H(19B) 108.2 
C(18)-C(20)-C(13) 109.9(3) 
C(18)-C(20)-H(20A) 109.7 
C(13)-C(20)-H(20A) 109.7 
C(18)-C(20)-H(20B) 109.7 
C(13)-C(20)-H(20B) 109.7 
H(20A)-C(20)-H(20B) 108.2 
O(1)-C(21)-N(1) 122.2(3) 
O(1)-C(21)-C(22) 121.0(2) 
N(1)-C(21)-C(22) 116.7(3) 
C(21)-C(22)-C(23) 110.6(2) 
C(21)-C(22)-H(22A) 109.5 
C(23)-C(22)-H(22A) 109.5 
C(21)-C(22)-H(22B) 109.5 
C(23)-C(22)-H(22B) 109.5 
H(22A)-C(22)-H(22B) 108.1 
C(22)-C(23)-H(23A) 109.5 
C(22)-C(23)-H(23B) 109.5 
H(23A)-C(23)-H(23B) 109.5 
C(22)-C(23)-H(23C) 109.5 
H(23A)-C(23)-H(23C) 109.5 
H(23B)-C(23)-H(23C) 109.5 
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C(21)-N(1)-C(8) 122.6(2) 
C(21)-N(1)-H(1) 117(2) 
C(8)-N(1)-H(1) 120(2) 
C(10)-N(2)-C(11) 126.6(2) 
C(10)-N(2)-H(2) 113(3) 
C(11)-N(2)-H(2) 120(3) 
C(9)-O(2)-H(2B) 114(3) 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103).  The anisotropic 
displacement factor exponent takes the form: -2p2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 26(1)  26(1) 17(1)  -1(1) 1(1)  2(1) 
C(2) 38(2)  26(2) 38(2)  6(1) 10(1)  5(1) 
C(3) 39(2)  45(2) 48(2)  8(2) 12(2)  18(2) 
C(4) 26(2)  64(2) 29(2)  2(2) 6(1)  -1(2) 
C(5) 43(2)  40(2) 44(2)  1(2) 13(2)  -16(2) 
C(6) 40(2)  25(2) 39(2)  -2(1) 10(1)  3(1) 
C(7) 24(1)  32(2) 19(1)  -2(1) 0(1)  1(1) 
C(8) 16(1)  19(1) 20(1)  -1(1) 0(1)  2(1) 
C(9) 18(1)  19(1) 21(1)  -2(1) -2(1)  1(1) 
C(10) 17(1)  22(1) 23(1)  1(1) 4(1)  -2(1) 
C(11) 28(1)  17(1) 19(1)  -1(1) -2(1)  1(1) 
C(12) 27(1)  23(1) 33(1)  3(1) -2(1)  2(1) 
C(13) 46(2)  24(2) 37(2)  4(1) -17(2)  0(2) 
C(14) 74(3)  22(1) 26(1)  5(1) -10(2)  -9(2) 
C(15) 60(2)  27(2) 20(1)  -1(1) 7(1)  -14(2) 
C(16) 33(2)  24(1) 23(1)  -2(1) 3(1)  -3(1) 
C(17) 66(2)  30(2) 21(1)  -5(1) 7(2)  -8(2) 
C(18) 55(2)  18(1) 25(1)  -4(1) -5(1)  -9(1) 
C(19) 35(2)  19(1) 24(1)  2(1) -2(1)  -3(1) 
C(20) 54(2)  27(2) 33(2)  2(1) -18(2)  -8(2) 
C(21) 19(1)  21(1) 27(1)  0(1) 1(1)  -2(1) 
C(22) 21(1)  21(1) 42(2)  -1(1) -2(1)  -3(1) 
C(23) 55(2)  31(2) 42(2)  -7(1) -14(2)  -7(2) 
N(1) 19(1)  16(1) 23(1)  -2(1) 0(1)  2(1) 
N(2) 30(1)  19(1) 19(1)  0(1) -1(1)  5(1) 
O(1) 14(1)  25(1) 49(1)  -6(1) -2(1)  2(1) 
O(2) 14(1)  24(1) 32(1)  1(1) -1(1)  1(1) 
O(3) 34(1)  19(1) 29(1)  2(1) 3(1)  -1(1) 
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103). 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(2A) 1429 4118 4111 41 
H(3) -1481 4072 4477 53 
H(4) -2741 2200 4748 48 
H(5) -1105 375 4622 51 
H(6) 1809 435 4263 41 
H(7A) 4457 1573 3990 30 
H(7B) 4439 3049 4024 30 
H(8) 2887 3124 3205 22 
H(9) 6237 3231 3275 23 
H(12A) 3355 3764 1649 33 
H(12B) 2278 2476 1690 33 
H(13) 1715 3394 869 43 
H(14A) 4220 3668 289 49 
H(14B) 4547 4490 793 49 
H(15) 7282 3406 582 43 
H(16A) 7817 2489 1404 32 
H(16B) 6745 3771 1475 32 
H(17A) 5867 1681 173 47 
H(17B) 7282 1203 599 47 
H(18) 4486 99 680 39 
H(19A) 3984 464 1574 31 
H(19B) 6137 482 1457 31 
H(20A) 1774 1178 906 46 
H(20B) 2489 1640 357 46 
H(22A) -616 -311 2905 34 
H(22B) 1450 -624 2746 34 
H(23A) -971 811 2123 64 
H(23B) -486 -607 2014 64 
H(23C) 1065 429 1963 64 
H(1) 3550(40) 660(30) 3007(11) 14(7) 
H(2) 5680(60) 1420(40) 2292(14) 38(10) 
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H(2B) 7570(60) 1520(30) 3101(14) 33(10)
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Table 6.  Torsion angles [°]. 
________________________________________________________________ 
C(6)-C(1)-C(2)-C(3) -1.3(5) 
C(7)-C(1)-C(2)-C(3) 179.0(3) 
C(1)-C(2)-C(3)-C(4) 1.0(5) 
C(2)-C(3)-C(4)-C(5) -0.9(5) 
C(3)-C(4)-C(5)-C(6) 1.2(5) 
C(2)-C(1)-C(6)-C(5) 1.5(5) 
C(7)-C(1)-C(6)-C(5) -178.7(3) 
C(4)-C(5)-C(6)-C(1) -1.5(5) 
C(2)-C(1)-C(7)-C(8) -80.7(3) 
C(6)-C(1)-C(7)-C(8) 99.5(3) 
C(1)-C(7)-C(8)-N(1) -65.2(3) 
C(1)-C(7)-C(8)-C(9) 174.0(2) 
N(1)-C(8)-C(9)-O(2) -49.9(3) 
C(7)-C(8)-C(9)-O(2) 72.6(3) 
N(1)-C(8)-C(9)-C(10) 73.2(3) 
C(7)-C(8)-C(9)-C(10) -164.3(2) 
O(2)-C(9)-C(10)-O(3) -156.2(3) 
C(8)-C(9)-C(10)-O(3) 84.2(3) 
O(2)-C(9)-C(10)-N(2) 24.6(3) 
C(8)-C(9)-C(10)-N(2) -95.0(3) 
N(2)-C(11)-C(12)-C(13) -176.7(2) 
C(16)-C(11)-C(12)-C(13) 60.1(3) 
C(19)-C(11)-C(12)-C(13) -59.4(3) 
C(11)-C(12)-C(13)-C(14) -59.5(3) 
C(11)-C(12)-C(13)-C(20) 59.9(4) 
C(12)-C(13)-C(14)-C(15) 59.7(3) 
C(20)-C(13)-C(14)-C(15) -59.5(3) 
C(13)-C(14)-C(15)-C(17) 60.4(3) 
C(13)-C(14)-C(15)-C(16) -59.9(3) 
N(2)-C(11)-C(16)-C(15) 176.7(2) 
C(12)-C(11)-C(16)-C(15) -59.9(3) 
C(19)-C(11)-C(16)-C(15) 59.8(3) 
C(14)-C(15)-C(16)-C(11) 59.8(3) 
C(17)-C(15)-C(16)-C(11) -59.5(4) 
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C(14)-C(15)-C(17)-C(18) -60.6(3) 
C(16)-C(15)-C(17)-C(18) 59.3(4) 
C(15)-C(17)-C(18)-C(20) 60.3(3) 
C(15)-C(17)-C(18)-C(19) -59.2(4) 
N(2)-C(11)-C(19)-C(18) 179.5(3) 
C(16)-C(11)-C(19)-C(18) -60.7(3) 
C(12)-C(11)-C(19)-C(18) 59.2(3) 
C(20)-C(18)-C(19)-C(11) -59.8(3) 
C(17)-C(18)-C(19)-C(11) 60.2(3) 
C(17)-C(18)-C(20)-C(13) -59.0(3) 
C(19)-C(18)-C(20)-C(13) 60.5(3) 
C(12)-C(13)-C(20)-C(18) -60.8(4) 
C(14)-C(13)-C(20)-C(18) 58.5(3) 
O(1)-C(21)-C(22)-C(23) 67.4(4) 
N(1)-C(21)-C(22)-C(23) -111.8(3) 
O(1)-C(21)-N(1)-C(8) -0.5(4) 
C(22)-C(21)-N(1)-C(8) 178.7(2) 
C(9)-C(8)-N(1)-C(21) -140.4(2) 
C(7)-C(8)-N(1)-C(21) 97.6(3) 
O(3)-C(10)-N(2)-C(11) -7.3(5) 
C(9)-C(10)-N(2)-C(11) 171.9(2) 
C(16)-C(11)-N(2)-C(10) 73.0(3) 
C(12)-C(11)-N(2)-C(10) -49.5(4) 
C(19)-C(11)-N(2)-C(10) -168.5(3) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 7.  Hydrogen bonds [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 O(2)-H(2B)...O(1)#1 0.77(4) 1.91(4) 2.667(3) 167(4) 
 N(1)-H(1)...O(3)#2 0.86(3) 2.22(3) 3.052(3) 162(3) 
 N(2)-H(2)...O(2) 0.84(4) 2.25(4) 2.710(3) 115(3) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z    #2 -x+1,y-1/2,-z+1/2  
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APPENDIX II: 1H & 13C NMR SPECTRA 
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APPENDIX III 
1. The in vitro single-cycle phenotypic assay for HIV-1 
The HIV Virology Section at the National Institute for Communicable Diseases (NICD) employs a 
vector-based HIV-1 phenotypic assay for drug screening and resistance testing. For the assay, 
three vectors (plasmids) are used to create virus-like particles by transfection of mammalian 
cells (293T cells). Transient expression of the vectors in the cells produce the RNA of firefly 
luciferase that is packaged into a virus-like particle that contains the HIV-1 structural 
components (gag) and the three HIV-1 enzymes (reverse transcriptase, protease and integrase). 
Vesicular stomatitis virus G proteins are incorporated into the envelope surrounding the virus-
like particle and allows for viral entry into the host cell.  
Upon viral entry, the luciferase RNA is reverse transcribed by HIV-1 reverse transcriptase and 
the resulting cDNA integrated into the cell’s genomic DNA by HIV-1 integrase. The assay allows 
for only a single integration event per virus-like particle. Once integrated, the luciferase gene is 
expressed and produces functional firefly luciferase that can be detected by the addition of a 
substrate. The luminescence that is generated during conversion of the substrate can be 
quantified on a luminometer, and is directly proportional to the amount of virus-like particles 
that infected the cell. If inhibitors are present that target either the reverse transcriptase or 
integrase, a reduced luminescence will be observed. Since HIV-1 protease is involved in the 
maturation of virions, protease inhibitors need to be incorporated into the virus-like particle 
during transfection and before infection. The inhibition of protease will result in a decreased 
luminescence after infection. 
Procedure for screening the toxicity of compounds: 
Before determining the antiviral activity of compounds, it is important to assess whether they 
are toxic to the cells that are used in the assay. Cell death, brought on by toxic compounds, 
would lead to a reduced luminescence in the drug screen assay and could be mistaken for 
inhibition. Such “false inhibitions” can be prevented by testing over non-toxic concentrations. 
To perform a toxicity screen, serial dilutions of a compound is prepared in the wells of a 96-well 
culture plate. After addition of 293T cells, the plate is incubated for 48 hours at 37C under 5% 
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CO2 and a humidified atmosphere. A medium control, which contains no compound, is included 
to represent full (100%) cell viability. Cell viability is then assessed in the all wells using the 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) reagent. After 
approximately 1.5 – 2 hours of incubation at 37C under 5% CO2 and a humidified atmosphere, 
the absorbance of the wells are measured on a 96-well plate reader at 490 nm. The viability of 
the cells in each well is calculated relative to medium control. Activity screens are performed at 
concentrations with ≥ 80% cell viability. 
Procedure for screening potential protease inhibitors: 
The transfection of 293T cells is performed 24 hours prior to the start of the assay. On the day 
of the assay, serial dilutions of potential protease inhibitors are prepared in the wells of a 96-
well culture plate (i.e the drug plate). The transfected 293T cells are harvested and added to 
the drug plate. A medium control, which contains no inhibitor, is included to represent full 
(100%) viral activity. The plate is incubated for 24 hours at 37C under 5% CO2 and a humidified 
atmosphere. Supernatant is then transferred from the drug plate to a new 96-well culture plate 
(i.e. an indicator plate) that contains 293T cells in medium only. The plate is incubated for 48 
hours at 37C under 5% CO2 and a humidified atmosphere. After incubation, the luciferase 
substrate (Bright-Glo™ Luciferase Assay System, Promega) is added to the wells of the plate and 
incubated at room temperature for 2 minutes. The contents of the wells are mixed by pipetting 
and transferred to a black 96-well plate. Luminescence is then measured and the amount of 
inhibition assessed. 
Assay for inhibition: 
During each assay, a medium control is included that will indicate the luciferase signal of a fully 
active virus. This is used to calculate the viral activity in the wells that contain the potential 
inhibitor. A decrease in luciferase activity (luminescence signal), relative to that of the medium 
control, indicates viral inhibition. A lack of inhibition is observed when the activities are similar. 
To quantify the amount of inhibition, the concentration needed to inhibit 50% of the luciferase 
activity (IC50) is determined for the medium control and potential inhibitors. The fold change 
(FC) in difference between the IC50 of the medium control and potential inhibitors is then 
calculated. A FC=1 indicates similar IC50’s and no inhibition, while FC>1 shows inhibition. Due to 
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variation in the assay, a FC≤3 does not indicate a significant amount of inhibition and such 
compounds can be considered inactive. 
2. SYBR Green antimalarial drug sensitivity assay 
The P. falciparum (FCR-3) strain was cultured in vitro at 37°C in 3% O2, 5% CO2, 92% N2 and 
adjusted to a 0.625% parasitaemia/ 1.25% haematocrit before being incubated along with the 
compounds for 72 hours. The plates were then frozen overnight and once thawed, they were 
incubated in the dark, for 1 hour at room temperature with buffered SYBR green I. The 
fluorescence was read in a microplate reader with excitation and emission wavelength bands 
centered at 485 and 528 nm, respectively. The percentage inhibition was calculated taking the 
untreated and dihydroartemisinin control into account. Dihydroartemisinin was used as the 
positive control. At least three independent experiments were conducted. 
